DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 1 of 116  
Phase I, Open -Label, Dose -Ranging Study of the Safety and Immunogenicity of 2019 -nCoV 
Vaccine ( mRNA -1273 ) in Healthy Adults  
 
DMID Protocol Number:  20-0003  
 
IND Sponsor: Division of Microbiology and Infectious Diseases (DMID)  
 
Version Number: 7.0 
 
30 July  2021  
 
  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 2 of 116 STATEMENT  OF COMPLIANCE  
Each institution engaged in this research will hold a current Federal  wide Assurance (FWA) 
issued by the Office of Human Research Protection (OHRP) for federally funded research.  The 
Institutional Review Board ( IRB)/Independent or Institutional Ethics Committee  (IEC) must be 
registered with OHRP as applicable to the research.  
 
The study will be carried out in accordance with the following as applicable:  
• United States (US) Code of Feder al Regulations (CFR) 45 CFR Part 46: Protection of 
Human Subjects  
• Food and Drug Administration (FDA) Regulations: 21 CFR Part 50 (Protection of 
Human Subjects), 21 CFR Part 54 (Financial Disclosure by Clinical Investigators), 21 
CFR Part 56 ( IRBs), 21 CFR Part 11, and 21 CFR Part 312 (Investigational New Drug 
Application), and/or 21 CFR 812 (Investigational Device Exemptions)  
• The International Council for Harmonisation (ICH) of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) E 6(R2) Good Clinical Practice  
(GCP) , and the Belmont Report: Ethical Principles and Guidelines for the Protection of 
Human Subjects of Research, Report of the National Commission for the Protection of 
Human Subjects of Biomedical and Behavioral Research  
• The policies and procedures of National Institutes of Health (NIH) Office of Extramural 
Research and Division of Microbiology and Infectious Diseases ( DMID ) 
• The National Institute of Allergy and Infectious Diseases (NIAID) Terms of Award  
• Any additional Federa l, State, and Local Regulations and Guidance  
 
The signature below provides the necessary assurance that this study will be conducted 
according to all stipulations of the protocol , including statements regarding confidentiality, and 
according to local legal and regulatory requirements , US federal regulations , and ICH E6 (R2) 
GCP guidelines.  
 
Site Investigator  Signature : 
 
 
Signed:   Date:   
 Name, Credentials  
Title  
   
  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 3 of 116 TABLE  OF CONTENTS  
1. PROTOCOL SUMMARY  ................................ ................................ ................................ ...........  8 
1.1 Synopsis  ................................ ................................ ................................ ................................  8 
1.2 Schedule of Activities (SOA)  ................................ ................................ ............................  16 
2. INTRODUCTION  ................................ ................................ ................................ ......................  17 
2.1 Background and Study Rationale  ................................ ................................ ......................  17 
2.1.1  Public Readiness and Emergency Preparedness Act  ................................ ...............  20 
2.2 Risk/Benefit Assessment  ................................ ................................ ................................ ... 21 
2.2.1  Known Potential Risks  ................................ ................................ ..............................  21 
2.2.2  Known Potential Benefits ................................ ................................ ..........................  26 
3. OBJECTIVES AND ENDPOINTS  ................................ ................................ ..........................  26 
4. STUDY DESIGN  ................................ ................................ ................................ .......................  28 
4.1 Overall Design ................................ ................................ ................................ ....................  28 
4.2 Scientific Rationale for Study Design  ................................ ................................ ..............  31 
4.3 Justification for Dose  ................................ ................................ ................................ .........  31 
4.4 Optional Third mRNA -1273 Vaccination Substudy ................................ ........................  31 
5. STUDY POPULATION  ................................ ................................ ................................ ............  32 
5.1 Inclusion Criteria  ................................ ................................ ................................ ................  32 
5.1.1  Leukapheresis Inclusion Criteria  ................................ ................................ ..............  34 
5.2 Exclusion Criteria ................................ ................................ ................................ ...............  35 
5.2.1  Exclusion of Specific Populations  ................................ ................................ ............  37 
5.3 Inclusion of Vulnerable Subjects  ................................ ................................ ......................  37 
5.4 Lifestyle Considerations  ................................ ................................ ................................ .... 37 
5.5 Screen Failures  ................................ ................................ ................................ ...................  38 
5.6 Strategies for Recruitment and Retention  ................................ ................................ .........  38 
5.6.1  Recruitment  ................................ ................................ ................................ ................  38 
5.6.2  Retention  ................................ ................................ ................................ ....................  38 
5.6.3  Compensation Plan for Subjects  ................................ ................................ ...............  38 
5.6.4  Costs  ................................ ................................ ................................ ...........................  39 
6. STUDY PRODUCT  ................................ ................................ ................................ ...................  39 
6.1 Study Product(s) and Administration  ................................ ................................ ...............  39 
6.1.1  Study Product Description  ................................ ................................ ........................  39 
6.1.2  Dosing and Administration  ................................ ................................ .......................  39 
6.1.3  Dose Escalation ................................ ................................ ................................ ..........  40 
6.1.4  Dose Modifications ................................ ................................ ................................ .... 41 
6.2 Accountability/Handling/Storage/Preparation  ................................ ................................ . 41 
6.2.1  Acquisition and Accountability  ................................ ................................ ................  41 
6.2.2  Formulation, Appearance, Packaging, and Labeling ................................ ...............  42 
6.2.3  Product Storage and Stability ................................ ................................ ....................  43 
6.2.4  Preparation  ................................ ................................ ................................ .................  43 
6.3 Measures to Minimize Bias: Randomization and  Blinding  ................................ .............  44 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 4 of 116 6.3.1  Treatment Assignment Procedures  ................................ ................................ ...........  44 
6.3.2  Randomization and Blinding  ................................ ................................ ....................  44 
6.3.3  Blinding and Masking Procedures  ................................ ................................ ............  44 
6.4 Study Intervention Compliance  ................................ ................................ .........................  45 
6.5 Concomitant Therapy  ................................ ................................ ................................ ........  45 
6.5.1  Rescue Medicine  ................................ ................................ ................................ ........  45 
6.5.2  Non-Research Standard of Care  ................................ ................................ ...............  45 
7. STUDY INTERVENTION DISCONTINUATION AND SUBJECT 
DISCONTINUATION/WITHDRAWAL  ................................ ................................ .........................  45 
7.1 Halting Criteria and Discontinuation of Study Intervention  ................................ ...........  45 
7.1.1  Halting Criteria  ................................ ................................ ................................ ..........  45 
7.1.2  Sentinel Halting Criteria ................................ ................................ ............................  46 
7.1.3  Criteria for Continuation of Dosing and Redosing  ................................ ..................  46 
7.1.3.1  Withdrawal Criteria for Second Study Vaccination  ................................ ............  46 
7.1.3.2  Delay of Study Vaccination  ................................ ................................ ..................  47 
7.1.4  Follow -up for Subjects that Discontinued Study Intervention  ...............................  47 
7.2 Subject Withdrawal from the Study and Replacement  ................................ ....................  48 
7.3 Lost to Follow -Up ................................ ................................ ................................ ..............  49 
8. STUDY ASSESSMENTS AND PROCEDURES  ................................ ................................ ... 49 
8.1 Screening and Immunogenicity Assessments  ................................ ................................ .. 49 
8.1.1  Screening Procedures  ................................ ................................ ................................  49 
8.1.2  Screening Procedures for Leukapher esis ................................ ................................ . 51 
8.1.3  Immunogenicity Evaluations  ................................ ................................ ....................  51 
8.1.4  Samples for Genetic/Genomic Analysis ................................ ................................ ... 51 
8.1.4.1  Genetic/Genomic Analysis  ................................ ................................ ...................  51 
8.1.4.2  Genetic Privacy and Confidentiality  ................................ ................................ .... 51 
8.1.4.3  Management of Results  ................................ ................................ .........................  52 
8.2 Safety and Other Assessments  ................................ ................................ ..........................  52 
8.2.1  Procedures to be Followed in  the Event of Abnormal Clinical Laboratory Test 
Values or Abnormal Clinical Findings  ................................ ................................ .....................  57 
8.3 Adverse Events and Serious Adverse Events  ................................ ................................ ... 57 
8.3.1  Definition of Ad verse Event (AE)  ................................ ................................ ............  57 
8.3.1.1  Solicited Adverse Events  ................................ ................................ ......................  57 
8.3.1.2  Unsolicited Adverse Events  ................................ ................................ ..................  58 
8.3.1.3  Possible Adverse Events Associated with Leukapheresis  ................................ .. 58 
8.3.1.4  Special Reporting of Adverse Events  ................................ ................................ ... 59 
8.3.2  Definition of Serious Adverse Event (SAE)  ................................ ............................  59 
8.3.3  Suspected Unexpected Serious Adverse Reactions (SUSAR) ................................  59 
8.3.4  Classification of an Adverse Event  ................................ ................................ ..........  59 
8.3.4.1  Severity of Adverse Events  ................................ ................................ ...................  60 
8.3.4.2  Relationship to Study Intervention  ................................ ................................ ....... 60 
8.3.5  Time Period and Frequency for Event Assessment and Follow -Up ......................  60 
8.3.6  Adverse Event Reporting  ................................ ................................ ..........................  61 
8.3.6.1  Investigators Reporting of AEs  ................................ ................................ ............  61 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 5 of 116 8.3.7  Serious Adverse Event Reporting  ................................ ................................ .............  61 
8.3.7.1  Investigators Reporting of SAEs  ................................ ................................ ..........  61 
8.3.7.2  Regulatory Reporting of SAEs  ................................ ................................ .............  61 
8.3.8  Reporting Events to Subjects  ................................ ................................ ....................  62 
8.3.9  Adverse Events of Special Interest (AESIs)  ................................ ............................  62 
8.3.10  Reporting of Pregnancy  ................................ ................................ .............................  63 
8.4 Unanticipated Problems  ................................ ................................ ................................ ..... 63 
8.4.1  Definition of Unanticipated Proble ms (UPs)  ................................ ...........................  63 
8.4.2  Unanticipated Problem Reporting  ................................ ................................ ............  63 
8.4.3  Reporting Unanticipated Problems to Subjects  ................................ .......................  63 
9. STATISTICAL CONSIDERATIONS  ................................ ................................ ......................  64 
9.1 Statistical Hypotheses  ................................ ................................ ................................ ........  64 
9.2 Sample Size Determination  ................................ ................................ ...............................  64 
9.3 Populations for Analyses  ................................ ................................ ................................ ... 65 
9.4 Statistical Analyses  ................................ ................................ ................................ ............  66 
9.4.1  General Approach  ................................ ................................ ................................ ...... 66 
9.4.2  Analysis of the Primary Endpoint(s)  ................................ ................................ ........  66 
9.4.3  Analysis of the Secondary Endpoint(s)  ................................ ................................ .... 66 
9.4.4  Safety Analyses ................................ ................................ ................................ ..........  66 
9.4.5  Baseline Descriptive Statistics  ................................ ................................ ..................  67 
9.4.6  Planned Interim and Early Analyses  ................................ ................................ ........  67 
9.4.6.1  Interim Safety Analyses  ................................ ................................ ........................  67 
9.4.6.2  Interim Immunogenicity Review  ................................ ................................ ..........  68 
9.4.6.3  Interim Immunogenicity and Safety Review  ................................ .......................  68 
9.4.7  Sub-Group Analyses  ................................ ................................ ................................ .. 68 
9.4.8  Tabulation of Individual Subject Dat a ................................ ................................ ..... 68 
9.4.9  Exploratory Analyses  ................................ ................................ ................................  69 
10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  .... 69 
10.1  Regulatory, Ethical, and Study Oversight Considerations  ................................ ..............  69 
10.1.1  Informed Consent Process ................................ ................................ .........................  69 
10.1.1.1  Requirements for Permission by Parents/Guardians and Assent by Children 
(in case of a minor)  ................................ ................................ ................................ ................  71 
10.1.1.2  Other Informed Consent Procedures  ................................ ................................  71 
10.1.2  Study Termination and Closure  ................................ ................................ ................  72 
10.1.3  Confidentiality and Privacy ................................ ................................ .......................  73 
10.1.4  Secondary Use of Stored Specimens and Data  ................................ ........................  74 
10.1.4.1  Samples for Secondary Research  ................................ ................................ ..... 74 
10.1.4.2  Data Sharing for Se condary Research  ................................ .............................  75 
10.1.5  Key Roles and Study Governance  ................................ ................................ ............  75 
10.1.6  Safety Oversight  ................................ ................................ ................................ ........  75 
10.1.6.1  Protocol Team Oversight  ................................ ................................ ..................  75 
10.1.6.2  Safety Monitoring Committee (SMC)  ................................ .............................  76 
10.1.7  Clinical Monitoring  ................................ ................................ ................................ ... 76 
10.1.8  Quality Control (QC) and Quality Assurance (QA)  ................................ ................  77 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 6 of 116 10.1.9  Data Handling and Record Keeping  ................................ ................................ .........  77 
10.1.9.1  Data Collection and Management Responsibilities  ................................ ........  77 
10.1.9.2  Study Record Retention  ................................ ................................ ....................  78 
10.1.9.3  Source Records  ................................ ................................ ................................ .. 78 
10.1.10  Protocol Deviations  ................................ ................................ ................................ ... 78 
10.1.11  Publication and Data Sharing Pol icy ................................ ................................ ........  79 
10.1.12  Human Data Sharing Plan  ................................ ................................ .........................  79 
10.1.13  Genomic Data Sharing (GDS) Plan  ................................ ................................ ..........  79 
10.1.14  Publication ................................ ................................ ................................ ..................  79 
10.1.15  Conflict of Interest Policy  ................................ ................................ .........................  79 
10.2  Additional Considerations  ................................ ................................ ................................ . 80 
10.2.1  Research Related Injuries  ................................ ................................ ..........................  80 
10.3  Abbreviations  ................................ ................................ ................................ .....................  80 
10.4  Protocol Amendment History  ................................ ................................ ............................  83 
11. REFERENCES  ................................ ................................ ................................ .......................  93 
12. APPENDIX A: OPTIONAL THIRD mRNA -1273 VACCINATION  SUBSTUDY  ........  98 
12.1  Overview ................................ ................................ ................................ .............................  98 
12.2  Background and Scientific Rationale ................................ ................................ ................  98 
12.2.1  Justification for Dose  ................................ ................................ ...............................  101 
12.3  Risk/Benefit Assessment  ................................ ................................ ................................ . 101 
12.3.1  Known Potential Risks  ................................ ................................ ............................  101 
12.3.2  Known Potential Benefits ................................ ................................ ........................  102 
12.4  Objectives and Endpoints  ................................ ................................ ................................  102 
12.5  Study Design  ................................ ................................ ................................ ....................  104 
12.6  Eligibility Criteria  ................................ ................................ ................................ ............  108 
12.6.1  Inclusion Criteria  ................................ ................................ ................................ ..... 108 
12.6.2  Exclusion Criteria  ................................ ................................ ................................ .... 108 
12.7  Study Product  ................................ ................................ ................................ ...................  109 
12.7.1  Study Product Description  ................................ ................................ ......................  109 
12.7.2  Dose Modifications ................................ ................................ ................................ .. 110 
12.7.3  Product Storage and Stability ................................ ................................ ..................  110 
12.8  Concomitant Therapy  ................................ ................................ ................................ ...... 111 
12.9  Immunogenicity Evaluations  ................................ ................................ ...........................  111 
12.10  Adverse Events and Serious Adverse Events  ................................ ................................ . 111 
12.10.1  Reporting of Adverse Events  ................................ ................................ ..................  111 
12.10.2  Reporting of Pregnancy  ................................ ................................ ...........................  112 
12.10.3  Unanticipated Problem Reporting  ................................ ................................ ..........  112 
12.11  Statistical Considerations  ................................ ................................ ................................  112 
12.11.1  Statistical Hypotheses  ................................ ................................ ..............................  112 
12.11.2  Sample Size Determination  ................................ ................................ .....................  112 
12.11.3  Populations for Analyses  ................................ ................................ .........................  113 
12.11.4  Statistical Analyses  ................................ ................................ ................................ .. 113 
12.11.5  General Approach  ................................ ................................ ................................ .... 113 
12.11.6  Analysis of the Primary Endpoint(s)  ................................ ................................ ...... 113 
12.11.7  Analysis of the Secondary Endpoint(s)  ................................ ................................ .. 114 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 7 of 116 12.11.8  Safety Analyses ................................ ................................ ................................ ........  114 
12.11.9  Baseline Descriptive Statistics  ................................ ................................ ................  114 
12.11.10  Planned Interim and Early Analyses  ................................ ................................ ...... 115 
12.11.10.1  Interim Saf ety Analyses  ................................ ................................ .................  115 
12.11.10.2  Interim Immunogenicity Review  ................................ ................................ ... 115 
12.11.10.3  Interim Immunogenicity and Safety Review  ................................ ................  115 
12.11.11  Sub-Group Analyses  ................................ ................................ ................................  115 
12.11.12  Tabulation of Individual Subject Data  ................................ ................................ ... 115 
12.11.13  Exploratory Analyses  ................................ ................................ ..............................  115 
12.12  Regulatory, Ethical, and Study Oversight Considerations  ................................ ............  116 
 
LIST  OF TABLES  
Table 1: Treatment Arms  ................................ ................................ ................................ .....................  8 
Table 2: Objectives and Endpoints (Outcome Measures)  ................................ ................................  11 
Table 3: Dosing and Administration  ................................ ................................ ................................ . 15 
Table 4: Schedule of Activities for the Main Study  ................................ ................................ .........  16 
Table 5: Objectives and Endpoints (Outcome Measures)  ................................ ................................  26 
Table 6: Treat ment Arms  ................................ ................................ ................................ ...................  28 
Table 7: Dosing and Administration  ................................ ................................ ................................ . 39 
Table 8: Venipuncture Volumes  ................................ ................................ ................................ ........  55 
Table 9: Probability of Observing an Adverse Event for Various Event Rates  .............................  64 
Table 10: Abbreviations  ................................ ................................ ................................ .....................  80 
Table 11: Protocol Amendme nt History  ................................ ................................ ...........................  83 
Table 12: Objectives and Endpoints (Outcome Measures)  ................................ ............................  102 
Table 13: Treatment Arms and Substudy Dosing ................................ ................................ ...........  105 
Table 14: Schedule of Activities for the Optional Third mRNA -1273 Vaccination Substudy  ... 107 
 
 
LIST  OF FIGURES  
Figure 1 . The SARS -CoV -2 full -length stabilized spike protein (S -2P) delivered by mRNA is 
expressed on the cell surface  ................................ ................................ ................................ ..............  20 
 
  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 8 of 116 1. PROTOCOL  SUMMARY  
1.1 Synopsis  
Rationale for Proposed Clinical Study  
In December 2019 the Wuhan Municipal Health Committee identified an outbreak of viral 
pneumonia cases of unknown cause. Coronavirus ribonucleic acid ( RNA ) was quickly identified 
in some of these patients. On January 5, 2020 there were 59 confirmed cases, 2 78 cases on 
January 20, rising to more than 110,000  confirmed cases and 3996 deaths as of March 9 , 2020. 
On March 11, 2020 the World Health Organization ( WHO ) declared Coronavirus disease 2019 
(COVID -19) a pandemic.  SARS -CoV -2 has continued to spread globa lly with cases being 
reported in at least 216 countries, and as of May 14, 2020, 4,307,287 confirmed cases and 
295,101 deaths had been reported to the WHO.  There is currently no vaccine against the 2019 -
novel Coronavirus ( 2019 -nCoV; SARS -CoV -2). Therefore,  there is an urgent public health need 
for rapid development of novel interventions . 
ModernaTX, Inc. has developed a rapid response, proprietary messenger RNA (mRNA) -based 
vaccine platform. This is based on the principle and observations that antigens can be produced 
in vivo by delivery and uptake of the corresponding mRNA by cells. Moderna TX, Inc.  is using 
its mRNA -based technology to develop a novel lipid nanoparticle (LNP) -encapsulated 
messenger RNA (mRNA) -based vaccine against SARS -CoV -2 (mRNA -1273) . Prior preclinical 
studies have demonstrated that coronavirus spike  (S) protein s are immunogenic and S protein -
based vaccines , including deoxyribonucleic acid ( DNA ) and mRNA delivery platforms , are 
protective in animals. Prior clinical trials of vaccines targeting related coronavirus es and other 
viruses have demonstrated that DNA and  mRNA -based vaccines are safe and  immunogenic. It is 
therefore anticipated that mRNA -1273 will generate robust immu ne responses to the SARS -
CoV -2 S protein.  
Based on current ly available information and clinical experience suggesting that older adults 
may be at higher risk for severe illness from COVID -19, it is important to rapidly assess clinical 
safety of novel vacci nes in this vulnerable population as early as possible. Th us, th is phase I 
clinical trial proposes to evaluate the safety and immunogenicity of different dosages of 
Moderna’s mRNA -1273 in healthy adults across the age spectr um (≥18 years of age).  
Study Des ign 
This is a phase I, open -label, dose -ranging clinical trial in males and non -pregnant females, ≥18 
years of age , who are in good health and meet all eligibility criteria. This clinical trial is designed 
to assess the safety, reactogenicity and immunogenicity of mRNA -1273 manufactured by 
ModernaTX, Inc. mRNA -1273 is a novel LNP -encapsulated mRNA -based vaccine that enc odes 
for a full -length, prefusion stabilized spike (S) protein of SARS -CoV -2. Enrollment will occur at 
up to three  domestic clinical research sites. 
Table 1: Treatment Arms  
Cohort  Sample Size  Stratum  
(Years of Age)  First and Second Dose  
1 15 18-55 25 mcg mRNA -1273  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 9 of 116 Cohort  Sample Size  Stratum  
(Years of Age)  First and Second Dose  
2 15 18-55 100 mcg mRNA -1273  
3 15 18-55 250 mcg mRNA -1273  
4 10 56-70 25 mcg mRNA -1273  
5 10 56-70 100 mcg mRNA -1273  
6* 10 56-70 250 mcg mRNA -1273  
7 10 ≥71 25 mcg mRNA -1273  
8 10 ≥71 100 mcg mRNA -1273  
9* 10 ≥71 250 mcg mRNA -1273  
10 15 18-55 50 mcg mRNA -1273  
11 10 56-70 50 mcg mRNA -1273  
12 10 ≥71 50 mcg mRNA -1273  
13* 15 18-55 10 mcg mRNA -1273  
*Cohorts 6, 9 and 13 were not enrolled.  
Up to o ne hundred and fifty-five ( 155) subjects will be enrolled into one of thirteen  cohorts ( 10 
micrograms [mcg], 25 mcg, 50 mcg, 100 mcg, or 250 mcg). Subjects will receive an 
intramuscular ( IM) injection (0.5 milliliter s [mL]) of mRNA -1273 on Days 1 and 29 in the 
deltoid muscle and will be followed through 12 months post second vaccination (Day 394). The 
second dose of vaccine (0.5 mL) will be administered preferably in the same arm used for the 
first dose.  
Follow -up visits will occur 1, 2 and 4 weeks post each vaccination (Days 8, 15, 29, 3 6, 43, and 
57), as well as 3, 6 and 12 months post second vaccination (Days 119, 209 and 394).  
Reactogenicity will be assessed at these visits , as well as blood will be drawn for 
immunogenicity assays. Additional safety and reactogenicity data will be soli cited via telephone 
calls to subjects 1 and 2 days post each vaccination (Days 2, 3, 30, and 31).  
To determine early safety signals for this phase I clinical trial , vaccination will proceed in a 
staged fashion. Sentinel subject dosing will begin with 4 subjects in cohort 1 (25 mcg). The 4 
sentinel subjects for cohort 2 (100 mcg) will be enrolled no earlier than one day after enrollment 
of the last of the 4 sentinel subjects in cohort 1. If no halting rules have been met after the 8 
sentinel subjects have completed Day 5, then full enrollment will proceed first with the 
remaining subjects in cohort 1, followed by the remaining subjects in cohort 2 without 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 10 of 116 interruption . If no halting rules have been met after all subjects in cohort 2 have completed Day 
8, then dosing of 4 sentinel subjects will begin in cohort 3. If no halting rules have been met after 
the 4 sentinel subjects in cohort 3 have completed Day 5, then full enrollment of cohort 3 will 
proceed.  
If no halting rules have been met after all subjects in cohorts 1 and 2 have completed Day 8, 
dosing will begin for cohorts 4 (25  mcg; 56 -70 years of age) and 5 (100 mcg; 56 -70 years of 
age). If no halting rules have be en met after all subjects in cohorts 4 and 5 have completed Day 
8, dosing will begin for cohorts 7 (25 mcg; ≥71 years of age) and 8 (100 mcg; ≥71 years of age).  
Based on the interim immunogenicity data available as of May 15, 2020, enrollment into cohorts 
6 and 9 (250 mcg; 56 -70 years of age and ≥71 years of age) will be deferred in order to explore 
lower dosages. Therefore, enrollment of cohorts 10 -12 (50 mcg; 18 -55 years of age, 56 -70 years 
of age and ≥71 years of age) will be prioritized. Subjects will b e enrolled simultaneously in 
cohorts 10 -12; there will be no staging. To further explore dosage sparing, cohort 13 (10 mcg 
dose; 18 -55 years of age) may be enrolled. A decision regarding the enrollment of cohorts 6, 9 
and 13 will be made after review of in terim immunogenicity data from cohorts 1 -5, 7, 8, and 10 -
12. 
If no halting rules have been met after all subjects in cohorts 5 and 8 have completed Day 8, 
dosing will begin concurrently for cohorts 10 -12. If no halting rules have been met after all 
subject s in cohorts 3, 7 and 8 have completed Day 8, dosing may begin for cohort 6, if enrolled. 
If no halting rules have been met after all subjects in cohort 6 have completed Day 8, dosing may 
begin for cohort 9, if enrolled.  
Reactogenicity will be measured by the occurrence of solicited injection site and systemic 
reactions from the time of each vaccination through 7 days post each vaccination. Unsolicited 
non-serious adverse events (AEs) will be collected from the time of each vaccination through 28 
days post each vaccination. Serious adverse events (SAEs), protocol specified adverse events of 
special interest ( AESIs ), new-onset chronic medical conditions ( NOCMCs ), and medically -
attended adverse events ( MAAEs ) will be collected through 12 months after the secon d 
vaccination (Day 394).  
Clinical safety laboratory evaluations will be performed at screening, as well as immediately 
prior to and 7 days post each vaccination (Days 1, 8, 29, and 36).  
To support development of diagnostics, therapeutics and vaccines, a su bset of subjects enrolled 
in cohorts 2 , 3, 5, 10, and 11 may undergo leukapheresis to collect additional samples for 
secondary research.  If enrollment in cohort 6 proceeds, a subset of subjects in this cohort may 
also undergo leukapheresis.  
Based on interim immunogenicity and reactogenicity data, Cohorts 6, 9 and 13 were not 
enrolled . 
During the course of this clinical trial, i nterim effic acy data from a Phase 3 placebo -controlled 
clinical trial of mRNA -1273 (COVE) , administered as 2 doses of 100 mcg given 28 days apart, 
demonstrated vaccine efficacy of 94.1% (95% CI: 89.3%, 96.8%) for the prevention of 
symptomatic , confirmed COVID -19. After review of the interim safety and efficacy data from 
that clinical trial, the FDA granted on December 18, 2020 an Emergency Use Authorization 
(EUA) for the mRNA -1273 vaccine in adults 18 years of age and older.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 11 of 116 To potentially enhance and extend the durati on of protection provided by the 2-dose vaccination  
schedule of mRNA -1273 administered in the main study , and to gain an understanding of the 
immune responses to a third dose of mRNA -1273 , subjects  in the main study  may participate in 
an optional third mRNA -1273 vaccination substudy, detailed in Section 12, Appendix  A. 
Substudy subjects will receive a third mRNA -1273 vaccination, administered via an IM injection 
at a dos age of 100 mcg /0.5 mL, given six to twelve months after receipt of their second 
vaccination  in the main study . Substudy subjects will be followed for safety , reactoge nicity,  and 
immunogenicity endpoints through 12 months post third vaccination ( Substudy Day 366). 
To be eligible to participate in the substudy, subjects must have received both the first and 
second mRNA -1273 vaccinations in the main study. Other eligibility criteria are specified in 
Appendix A . Subjects who received only one mRNA -1273 vaccination in the main study will be 
advised to receive an FDA authorized or approved COVID -19 vaccine, according to the 
recommended schedule, when available to them outside of this trial, unless they have a  
contraindication to COVID -19 vaccines that are available.  
Subjects  who elect not to participate in the optional third  mRNA -1273 vaccination substudy or 
are not eligible for the substudy will continue to be followed according to the Schedule of 
Activities for the main study ( see Table 4) with the Final Study Visit 14 occurring at Day 394 
(±14 days) . 
Objectives and Endpoints  
Table 2: Objective s and Endpoints (Outcome Measures)  
OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
Primary   
• To evaluate the safety and reactogenicity 
of a 2 -dose vaccination schedule of 
mRNA -1273, given 28 days apart, across 
5 dosages in healthy adults.  • Frequency and grade of each solicited 
local and systemic reactogenicity AE 
during a 7 -day follow -up period pos t each 
vaccination.  
• Frequency and grade of any unsolicited 
AEs during the 28 -day follow -up period 
post each vaccination.  
• Frequency of any SAEs, Protocol 
Specified AESIs , NOCMCs , and MAAEs 
from Day 1 to Day 394.  
Secondary   
• To evaluate the immunogenicity as 
measured by Immunoglobulin G ( IgG) 
enzyme -linked immunosorbent assay  
ELISA to the SARS -CoV -2 S (spike) 
protein following a 2 -dose vaccination 
schedule of mRNA -1273 at Day 57.  • Geometric mean titer (GMT) of antibody 
at Day 5 7. 
• Percentage of subjects who seroconverted, 
defined as a 4 -fold change in antibody 
titer from baseline.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 12 of 116 OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
• The geometric mean fold rise (GMFR) in 
IgG titer from baseline.  
Exploratory   
• To evaluate the immunogenicity as 
measured by IgG ELISA to the SARS -
CoV -2 S (spike) protein following a 2 -
dose vaccination schedule of mRNA -1273 
at all timepoints, other than Day 57.  • GMT of antibody at each timepoint.  
• Percentage of subjects who seroconverted 
at each timepoint.  
• The GMFR in IgG titer from baseline at 
each post -vaccination timepoint.  
• To evaluate the immunogenicity as 
measured by Immunoglobulin M ( IgM) 
and Immunoglobulin A  (IgA) ELISA to 
the SARS -CoV -2 S (spike) protein 
following a 2-dose vaccination schedule of 
mRNA -1273 given 28 days apart.  • GMT at each timepoint.  
• Percentage of subjects who seroconverted 
at each timepoint.  
• The GMFR in IgM and IgA titer from 
baseline at each post -vaccination 
timepoint.  
• To evaluate the immunogenicity  as 
measured by pseudovirus neutralization 
following a 2 -dose vaccination schedule of 
mRNA -1273 given 28 days apart.  • GMT of neutralizing (Neut) antibody at 
each timepoint.  
• Percentage of subjects who seroconverted, 
defined as a 4 -fold change in Neut 
antibod y titer from baseline at each 
timepoint.  
• The GMFR Neut antibody titer from 
baseline at each post -vaccination 
timepoint.  
• To evaluate the immunogenicity as 
measured by live wild-type SARS -CoV -2 
neutralization following a 2 -dose 
vaccination schedule of mRNA -1273 
given 28 days apart.  • GMT of Neut antibody at each timepoint.  
• Percentage of subjects who seroconverted, 
defined as a 4 -fold change in Neut 
antibody titer from baseline at each 
timepoint.  
• The GMFR in Neut antibody titer from 
baseline at each post -vaccination 
timepoint.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 13 of 116 OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
• To assess, in at least a subset of samples, 
the SARS -CoV -2 S protein -specific T cell 
responses.  • Magnitude, phenotype, and percentage of 
cytokine producing S protei n-specific T 
cells, as measured by flow cytometry at 
different timepoints post vaccination 
relative to baseline.  
Inclusion Criteria  (abbreviated)  
See full inclusion criteria in Section 5.1. 
A subject must meet all the following criteria to be eligible to participate in this study:  
1. Provides written informed consent prior to initiation of any study procedures.  
2. Be able to understan d and agrees to comply with planned study procedures and be 
available for all study visits.  
3. Agrees to the collection of venous blood per protocol.  
4. Male or non -pregnant female, ≥18 years of age  at time of enrollment.  
5. Body mass index (BMI) 18 .0-35.0 kg/m2, inclusive (<56 years of age), at screening; BMI 
18.0-30.0 kg/m2, inclusive (≥56 years of age), at screening . 
6. Women of childbearing potential must agree to use or have practiced true abstinence or 
use at least one acceptable primary form of contrace ption.  
7. In good health.  
8. Oral temperature is less than 100.0°F (37.8°C).  
9. Pulse no greater than 100 beats per minute.  
10. Systolic blood pressure  (BP)  is 85 to 1 50 mm  Hg, inclusive.  
11. Clinical s creening  laborator y evaluations (White Blood Cell s [WBC s], hemoglobin 
[Hgb], platelets [ PLTs ], Alanine Transaminase [ ALT ], Aspartate Transaminase [ AST ], 
Creatinine  [Cr], Alkaline Phosphatase [ ALP ], Total Bilirubin  [T. Bili] , Lipase,  
Prothrombin Time [ PT], Partial Thromboplastin Time [ PTT]) are within acceptable 
normal reference ranges at the clinical lab oratory  being used.  
12. Must agree to have samples stored for secondary research.  
Exclusion Criteria  (abbreviated)  
See full exclusion criteria in Section 5.2. 
A subject who meets any of the following criteria will be excluded from participation in this 
study:  
1. Positive pregnancy test either at screening or just prior to each vaccine administration.  
2. Female subject who is breastfeeding or p lans to breastfeed from the time of the first 
vaccination through 60 days after the last vaccination.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 14 of 116 3. Has any medical disease or condition that, in the opinion of the participating site 
Principal Investigator ( PI) or appropriate sub -investigator, precludes study participation.  
4. Presence of self -reported or medically documented significant medical or psychiatric 
condition(s).  
5. Has an acute illness, as determined by the participating site PI or appropriate sub -
investig ator, with or without fever [ oral temperature ≥38.0°C (100.4 °F)] within 72 hours 
prior to each vaccination.  
6. Has a positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or 
human immunodeficiency virus  (HIV)  types 1 or 2 antibodie s at screening.  
7. Has participated in another investigational study involving any investigational product 
within 60 days, or 5 half -lives, whichever is longer, before the first vaccine 
administration.  
8. Has previously participated in an investigational study i nvolving LNPs (a component of 
the investigational vaccine assessed in this trial).  
9. Has a history of hypersensitivity or severe allergic reaction (e.g., anaphylaxis, 
generalized urticaria, angioedema, other significant reaction) to any previous licensed or 
unlicensed vaccines.  
10. History of COVID -19 diagnosis.  
11. Reside in a nursing home or other skilled nursing facility or have a requirement for 
skilled nursing care.  
Study Phase  
• 1 
Study Population  
Up to o ne hundred and fifty-five (155) males and non -pregnant females, ≥18 years of age, who 
are in good health and meet all eligibility criteria will be enrolled.  
Sites  
Up to three domestic clinical  research  sites 
Study Intervention : 
• mRNA -1273 is an LNP dispersion containing an mRNA that enc odes for the pre fusion 
stabilized spike protein SARS -CoV -2. mRNA -1273 consists of an mRNA Drug 
Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, 
SM-102, and 3 commercially available lipids, cholesterol, 1,2-distearoyl -sn-glycero -3-
phosphocholine ( DSPC ), and PEG2000 DMG.  
• mRNA -1273 (0.5 milligrams [ mg]/mL) will be diluted in 0.9% Sodium Chloride ( NaCl ) 
for injection, United States Pharmacopeia ( USP) to obtain 10, 25, 50, 100, and 250 mcg 
in 0.5 mL dosages. Each dose will be administered via IM injection (0.5 mL) into the 
deltoid muscle on Days 1 and 29 . The second dose of vaccine (0.5 mL) will be 
administered preferably in the same arm used for the first dose. The pharmacist w ill 
prepare a single dose (0.5 m L) for each subject  based on cohort  assignment . 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 15 of 116 Table 3: Dosing and Administration  
Cohort  Product 
Name  Dose  Route  Frequency of 
Administration  
1 mRNA -1273  25 mcg  IM D1, D29  
2 mRNA -1273  100 mcg  IM D1, D29  
3 mRNA -1273  250 mcg  IM D1, D29  
4 mRNA -1273  25 mcg  IM D1, D29  
5 mRNA -1273  100 mcg  IM D1, D29  
6* mRNA -1273  250 mcg  IM D1, D29  
7 mRNA -1273  25 mcg IM D1, D29  
8 mRNA -1273  100 mcg  IM D1, D29  
9* mRNA -1273  250 mcg  IM D1, D29  
10 mRNA -1273  50 mcg  IM D1, D29  
11 mRNA -1273  50 mcg  IM D1, D29  
12 mRNA -1273  50 mcg  IM D1, D29  
13* mRNA -1273  10 mcg  IM D1, D29  
*Cohorts 6, 9 and 13 were not enrolled.  
Study Duration  
• The duration of the main  study is anticipated to be 20 months (from start of screening to 
last subject last visit  in the main  study ). 
• The duration of the optional third mRNA -1273 vaccination substudy  is anticipated to be 
12 months from the last subject vaccinated with the third mR NA-1273 vaccination . 
Subject  Duration  
• The duration for each individual subject in the main  study is approximately 14 months 
(from first contact to last visit  in the main  study ). 
• The duration for each individual subject in the optional third mRNA -1273 vaccination 
substudy  is approximately 26 months (from first contact to last visit).  
Safety  
• The study will use a series of halting rules – for sentinel subjects, for the halting of eac h 
cohort, and for not vaccinating individual subjects. See Section 7.1 for details.  
• This study will use a Safety Monitoring Committee (SMC) for objective oversight of the 
study. SMC reviews are required for study halting. The SMC does not need to meet for 
dose es calation  or for initiation of the optional third mRNA -1273 vaccination substudy . 
 
 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 16 of 116 1.2 Schedule of Activities (S OA) 
Table 4: Schedule of Activities  for the Main Study  
Procedures  
Screening  
Visit 00, Day -42 to -1 
Enrollment/Baseline  
Visit 01, Day 1  
Visit 02 , Day 2  
1 day post Dose 1 
Visit 03 , Day 3  
2 days post Dose 1 
Visit 04  
Day 8 +/- 1 day  
Visit 05  
Day 15 +/ - 2 day s 
Visit 06  
Day 29 +/ - 2 days 
Visit 07 , Day 30  
1 day post Dose 2  
Visit 08 , Day 31  
2 days post Dose 2  
Visit 09f 
Day 36 +/ - 1 day 
Visit 10f 
Day 43 +/ - 2 days  
Visit 11f 
Day 57 +/ - 2 days 
Visit 11Af 
Day 71 -7/+ 21 days 
Visit 12f 
Day 119 +/ - 7 days 
Visit 13f 
Day 209 +/ -7 days 
Final Study Visit 14f,g 
Day 394 +/ - 14 days 
Unscheduled Visit 
Early Termination 
Visit 
Informed Consent  X                  
Review Eligibility Criteria  X X     X            
Medical History  X                  
Concomitant Medications  X X X X X X X X X X X X  X X X X X 
Vaccination   X     X            
Telephone Contact    X X    X X          
Interim History   X   X X X   X X X  X X X X X 
Physical Exam inationa X X   X X X   X X X  X X X X X 
Vital Signs  X X   X X X   X X X  X X X X X 
Height and Weight (for BMI)  X                  
Hematologyb X X   X  X   X         
Chemistryb X X   X  X   X         
Serologyb X                  
Pregnancy Testc X X     X            
Urine Drug Screen  X                  
Memory Aid: Solicited AEs   Days 1 -8  Days 29 -36         
Unsolicited AEs   Days 1 -57       
SAEs, Protocol Specified AESIs, MAAEs , 
and NOCMCs    Days 1 -394   
Serum for Serological  Immunogenicity 
Assays   X    X X   X X X  X X X  X 
Peripheral Blood Mononuclear Cells 
(PBMCs ) for Cellular Immunology Assays   X    X X   X X X  X X   X 
Serum for Secondary Researchd  X    X X   X X X  X X X  X 
Serum for Product Assay Development   X    X X   X X X  X X X  X 
Leukocytes for Secondary Research  
(subset of subjects)              Xe      
 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 17 of 116 a) Full physical examination will be performed at screening and symptom -directed (targeted) 
physical examination at all other timepoints  if indicated . 
b) Clinical screening laborator y evaluations will include WBC s, Hgb, PLTs , Cr, ALT, AST, 
ALP , T. Bili , Lipase,  PT, PTT, hepatitis B surface antigen, hepatitis C virus antibody, and HIV 
types 1 and 2 antigen/antibody. Clinical s afety laborator y evaluations  obtained on Days 1, 8, 29, 
and 36 will include WBC s, Hgb, PLTs , Cr, ALT, AST, ALP , T. Bili , and Lipase . 
c) For women of childbearing potential s erum pregnancy test at screening , and urine or serum 
pregnancy test on Days 1 and 29  with results confirmed as negative prior to enroll ment  on Day 1 
and administration of each vaccination . 
d) Depending on the timepoint a pproximately 8 or 16  mL of each venous blood sample is 
designated for secondary research.  
e) For those subjects consented for leukapheresis, screening procedures, including screening 
laboratory evaluations, will be performed locally prior to the  leukapheresis procedure . Refer to 
the protocol -specific MOP for details on the leukapheresis procedure.  
f) Visits 09 -14 windows should be based off the actual Visit 06 date.  
g) Subjects who participate in the optional third mRNA -1273 vaccination substudy will exit the 
Schedule of Activities for the main study  between Visit 13 and the close of the window for Visit 
14 and will not have Visit 14 , instead will have Visit 14A and subsequent substudy visits . See 
Section 12, Appendix A for the Schedule of Activities for the optional third mRNA -1273 
vaccination substudy . 
2. INTRODUCTION  
2.1 Background and Study Rationale  
In December 2019 the  Wuhan Municipal Health Committee identified an outbreak of viral 
pneumonia cases of unknown cause. Coronavirus RNA was quickly identified in some of these 
patients. This novel Coronavirus (nCoV) was originally referred to as  2019 -nCoV  but has now 
been  named SARS -CoV -2 (due to its similarity to the Severe Acute Respiratory Syndrome 
[SARS ] Coronavirus  [CoV; SARS -CoV] ). It has 89% nucleotide identity with bat SARS -like-
CoVZXC21 and 82% with that of human SARS -CoV (Chan JF et al., 2020). The disease caused 
by SARS -CoV -2 is called Coronavirus disease  2019  (COVID -19). On January 5, 2020 there 
were 59 confirmed cases, 278 cases  on January 20, 2118 cases on January 26, rising to more than 
110,000  confirmed cases and 3996  deaths as of March 9 , 2020 according to various international 
health reporting agencies. Outbreak forecasting and modeling suggest that these numbers will 
contin ue to rise ( Wu et al.,  Lancet, Jan. 31, 2020). On January 30, 2020, the International Health 
Regulations Emergency Committee of the World Health Organization (WHO) declared the 
COVID -19 outbreak a Public Health Emergency of International Concern. On Januar y 31, 2020, 
the US Department of Health and Human Services declared a public health emergency in the 
United States.  On March 11, 2020 the WHO declared COVID -19 a pandemic.  SARS -CoV -2 has 
continued to spread globally with cases being reported in at least 21 6 countries, and as of May 
14, 2020, 4,307,287 confirmed cases and 295,101 deaths had been reported to the WHO [WHO, 
2020].  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 18 of 116 Global efforts to evaluate novel antivirals and therapeutic strategies to treat SARS -CoV -2 severe 
infections have intensified, but n o proven therapeutic currently exists. There is currently no 
vaccine against the SARS -CoV -2 virus. Therefore, there is a n urgent public health need for rapid 
development of novel interventions . Based on current ly available information and clinical 
experien ce suggesting that older adults may be at higher risk for severe illness from COVID -19, 
it is important to rapidly assess clinical safety of novel vaccines in this vulnerable population as 
early as possible. This phase I clinical trial proposes to evaluate  safety and immunogenicity of 
Moderna’s mRNA -1273 in healthy adults across the age spectr um (≥18 years of age).  To further 
explore dos e-ranging , additional cohorts will be enrolled.  
ModernaTX, Inc. has developed a rapid response, proprietary messenger RNA (mRNA) -based 
vaccine platform. This is based on the principle and observations that antigens can be produced 
in vivo by delivery and uptake of the corresponding mRNA by cells. The mR NA then undergoes 
intracellular ribosomal translation to endogenously express the protein antigen(s) encoded by the 
vaccine mRNA. This mRNA -based vaccine does not enter the cellular nucleus or interact with 
the genome, is nonreplicating, and expression is transient. mRNA vaccines thereby offer a 
mechanism to stimulate endogenous production of structurally intact protein antigens in a way 
that mimics wild -type viral infection and are able to induce good immune responses against 
infectious pathogens such as cytomegalovirus ( CMV ) ([STUDY_ID_REMOVED]), human 
metapneumovirus ( hMPV ) and parainfluenza virus type 3 ( PIV3 ) ([STUDY_ID_REMOVED]) and influenza 
virus ([STUDY_ID_REMOVED] and [STUDY_ID_REMOVED]). Moderna TX, Inc.  is using its mRNA -based 
technology to develop a novel LNP -encapsulated m essenger RNA (mRNA) -based vaccine 
against SARS -CoV -2. mRNA -1273 is a novel LNP  mRNA -based vaccine that encodes for the 
full-length spike (S) protein of SARS -CoV -2, modified to introduce two proline residues to 
stabilize the S protein into a pre -fusogenic f orm.  
The coronavirus spike (S) protein mediates attachment and entry of the virus into host cells, 
making it a primary target for neutralizing antibodies that prevent infection (Johnson et al. 2016; 
Wang et al. 2016; Wang et al. 2015; Wang et al. 2018; Chen et al. 2017; Corti et al. 2015; Yu et 
al. 2015; Kim et al. 2019; Widjaja et al. 2019). The Vaccine Research Center (VRC) and 
collaborators have identified 2 proline mutations at the apex of the S2 central helix that stabilize 
the S protein in its prefusion co nformation (S -2P) (Pallesen et al. 2017). These mutations have 
been applied to 9 diverse coronaviruses from three coronavirus genera and found to stabilize the 
prefusion conformation and improve protein expression. Since this mutation has consistently 
stabilized other beta -CoV S proteins, this mutation was applied to the SARS -CoV -2 S protein . 
The VRC and collaborators found that the stabilized SARS -CoV -2 S-2P expressed well and is in 
the prefusion conformation based on negative -stain electron microscopy.  
The S proteins of closely related beta -CoVs stabilized by the 2P mutation, including HKU1, 
Middle East Respiratory Syndrome ( MERS ), SARS, and WIV1, are potent immunogens in mice. 
In collaboration with ModernaTX, Inc, mRNA expressing the MERS S -2P protein sequence was 
produced and compared to mRNA expressing wild -type S protein. mRNA expressing the MERS 
S-2P protein was more immunogen ic than mRNA expressing wild -type S protein, and mice 
immunized with a dose as low as 0.016 mcg of MERS S -2P mRNA had neutralizing activity 
above the threshold of protection in dipeptidyl peptidase 4 ( hDPP4 ) mice and protected mice 
from MERS challenge. Bas ed on the robust immunogenicity of the MERS S -2P mRNA vaccine 
in mice, the VRC and Moderna TX, Inc.  designed mRNA expressing a membrane -anchored 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 19 of 116 SARS -CoV -2 S protein stabilized with the 2P mutation. HEK293 cells transfected with mRNA 
expressing the SARS -CoV -2 S-2P protein successfully expressed the protein.  
mRNA -1273 is immunogenic in BALB/c mice, demonstrating a dose -dependent antibody 
response as measured in both SARS -CoV -2 S protein binding and virus neutralizing antibody 
assays. A strong correlation was measured between S protein binding antibody and virus 
neutralization. In addition, a single dose of mRNA -1273 elicited robust S protein binding 
antibody titers, but with no virus neutralization titers observed. Mice from this study were 
challenged with mou se-adapted SARS -CoV -2 virus, and preliminary results indicate that 
mRNA -1273 -induced immunity is protective after challenge. Mice immunized with a single dose 
of 10 or 1 mcg of mRNA -1273 were protected from viral replication in the lung following 
challenge  7 weeks after vaccination, despite the absence of measurable neutralization titers. Mice 
immunized with 2 doses of either 1 or 0.1 mcg of mRNA -1273 were also protected, dependent 
upon the dosing schedule.  
There is some clinical experience with vaccines ta rgeting coronavirus S proteins. The first 
candidate DNA vaccine expressing SARS S protein was evaluated in 10 healthy adults age 21 to 
49 years in 2004 and 2005 following a rapid vaccine development response to the SARS 
outbreak  (Martin et al. 2008) . DNA v accine at a dosage of 4 mg was administered IM by a 
Biojector needle free device at baseline, week 4 and week 8. The vaccine was safe and well 
tolerated. Local and systemic reactogenicity events were mild and transient. There were no SAEs  
and no grade 3 or  4 AEs. The SARS candidate vaccine was immunogenic as assessed by ELISA 
and pseudotyped lentiviral vector reporter neutralization assay following the first injection in 
most subjects with peak response after the 3rd vaccination. Vaccine induced T cell resp onses as 
assessed by ICS and ELISPOT were detected in all subjects  (Martin et al. 2008) . 
Additionally, a candidate DNA vaccine expressing MERS S was evaluated in 75 healthy subjects 
ages 19 to 50 years in 2016 (Modjarrad et al. 2019). In a dose escalation trial, DNA vaccine at a 
dosage of 0.67 mg, 2 mg or 6 mg was administered IM followed by electroporation at baseline, 
week 4 and week 12. Overall, the vaccine was safe and well tolerated. Local and systemic 
reactogenicity events were generally mild and tran sient. There were no SAEs  or grade 3 or 4 
laboratory abnormalities attributed to vaccination. The MERS candidate vaccine was 
immunogenic as assessed by seroconversion and vaccine induced T cell responses in most 
vaccine recipients. (Modjarrad et al. 2019).  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 20 of 116 The expression of functional prefusion stabilized S -protein delivered by mRNA was evaluated in 
HEK293 cells (Figure 1).
 
Figure 1. The SARS -CoV -2 full-length stabilized spike protein (S -2P) delivered by mRNA is 
expressed on the cell surface.  HEK293T cells were transfected with mRNA en coding for the 
SARS -CoV -2 S-2P protein. After 24hrs, cell flow cytometry was used to measure surface 
expression by staining with (A) mouse polyclonal antibody raised against SARS S -2P protein; 
(B) a flag -tagged ace2 receptor and anti -flag antibody; (C) a S ARS S -protein monoclonal 
antibody (mAb -103) that cross -reacts with SARS -CoV -2 S-2P; (D) a SARS S protein -specific 
monoclonal antibody (mAb 16)  that does not bind SARS -CoV -2 was used as a negative control . 
The expressed prefusion, stabilized S protein binds to the its proposed receptor, human ACE -2, 
and is recognized by cross reactive antibodies to SARS S protein. It is therefore anticipated that 
mRNA -1273 will generate robust immune responses to the SARS -CoV -2 S protein.  
2.1.1 Public Readiness and Emergency Preparedness Act  
The study vaccine, mRNA -1273, and the efforts for this clinical trial are covered under the 
Public Readiness and Emergency Preparedness Act (PREP Act) and the Declaration issued by 
the Secretary of the U.S. Department of Health a nd Human Services under that Act. Under the 
PREP Act and the Declaration, covered persons (such as manufacturers, distributers, program 
planners, and other qualified persons who prescribe, administer or dispense study product) are 
immune from liability fro m the administration, or use of a covered countermeasure, such as 
mRNA -1273. The PREP Act provides immunity for covered persons from liability, unless the 
injury was caused by willful misconduct. The Declaration invoking the PREP Act for COVID -19 
covered c ountermeasures was made on March 10, 2020 and is retroactively effective from 
February 4, 2020.  
The PREP Act also established the Countermeasures Injury Compensation Program (CICP) to 
provide compensation for serious injuries or death that occur as the dir ect result of the 
administration or use of certain countermeasures. Any requests for compensation must be filed 
within one year of the administration or use of the covered countermeasure. Requests for 
Benefits must be made to the Health Resources and Servi ces Administration’s (HRSA) 
Countermeasures Injury Compensation Program (http://www.hrsa.gov/cicp/) by filing a Request 
for Benefits Form and all required medical records and supporting documentation. Additional 
information on filing a Request for Benefits  is available on the CICP’s website at 
http://www.hrsa.gov/cicp/. Compensation may then be available for reasonable and necessary 

DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 21 of 116 medical benefits, lost wages and/or death benefits to eligible individuals for certain injuries in 
accordance with regulations  published by the Secretary of HHS (found at 42 CFR part 110).  
If an individual suffers a serious physical injury or death from the administration or use of a 
covered countermeasure in this study, the individual, the individual’s legal or personal 
represen tative, the administrator/executor of a deceased individual’s estate, or certain survivors 
may request benefits from the CICP. A serious physical injury means an injury that warranted 
hospitalization (whether or not the person was actually hospitalized) or  that led to a significant 
loss of function or disability. The CICP is the payer of last resort. This means that it only covers 
expenses or provides benefits that other third -party payers (such as health insurance, the 
Department of Veterans Affairs, or Wo rkers’ Compensation programs) do not have an obligation 
to pay.  
If the Secretary of HHS does not make a final determination on the individual’s request within 
240 days, or if the individual decides not to accept the compensation, the injured individual or 
his representative may pursue a tort claim in the US District Court for the District of Columbia, 
but only if the claim involves willful misconduct and meets the other requirements for suit under 
the PREP Act. Any award is reduced by any public or private insurance or worker’s 
compensation available to the injured individual. Awards for non -economic damages, such as 
pain, suffering, physical impairment, mental anguish, and loss of consortium are also limited. If 
the individual accepts compensation, or if th ere is no willful misconduct, then the individual does 
not have a tort claim that can be filed in a US Federal or a State court.  
2.2 Risk/Benefit Assessment  
2.2.1 Known Potential Risks  
The potential risks of participating in this trial are those associated with havi ng blood drawn, IM 
injection, leukapheresis (only for those subjects consented for leukapheresis), possible reactions 
to mRNA -1273 , and breach of confidentiality.  
Drawing blood may cause transient discomfort and fainting. Fainting is usually transient and 
managed by having the subject lie down and elevate his/her legs. Bruising at the blood draw site 
may occur but can be prevented or lessened by applying pressure to the blood draw site for a few 
minutes after the blood is taken. IM injection may also cause transient discomfort and fainting. 
Drawing blood and IM injection may cause infection. The use of aseptic (sterile) technique will 
make infection at the site where blood will be drawn or where the vaccination will be given 
extremely unlikely.  
Risks of Leuk apheresis  (only for those subjects consented for leukapheresis)  
Leukapheresis may be associated with pain, bruising, and discomfort in the arms at the site of 
needle placement. Vasovagal episodes, characterized by transient hypotension, dizziness, nausea, 
and rarely syncope, are seen in less than 5% of procedures. Additional risks include increased 
pulse, seizures, and blood loss. Anticoagulants added to prevent the blood from clotting may lead 
to a sour taste in the mouth, mild muscle cr amps and/or tingling sensation around the mouth, feet 
or hands. These reactions may be seen to a mild degree in 30 -50% of leukapheresis procedures 
and can usually be relieved by slowing or temporarily interrupting the procedure or 
administering calcium car bonate tablets.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 22 of 116 A temporary decrease (1 -2 days) in red blood cell count is common.  Rarely, machine 
malfunction or if the procedure needs to be stopped before completion may result in the loss of a 
half pint to a pint of blood. Leukapheresis  does not affect the blood’s ability to form clots in the 
event of subsequent cuts or injuries.  
There may be additional risks that are unknown at this time.  
Preclinical evaluations will occur in parallel with th is phase I clinical trial . However, in suppor t 
of the development of mRNA -1273 for prophylaxis against SARS -CoV -2 infection, nonclinical 
immunogenicity, a Good Laboratory Practice ( GLP )-compliant , repeat dose toxicology study, as 
well as biodistribution and genotoxicity studies have been completed wi th similar mRNA -based 
vaccines formulated in SM -102-containing LNPs.  
Risks of mRNA -1273  
In preclinical models, the aggregate toxicity profile observed across multiple repeat -dose 
toxicology studies at IM doses ranging from 9 to 150 mcg/dose administered on ce every 2 weeks 
for up to 6 weeks is generally consistent and considered as being representative of mRNA 
vaccines formulated in the same SM -102 LNP formulation, differing only by the encapsulated 
mRNA sequence(s). All doses administered were tolerated and  the lowest no -observed -adverse -
effect -level (NOAEL) determined across the aggregate of the completed studies was 89 
mcg/dose.  
In a non -GLP biodistribution study with mRNA -1647, a similar mRNA -based vaccine 
formulated in SM -102-containing LNPs , only a rela tively small fraction of the administered 
mRNA -1647 dose distributed to distant tissues, and the mRNA constructs did not persist past 1 
to 3 days in tissues other than the injection site, lymph nodes, and spleen in male Sprague 
Dawley rats.  
In GLP -complian t studies, SM -102, the novel lipid component of the LNP formulation, was not 
genotoxic when tested in a bacterial reverse mutation (Ames) test or an in vitro micronucleus 
test. An in vivo micronucleus study in Sprague Dawley rats showed that a similar mRNA -based 
vaccine formulated in SM -102-containing LNPs (mRNA -1706, which encodes the ZIKV pre -
membrane and envelope polypeptide [different from the sequence encoded in mRNA -1893]), 
induced statistically significant increases in micronucleated immature erythro cytes in male rats at 
both 24 and 48 hours and in female rats at 48 hours only; however, there was no clear dose 
response, and the increases were generally weak and associated with minimal bone marrow 
toxicity. These observations indicate that the risk to humans after IM administration is low due to 
minimal systemic exposure.  
In a non -GLP study in Sprague Dawley rats to characterize the potential toxicity of mRNA -1273 
at clinically relevant doses, mRNA -1273 exhibited clinical signs consisting of transient d ose-
dependent injection site edema with or without hindlimb impairment at approximately 24 hours 
post-dose that generally resolved within 7 days after dose administration. mRNA -1273 -related 
clinical pathology changes associated with inflammation, including  increased neutrophils, 
eosinophils, and/or globulin, were observed as well as other mild mRNA -1273 -related changes 
including decreased red cell mass, reticulocytes, and lymphocytes and increased creatinine, 
triglyceride, cholesterol, and/or glucose. There  were no mRNA -1273 -related effects on body 
weight. In general, these changes are consistent with the results from previous GLP rat toxicity 
studies conducted with other mRNAs formulated in SM -102 LNP.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 23 of 116 Information on possible risks and adverse reactions ass ociated with IM administration of mRNA -
1273 is derived from animal studies with mRNA -1273, interim safety information from this 
ongoing phase I clinical trial of mRNA -1273 ([STUDY_ID_REMOVED]), interim findings from the Phase 3 
placebo -controlled clinical trial o f mRNA -1273 (NCT04 470427 , the COVE study ), and the LNP 
components or animal and human studies of similar mRNA -based vaccines (mRNA -1647 and 
mRNA -1653).  
As of March 2020, there ha d been 8 non-SARS -CoV -2 clinical studies initiated across 
Moderna’s infectious disease vaccine platform with over 1,000 subjects receiving at least one 
dose of an mRNA vaccine . mRNA vaccines with SM -102-containing lipid formulations are 
currently being evaluated in 3 indications:  prophylactic protection against human CMV 
([STUDY_ID_REMOVED]),  hMPV/PIV3 ( [STUDY_ID_REMOVED] ), and Zika virus ( [STUDY_ID_REMOVED] ). In three Phase 
1 studies as of January 6, 2020, approximately 365 subjects were dosed with either an SM -102-
containing lipid vaccine or placebo  (doses ranging from 10 mcg to 300 mcg). Of the 365 subjects 
dosed 264 subjects experienced at least 1 solicited AE. The most common solicited events were 
pain 28% of total events reported, headache 15%, fatigue 15%, myalgia 13%, arthralgia 9%, 
nausea 7%, chills 6%, fever, 4%, erythema, 2%, and swelling 2%. The majority of the events 
were grade 1 -2 with approximately 9% being reported as grade 3; the most common grade 3 
events were pain, myalgia, fatigue, headache, and chills. Grade 3 events were typically recorded 
on Day 1 or Day 2 following injection with most occurring on Day 2 and resolving by Day 6.  
In an hMPV/PIV3 Phase 1 study, which is unblinded, unsolicited related AEs included mild to 
moderate chills, hot flushes, diarrhea, pyrexia, temperature int olerance, elevated WBC count, 
headache and erythematous rash, as well as severe injection site pain, prolonged PT and myalgia. 
All of the severe events occurred at the 300 mcg x 2 dose level. In the blinded Phase 1 CMV 
study, unsolicited related AEs in mor e than 2 subjects included chills (19 subjects, or 10.5%); 
fatigue (10 subjects, 5.5%);, lymphadenopathy, injection site pain, and pyrexia, (9 subjects each, 
5.0%); arthralgia (8 subjects, 4.4%); myalgia (7 subjects, 3.9%); headache (5 subjects, 2.8%);, 
diarrhea (4 subjects, 2.2%); and injection site bruising ( 3 subjects, 1.7%). Of these AEs, severe 
events were reported in 3 of 19 subjects with chills, 5 of 10 subjects with fatigue, 4 of 9 subjects 
with pyrexia, 4 of 8 subjects with arthralgia, and 4 of 7 subjects with myalgia. There were no 
related SAEs reported in the Phase 1 CMV, hMPV/PIV3 or Zika virus vaccine studies.  
In addition, other AEs that have been generally associated with approved IM administered 
vaccines have included mild hematological and c linical chemistry abnormalities, which are 
usually reversible.  
To date, i nterim safety data from this phase I clinical trial of mRNA -1273  indicate that solicited 
adverse reactions within 7 days after the first or second vaccination were reported by over 90 % 
of the 120 subjects (Jackson, LA, et al. 2020; Anderson, EJ, et al, 2020). Most were mild or 
moderate in severity. Moderate or severe solicited adverse reactions were reported more 
commonly after the second vaccination compared with the first and with hi gher dosages. Severe 
solicited systemic adverse reactions were reported in 6 (5%) of subjects. Evaluation of safety 
clinical laboratory values of grade 2 or higher and unsolicited adverse events revealed no 
patterns of concern.  No deaths or SAEs related to  mRNA -1273 have been reported in this trial 
and no prespecified halting rules for vaccination were met. Three study subjects discontinued 
due to an AE. One subject in the 25 mcg vaccination group (age stratum: 18 to 55 years) reported 
mild urticaria (hives  on lower extremities) on Day 5 after Dose 1. The event was deemed related 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 24 of 116 to mRNA -1273 by the investigator. One subject in the 250 mcg vaccination group (age stratum: 
18 to 55 years) reported mild oropharyngeal pain (sore throat) on Day 24 after Dose 1 an d one 
subject in the 100 mcg vaccination group (age stratum: 56 to 70 years) reported moderate 
maculopapular rash on Day 9 after Dose 1. These two events were deemed not related to mRNA -
1273 by the investigator.  
Participants 18 year s of age and older recei ved a 2 -dose regimen (0, 28 days) of mRNA -1273 in 
the Phase 3 placebo -controlled clinical trial (COVE) conducted in the United States , and were 
followed for the development of COVID -19 disease. Interim findings indicated that vaccine 
recipients had higher rates of local reactions (e.g., pain, erythema, swelling) and systemic 
reactions (e.g., headache, fatigue, myalgia) than placebo recipients and that most reactions were 
mild to moderate and resolved over 1 -3 days (Baden LR, et al. 2020). The severity of th e 
solicited systemic events increased after the second dose of mRNA -1273, with an increase in 
events of moderate severity of from 16.5% after the first dose to 38.1% after the second dose , 
and with an increase in events graded as severe of from 2.9% after the first dose to 15.8% after 
the second dose. Both solicited injection -site and systemic adverse events were more common 
among younger subjects (18 to <65 years of age) than among older subjects (≥65 years of age). 
The frequency of severe unsolicited even ts was similar in the placebo (1.3%) and vaccine (1.5%) 
groups, as were the frequencies of medically attended adverse events (9.7% vs. 9.0%) and 
serious adverse events (0.6% in both groups).  Three deaths occurred in the placebo group (one 
from intraabdomin al perforation, one from cardiopulmonary arrest, and 1 from severe systemic 
inflammatory syndrome in a subject with chronic lymphocytic leukemia and diffuse bullous 
rash) and 2 in the vaccine group (one from cardiopulmonary arrest and one by suicide). Bell ’s 
palsy occurred in the vaccine group (3 subjects [<0.1%]) and the placebo group (1 subject 
[<0.1%]) during the observation period of the trial (more than 28 days after injection).  
Hypersensitivity reactions occurred in 1.5% and 1.1% of subjects in the va ccine and placebo 
groups, respectively.  
Following the issuance  of the Emergency Use Authorization  (EUA) , rare anaphylactic -like 
reactions have occurred among recipients of both mRNA COVID -19 vaccines (Pfizer -BioNTech 
and Moderna). As of January 22, 2021, 1 0 cases of anaphylaxis , with no associated deaths,  have 
been reported in patients who received mRNA -1273 under EUA ( CDC COVID -19 Response 
Team; Food and Drug Administration , 2021) . Based on the clinical experience to date with 
mRNA -based vaccines, mRNA -1273 should not be administered to individuals with a known 
hypersensitivity to any component of the study product, including polyethylene glycol ( PEG ). 
Recently , myocarditis and peri carditis have been reported rarely following  vaccination with the 
Moderna COVID -19 EUA Vaccine. Although causality has not been established, the majority of 
cases have been in young males (<30 years old), occurr ing a few days to up to a week after the 
vacc ination and seen more commonly after the second dose . However, cases have been reported 
in older males, females, as well as after the first dose of vaccine . Most  cases  are generally  mild , 
and individuals tend to recover within a short time after  treatment . However, l ong term outcomes 
are un known.  Additionally, i t is not known whether the risks of myocarditis or pericarditis are 
increased following additional  doses of vaccine.  
Subjects will be informed of the potential risk of myocarditis  or pericarditis and be advised to 
monitor for symptoms of myocarditis  or pericarditis, including chest pain, shortness of breath, 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 25 of 116 tachycardia, or palpitations. Subjects will be encouraged to immediately contact research staff 
and their medical provider s if these symptoms occ ur following a study vaccination.  
Several animal studies with experimental whole -virus inactivated and subunit vaccines of other 
coronaviruses have shown enhanced immunopathology in a greater number of vaccinated 
animals compared to controls upon subsequen t virus infection. These experimental vaccines 
often exhibited Th2 -biased immune responses or elicited antibodies that had poor neutralizing 
activity against the virus. In mice vaccinated with two doses of mRNA -1273, a balanced 
antibody response resulting in high titers of both IgG1 and IgG2a was observed. A predominant 
Th2-focused immune response with only IgG1 responses was not observed.  Data from mice and 
non-human primates have not identified risk with mRNA -1273  (Corbett KS et al, N Engl J Med 
2020; Cor bett KS et al, Nature 2020) . 
Most people during their lifetimes have likely been infected with one or more of the 4 endemic 
strains of human coronaviruses (hCoV 229E, NL63, OC43, and HKU1) that circulate globally 
and are responsible for 10 -30% of mild to moderate upper respiratory tract infections. Despite 
the likelihood of cross -reactive antibody responses with poor functional activity, no evidence of 
enhanced CoV disease in humans has ever been reported.  
Interim immunogenicity data from this phase I clinical trial of mRNA -1273 have indicated that 
vaccination induced type 1 helper T  cell (Th1) –biased CD4+ T cell responses and low or 
undetectable Th2 or CD8+ T cell responses  (Jackson LA et al, 2020; Anderson EJ et al, 2020) . 
Additionally, no enhancement of respiratory disease has occurred in recipients of mRNA 
vaccines that ha d breakthrough SARS -CoV -2 infections (Baden LR et al, 2020; Polack FP et al, 
2020) . Importantly, of the 30 protocol -defined severe cases of COVID -19 that occurred in the 
Phase 3 placebo -controlled clinical trial of mRNA -1273 (COVE) , all 30 occurred in the placebo 
group  (Baden LR et al, 2020) . Thus, to date , enhanced SARS -CoV -2 respiratory disease has not 
been observed after mRNA -1273  administration.  
Risks to Privacy  
Subjects will be asked to provide personal health information (PHI). All attempts will be made to 
keep this PHI confidential within the limits of the law. However, there is a chance that 
unauthorized persons will see the subject’s PHI. All study records wi ll be kept in a locked file 
cabinet or maintained in a locked room at the participating site . Electronic files will be password 
protected . Only people who are involved in the conduct, oversight, monitoring, or auditing of 
this trial will be allowed access to the PHI that is collected. Any publications from this trial will 
not use information that will identify subjects by name. Organizations that may inspect and/or 
copy research records maintained at the participating site  for quality assurance (QA) and dat a 
analysis include groups such as the IRB, NIAID and the FDA.  
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required 
by US Law. This web site will not include information that can identify subjects.  
There may b e other risks, discomforts or side effects that are unknown at this time.  
Risks of Genetic Testing  
Any genetic data generated will be kept private. There may be a risk that information resulting 
from research genetic testing could be misused for discriminatory purposes. However, state and 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 26 of 116 federal laws provide protections against genetic discrimination. Researchers will need to 
maintain confidentiality in order to be granted access to genetic information.  
2.2.2 Known Potential Benefits  
There is no direct  benefit to the subjects. There is potential benefit to society resulting from 
insights gained from participation in this study due to the emerging threat of the SARS -CoV -2 
outbreak. Vaccination using mRNA -1273 may or may not provide protection against inf ection 
by SARS -CoV -2. The duration of any such protection is currently unknown.  
As outlined in Section 12.2, data from the Phase 3 placebo -controlled clinical trial  of mRNA -
1273 (COVE) suggests 94.1% efficacy of the vaccine when administered at 100 mcg versus 
placebo against SARS -CoV -2 infection when assessed on November 25, 2020  (Baden LR et al, 
2020) . The efficacy of other doses of mRNA -1273 (e.g., 25 , 50, or 250 mcg) is not known. 
Although declines in binding and neutralizing antibodies are observed over time, 100 mcg of 
mRNA -1273 has the potential to provide durable humoral immunity  (Widge AT et al, 2020) . 
3. OBJECTIVES  AND  ENDPOINTS  
Table 5: Objectives and Endpoints (Outcome Measures)  
OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES ) 
Primary   
• To evaluate the safety and reactogenicity 
of a 2 -dose vaccination schedule of 
mRNA -1273 , given 28 days apart, across 
5 dosages in healthy adults.  • Frequency and grade of each solicited 
local and systemic reactogenicity AE 
during a 7 -day follow -up period post each 
vaccination.  
• Frequency and grade of any unsolicited 
AEs during the 28 -day follow -up period 
post each vaccination.  
• Frequency of any SAEs, Protocol 
Specified AESIs, NOCMCs, and MAAEs 
from Day 1 to Day 394.  
Secondary   
• To evaluate the immunogenicity as 
measured by IgG ELISA to the SARS -
CoV -2 S (spike) protein following a 2 -
dose vaccination schedule of mRNA -1273  
at Day 57.  • GMT of antibody at Day 57.  
• Percentage of subjects who seroconverted, 
defined as a 4 -fold change in antibody 
titer from baseline.  
• The GMFR in IgG titer from baseline.  
Exploratory   
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 27 of 116 OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES ) 
• To evaluate the immunogenicity as 
measured by IgG ELISA to the SARS -
CoV -2 S (spike) protein following a 2 -
dose vaccination schedule of mRNA -1273  
at all timepoints, other than Day 57.  • GMT of antibody at each timepoint.  
• Percentage of subjects who seroconverted 
at each timepoint.  
• The GMFR in IgG titer from baseline  at 
each post -vaccination timepoint . 
• To evaluate the immunogenicity as 
measured by IgM and IgA ELISA to the 
SARS -CoV -2 S (spike) protein following 
a 2-dose vaccination schedule of mRNA -
1273  given 28 days apart.  • GMT at each timepoint.  
• Percentage of subjects who seroconverted 
at each timepoint.  
• The GMFR in Ig M and IgA t iter from 
baseline  at each post -vaccination 
timepoint . 
• To evaluate the immunogenicity as 
measured by pseudovirus neutralization 
following a 2 -dose vaccination schedule 
of mRNA -1273  given 28 days apart.  • GMT of Neut antibody at each timepoint.  
• Percentage of subjects who seroconverted, 
defined as a 4 -fold change in Neut 
antibody titer from baseline at each 
timepoint.  
• The GMFR Neut antibody titer from 
baseline  at each post -vaccination 
timepoint . 
• To evaluate the immunogenicity as 
measured by live wild-type SARS -CoV -2 
neutralization following a 2 -dose 
vaccination schedule of mRNA -1273 
given 28 days apart.  • GMT of Neut antibody at each timepoint.  
• Percentage of subjects who seroconverted, 
defined as a 4 -fold change in Neut 
antibody titer from baseline at each 
timepoint.  
• The GMFR in Neut antibody titer from 
baseline  at each post -vaccination 
timepoint . 
• To assess, in at least a subset of samples, 
the SARS -CoV -2 S protein -specific T cell 
responses.  • Magnitude, phenotype, and percentage of 
cytokine producing S protein -specific T 
cells, as measured by flow cytometry at 
different timepoints post  vaccination  
relative to baseline . 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 28 of 116 4. STUDY  DESIGN  
4.1 Overall Design  
This is a phase I , open -label, dose -ranging clinical trial in males and non -pregnant females, ≥18 
years of a ge, who are in good health and meet all eligibility criteria. This clinical trial is designed 
to assess the safety, reactogenicity and immunogenicity of mRNA -1273 manufactured by 
ModernaTX, Inc. mRNA -1273 is a novel LNP -encapsulated mRNA -based vaccine that  encodes 
for a full -length, prefusion stabilized spike (S) protein of SARS -CoV -2. Enrollment will occur at 
up to three  domestic clinical research sites. 
Table  6: Treatment Arms  
Cohort  Sample Size  Stratum  
(Years of Age)  First and Second Dose  
1 15 18-55 25 mcg mRNA -1273  
2 15 18-55 100 mcg mRNA -1273  
3 15 18-55 250 mcg mRNA -1273  
4 10 56-70 25 mcg mRNA -1273  
5 10 56-70 100 mcg mRNA -1273  
6* 10 56-70 250 mcg mRNA -1273  
7 10 ≥71 25 mcg mRNA -1273  
8 10 ≥71 100 mcg mRNA -1273  
9* 10 ≥71 250 mcg mRNA -1273  
10 15 18-55 50 mcg mRNA -1273  
11 10 56-70 50 mcg mRNA -1273  
12 10 ≥71 50 mcg mRNA -1273  
13* 15 18-55 10 mcg mRNA -1273  
*Cohorts 6, 9 and 13 were not enrolled.  
Up to o ne hundred and fifty-five ( 155) subjects will be enrolled into one of thirteen cohorts ( 10 
mcg, 25 mcg, 50 mcg, 100 mcg, or 250 mcg). Subjects will receive an IM injection (0.5 mL) of 
mRNA -1273  on Days 1 and 29 in the deltoid muscle and will be followed through 12 months  
post second  vacc ination (Day 394). The second dose of vaccine (0.5 mL) will be administered 
preferably in the same arm used for the first dose.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 29 of 116 Follow -up visits will occur 1, 2 and 4 weeks post each vaccination (Days 8, 15, 29, 36, 43, and 
57), as well as 3, 6 and 12 mont hs post second  vaccination (Days 119, 209 and 394).  
Reactogenicity will be assessed at these visits , as well as blood will be drawn for 
immunogenicity assays. Additional safety and reactogenicity data will be solicited via telephone 
calls to subjects 1 and  2 days post each vaccination (Days 2, 3, 30, and 31).  
To determine early safety signals for this phase I  clinical trial , vaccination will proceed in a 
staged fashion. Sentinel subject dosing will begin with 4 subjects in cohort 1 (25 mcg). The 4 
sentinel subjects for cohort 2 (100 mcg) will be enrolled no earlier than one day after enrollment 
of the last of the 4 sentinel subjects in cohort 1. If no halting rules have been met after the 8 
sentinel subjects have completed Day 5, then full enrollment will pr oceed first with the 
remaining subjects in cohort 1, followed by the remaining subjects in cohort 2 without 
interruption. If no halting rules have been met after all subjects in cohort 2 have completed Day 
8, then dosing of 4 sentinel subjects will begin i n cohort 3. If no halting rules have been met after 
the 4 sentinel subjects in cohort 3 have completed Day 5, then full enrollment of cohort 3 will 
proceed.  
If no halting rules have been met after all subjects in cohorts 1 and 2 have completed Day 8, 
dosing will begin for cohorts 4 (25  mcg; 56 -70 years of age) and 5 (100 mcg; 56 -70 years of 
age). If no halting rules have been met after all subjects in cohorts 4 and 5 have completed Day 
8, dosing will begin for cohorts 7 (25 mcg; ≥71 years of age) and 8  (100 mcg; ≥71 years of age).  
Based on the interim immunogenicity data available as of May 15, 2020, enrollment into cohorts 
6 and 9 (250 mcg; 56 -70 years of age and ≥71 years of age) will be deferred in order to explore 
lower dosages. Therefore, enrollment of cohorts 10 -12 (50 mcg; 18 -55 years of age, 56 -70 years 
of age and ≥71 years of age) will be prioritized. Subjects will be enrolled simultaneously in 
cohorts 10 -12; there will be no staging. To further explore dosage sparing, cohort 13 (10 mcg  
dose; 18 -55 years of age) may be enrolled. A decision regarding the enrollment of cohorts 6, 9 
and 13 will be made after review of interim immunogenicity data from cohorts 1 -5, 7, 8, and 10 -
12. 
If no halting rules have been met after all subjects in cohor ts 5 and 8 have completed Day 8, 
dosing will begin concurrently  for cohorts 10 -12. If no halting rules have been met after all 
subjects in cohorts 3, 7 and 8 have completed Day 8, dosing may begin for cohort 6, if enrolled. 
If no halting rules have been me t after all subjects in cohort 6 have completed Day 8, dosing may 
begin for cohort 9, if enrolled.  
For public health reasons the following early data reviews by the study team are anticipated:  
• Sentinel  subjects  in cohorts 1 and 2, ELISA IgG data through Da y 29;  
• All subjects in cohorts 1 and 2, ELISA IgG data through Day 29;  
• Sentinel  subjects  in cohort 3, ELISA IgG data through Day 29;  
• All subjects in cohort 3, ELISA IgG data through Day 29;  
• All subjects in cohorts 4, 5, 7 and 8, ELISA IgG data through Day 2 9; 
• All subjects in cohorts 10-12, ELISA IgG data through Day 29;  
• All subjects in cohort 13, ELISA IgG data through Day 29  (if cohort is enrolled) ; 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 30 of 116 • All subjects in cohorts 6 and 9, ELISA IgG data through Day 29 (if cohorts are enrolled) ; 
• Sentinel  subjects  in cohorts 1 and 2, ELISA IgG data through Day 57;  
• All subjects in c ohorts 1 and 2, ELISA IgG data through Day 57;  
• Sentinel  subjects  in cohort 3, ELISA IgG data through Day 57;  
• All subjects in c ohort 3, ELISA IgG data through Day 57 ; 
• All subjects in cohorts 4, 5, 7 and 8, ELISA IgG data through Day 57;  
• All subjects in cohorts 10-12, ELISA IgG data through Day 57;  
• All subjects in cohort 13, ELISA IgG data through Day 57  (if cohort is enrolled)  
• All subjects in cohorts 6 and 9, ELISA IgG data through Day  57 (if cohorts are enrolled) . 
• Additional data review of immunogenicity may be performed to inform public health 
decisions.  
• AEs and SAEs by cohort can be reviewed as necessary.  
• After Day 57 of the last subject in cohort 3, all available data can be reviewe d when 
applicable.  
• After Day 57 of the last subject in cohort 8, all available data can be reviewed when 
applicable . 
• After Day 57 of the last subject in cohort 1 2, all available data can be reviewed when 
applicable . 
• After Day 57 of the last subject in cohort s 6 and 9  (if cohorts are enrolled) , all available 
data can be reviewed when applicable.  
• After Day 57 of the last subject in cohort 13  (if cohort is enrolled) , all available data can 
be reviewed when applicable.  
Data  may be disseminated to public hea lth officials and partners  as needed  and included in 
publications and presentations to inform the global scientific community . 
Reactogenicity will be measured by the occurrence of solicited injection site and systemic  
reactions from the time of each vaccination through 7 days post  each vaccination. Unsolicited 
non-serious AEs will be collected from the time of each vaccination through 28 days post each 
vaccination. SAEs, Protocol Specified AESIs, NOCMCs , and MAAEs, will be collected through 
12 months after the second  vaccination  (Day 394) . 
Clinical safety laboratory evaluations will be performed at screening, as well as immediately 
prior to and 7 days post each vaccination (Days 1, 8, 29, and 36). 
Evaluation of immunogenicity will include quantitation of antibodies to the SARS -CoV -2 S 
protein at multiple timepoints post vaccination as measured by ELISA, pseudovirus and live 
wild-type virus neutralization assays. In addition, exploratory studies to characterize T cell 
responses are planned. Venous blood will also be collected at multiple timepoints post 
vaccination for the secondary research use of serum, plasma and PBMCs.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 31 of 116 To support development of diagnostics, therapeutics and vaccines, a subset of subjects enrolled 
in cohorts 2, 3, 5, 10, and 11 may und ergo leukapheresis to collect additional samples for 
secondary research. If enrollment in cohort 6 proceeds, a subset of subjects in this cohort may 
also undergo leukapheresis.  
Based on interim immunogenicity and reactogenicity data, Cohorts 6, 9 and 13 we re not 
enrolled.  
After the IND is in effect, IRB review  and approval,  and site activation, the participating site will 
begin recruitment outreach efforts, which can include fliers, letters, telephone calls, etc. 
Information regarding this trial may be prov ided to potential subjects who have previously 
participated in other vaccine trials conducted at the participating site. Other forms and/or 
mechanisms of recruitment may also be used. The IRB will approve the recruitment process and 
all materials prior to use. Screening can occur up to 42 days prior to the first dose.  
Schedule of assessments are found in Section 1.2, Schedule of Activities  for the Main Study . 
Dose escalation or dose -ranging details are found in Section 6.1.2 , Dosing and Administration . 
Full details of the interim analysis are found in Section 9.4.6 , Planned Interim and Early 
Analys es. 
4.2 Scientific Rationale for Study Design  
This phase I clinical trial  is designed as an open -label study, without a placebo arm . Given the 
small sample size, t he use of a placebo group is unlikely to improve understanding of AEs. 
Additionally, having the study unblinded will facilitate the need for rapid review and 
dissemination of study data for public health reasons.  
4.3 Justification for Dose  
No human trials of mRNA -1273 have been conducted to date. Preclinical evaluations will occur 
in parallel with th is phase I  clinical trial . In several ongoing Phase 1  dose -ranging studies 
(mRNA -1653, a combination vaccine against human metapneumovirus, hMPV and huma n 
parainfluenza type 3; mRNA -1647 and mRNA -1443, both CMV vaccines ; mRNA -1893 against 
Zika virus ) dosage levels of mRNA between 10  and 300 mcg were administered IM as one -, 
two- or three -dose vaccination schedules. Immunogenicity and reactogenicity increas ed in a 
dose -dependent manner. The dosage levels proposed for this trial (10 mcg, 25 mcg, 50 mcg, 100 
mcg, and 250 mcg) are within the range of previous trials. However, in support of development 
of mRNA -1273 for prophylaxis against SARS -CoV -2 infection, n onclinical immunogenicity, 
biodistribution, and safety studies have been completed with similar mRNA -based vaccines 
formulated in SM -102-containing LNPs . 
4.4 Optional Third mRNA -1273 Vaccination Substudy  
All subjects in this clinical trial were scheduled to re ceive two mRNA -1273 vaccinations, 28 
days apart, at dosages of 25, 50, 100, or 250 mcg (seeTable 1), with the last scheduled follow -up 
visit occurring at 365 days after the second vaccination (see Table 4). During the course of the 
main study , interim efficacy data from a Phase 3 placebo -controlled clinical trial of mRNA -1273 
(COVE) , administered as 2 doses of 100 mcg given 28 days apart, demonstrated vaccine efficacy 
of 94.1% (95% CI: 89. 3%, 96.8%) for the prevention of symptomatic, confirmed COVID -19 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 32 of 116 (Baden, LR, et al. 2020). After review of the interim safety and efficacy data  from that clinical 
trial, the FDA granted on December 18, 2020 an Emergency Use Authorization (EUA) for the 
mRNA -1273 vaccine in adults 18 years of age and older.  
To potentially enhance and extend the duration of protection provided by the 2 -dose vaccination 
schedule of mRNA -1273 administered in the main study , and to gain an understanding of the 
immune responses to a third dose of mRNA -1273, subjects in the main study may participate  in 
an optional third mRNA -1273 vaccination substudy, detailed in Section 12, Appendix A . 
Substudy subjects will receive a third mRNA -1273 vaccination, administered via an IM injection 
at a dosage of 100 mcg/0.5  mL, given six to twelve months after receipt of their second 
vaccination in the main study.  Subst udy subjects will be followed for safety , reactogenicity,  and 
immunogenicity endpoints through 12 months post third vaccinatio n (Substudy Day 366). 
To be eligible to participate in the substudy, subjects must have received both the first and 
second mRNA -1273 vaccinations in the main study. Other eligibility criteria are specified in 
Appendix A . Subjects who received only one mRNA -1273 vaccination in the main study will be 
advised to receive an FDA authorized or approved COVID -19 vaccine, according to the 
recommended schedule, when available to them outside of this trial , unless they have a 
contraindication to COVID -19 vaccines that are available.  
Subjects who elect not to participate in the opti onal third mRNA -1273 vaccination substudy or 
are not eligible for the substudy will continue to be followed according to the Schedule of 
Activities for the main study ( see Table 4) with the Final Study Visit 14 occurring at Day 394 
(±14 days).  
Dosing for the optional third mRNA -1273 vaccination substudy  is found in Table 13. 
Schedule of assessments for the optional third mRNA -1273 vaccination substudy is found in 
Table 14. 
Statistical Considerations for the optional third mRNA -1273 vaccination substudy  are found in  
Section 12.11 . 
5. STUDY  POPULATION  
Up to one hundred and fifty-five (155) males and non -pregnant females, ≥18 years of age, who 
are in good health and meet all eligibility criteria will be enrolled . The target population should 
reflect the community at large. The estimated time from initiation of enrollment  to complete 
enrollment in this clinical trial is approximately 16 weeks. Information regarding this trial may 
be provided to potential subjects who have previously participated in other vaccine trials 
conducted at the participating site. Other forms and/or mechanisms of recruitment may also be 
used. The IRB will approve the recruitment process and all materials prior to use.  Screening can 
occur up  to 42 days prior to the first dose.  
Subject Inclusion and Exclusion Criteria must be confirmed by a study clinician , licensed to 
make medical diagnoses and listed  on the  Form FDA  1572 as the participating site  PI or 
appropriate sub -investigator . No exempt ions are granted on Subject Inclusion  or Exclusion 
Criteria in DMID -sponsored studies.  
5.1 Inclusion Criteria  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 33 of 116 A subject must meet all of the following criteria to be eligible to participate in this study:  
1. Provides written informed consent prior to initiation o f any study procedures.  
2. Be able to understand and agrees to comply with planned study procedures and be 
available for all study visits.  
3. Agrees to the collection of venous blood per protocol.  
4. Male or non -pregnant female, ≥18 years of age at time of enrollme nt. 
5. BMI 18.0-35.0 kg/m2, inclusive  (<56 years of age), at screening; BMI  18.0-30.0 kg/m2, 
inclusive (≥56 years of age) , at screening.  
6. Women of childbearing potential1 must agree to use or have practiced true abstinence2 or 
use at least one acceptable primary form of contraception .3,4 
Note: These criteria are applicable to females in a heterosexual relationship and child -
bearing potential (i.e., the criteria do not appl y to subject s in a same sex relationship ). 
1Not of childbearing potential – post-menopausal females (defined as having a history of 
amenorrhea for at least one year) or a documented status as being surgically sterile 
(hysterectomy, bilateral oophorectomy, tubal ligation/salpingectomy, or Essure® 
placement).  
2True abstinence is 10 0% of time no sexual intercourse (male’s penis enters the female’s 
vagina). (Periodic abstinence [e.g. , calendar, ovulation, symptothermal, post -ovulation 
methods] and withdrawal are not acceptable methods of contraception).  
3Acceptable forms of primary contraception include monogamous relationship with a 
vasectomized partner  who has been vasectomized for  180 days or more prior to the 
subject ’s first vaccination , intrauterine devices, birth control pills, and 
injectable/implant able/insertable hormonal birth control products.  
4Must use at least one acceptable primary form of contraception for at least 30 days 
prior to the first vaccination and at least one acceptable primary form of contraception 
for 60 days after the last vaccin ation.  
7. Women of childbearing potential must have a negative urine or serum pregnancy test 
within 24 hours prior to each vaccination.  
8. Male subjects  of childbearing potential5: use of condoms to ensure effective 
contraception with a female  partner of childbearing potential from first vaccination until 
60 days  after the last vaccination . 
5Biological males who are post -pubertal and considered fertile until permanently sterile 
by bilateral orchiectomy or vasectomy.  
9. Male subjects  agree to refrain from sperm donation from the time of first vaccination 
until 60 days  after the last vaccination.  
10. In good health.6 
6As determined by medical history and physical examination to ev aluate acute or ongoing 
chronic medical diagnoses/conditions that have been present for at least 90 days, which 
would affect the assessment of safety of subjects. Chronic medical diagnoses/conditions 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 34 of 116 should be stable for the last 60 days (no hospitalizatio ns, ER, or urgent care for 
condition or need for supplemental oxygen). This includes no change in chronic 
prescription medication, dose, or frequency as a result of deterioration of the chronic 
medical diagnosis/condition in the 60 days before enrollment. Any prescription change 
that is due to change of health care provider, insurance company, etc., or done for 
financial reasons, and in the same class of medication, will not be considered a deviation 
of this inclusion criterion. Any change in prescription m edication due to improvement  of 
a disease outcome, as determined by the participating site PI or appropriate sub -
investigator, will not be considered a deviation of this inclusion criterion. Subjects may 
be on chronic or as needed (prn) medications if, in the opinion of the participating site PI 
or appropriate sub -investigator, they pose no additional risk to subject safety or 
assessment of reactogenicity and immunogenicity, and do not indicate a worsening of 
medical diagnosis/condition. Similarly, medicati on changes subsequent to enrollment and 
study vaccination are acceptable provided the change was not precipitated by 
deterioration in the chronic medical condition, and there is no anticipated additional risk 
to the subject or interference with the evaluat ion of responses to study vaccination.  
11. Oral temperature is less than 100.0°F (3 7.8°C). 
12. Pulse no greater than  100 beats per minute.  
13. Systolic BP is 85 to 1 50 mm Hg, inclusive.  
14. Clinical screening laboratory evaluations (WBC, Hgb, PLTs, ALT, AST, Cr, ALP , T. 
Bili, Lipase, PT, and PTT) are within acceptable normal reference ranges at the clinical 
laboratory  being used . 
15. Must a gree to have samples stored for secondary research . 
16. Agree s to adhere to Lifestyle Considerations (defined in Section 5.4) throughout study 
duration.  
17. Must agree to refrain from donating blood or plasma during the study (outside of this 
study).  
5.1.1 Leukapheresis Inclusion Criteria  
A subject must meet all of the following criteria to be eligible for leukapheresis:  
1. Written informed consent for leukapheresis is provided.  
2. Weight ≥110 pounds.  
3. Screening laboratory evaluations are within acceptable ranges at the site where the 
leukapheresis procedure will be performed.  
4. Negative urine or serum pregnancy test within 48 hours of the leukapheresis procedure 
for women of childbearing potential.  
5. Adequate bilateral antecubital venous access.  
6. No use of blood thinners, aspirin  or NSAIDs at least 5 days before the leukapheresis 
procedure.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 35 of 116 7. Enrolled in cohort s 2, 3, 5,  10, or 11, and possibly cohort 6, if enrolled,  and completed 
the two -dose vaccination series.  
5.2 Exclusion Criteria  
A subject who meets any of the following criteria will be excluded from participation in this 
study:  
1. Positive pregnancy test either at screening or just prior to each vaccine administration . 
2. Female subject who is breastfeeding or plans to breastfeed from the time of the first 
vaccination through 60 days after the last vaccination.  
3. Has any medical disease or c ondition that, in the opinion of the participating site PI or 
appropriate sub -investigator, precludes study participation .7 
7Including acute, subacute, intermittent or chronic medical disease or condition that 
would place the subject at an unacceptable risk of injury, render the subject unable to 
meet the requirements of the protocol, or may interfere with the evaluation of responses 
or the subject’s successful completion of this trial.  
4. Presence of self -reported or medically documented signi ficant medical or psychiatric 
condition(s) .8 
8Significant medical or psychiatric conditions include but are not limited to:  
Respiratory disease (e.g., chronic obstructive pulmonary disease [COPD], asthma) 
requiring daily medications currently or any treatment of respiratory disease 
exacerbations (e.g., asthma exacerbation) in the last 5 years . Asthma medications: 
inhaled, oral, or intravenous (IV) corticosteroids, leukotriene modifiers, long and short 
acting beta agonists, theophylline, ipratropium, biologics.  
Significant cardiovascular disease (e.g., congestive heart failure, cardiomyopathy, 
ischemic heart disease ), history of myocarditis or pericarditis as an adult , myocardial 
infarction ( MI) within past 6 months, coronary artery bypass surgery or stent placement, 
or uncontrolled cardiac arrhythmia . 
Neurological or neurodevelopmental conditions (e.g., history of migraines  in the past 5 
years , epilepsy, stroke, seizures  in the last 3 years , encephalopathy, focal neurologic 
deficits, Guillain -Barr é syndrome, encephalomyelitis , transverse myelitis , stroke or 
transient ischemic attack, multiple sclerosis, Parkinson's disease, amyotrophic lateral 
sclerosis, Creutzfeldt -Jakob disease, or Alzheimer's disease ). 
Ongoing malignancy or recent diagnosis of malignancy in the last five years excluding 
basal cel l and squamous cell carcinoma of the skin, which are allowed.  
An autoimmune disease , including hypothyroidism without a defined non -autoimmune 
cause, localized or history of psoriasis . 
An immunodeficiency of any cause.  
Chronic kidney  disease , estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2. 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 36 of 116 5. Has an acute illness9, as determined by the participating site PI or appropriate sub -
investigator, with or without fever [ oral temperature ≥38.0°C (100.4 °F)] within 72 hours 
prior to each vaccination.  
9An acute illness which is nearly resolved with only minor residual symptoms remaining 
is allowable if, in the opinion of the participating site PI or appropriate sub -investigator, 
the residual symptoms will not interfere with the ability to a ssess safety parameters as 
required by the protocol.  
6. Has a positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or 
HIV types 1 or 2 antibodies at screening.  
7. Has participated in another investigational study involving any invest igational product10 
within 60 days, or 5 half -lives, whichever is longer, before the first vaccine 
administration.  
10study drug, biologic or device  
8. Currently enrolled in or plans to participate in another clinical trial with an 
investigational agent11 that will be received during the study -reporting period .12 
11Including licensed or unlicensed vaccine, drug, biologic, device, blood product, or 
medication.  
1213 months after the first vaccination.  
9. Has previously participated in an investigational study involv ing LNPs  (a component of 
the investigational vaccine assessed in this trial) . 
10. Has a history of hypersensitivity or severe allergic reaction (e.g., anaphylaxis, 
generalized urticaria, angioedema, other significant reaction) to any previous licensed or 
unlicensed vaccines.  
11. Chronic use (more than 14 continuous days) of any medications that may be associated 
with impaired immune responsiveness .13 
13Including, but not limited to, systemic corticosteroids exceeding 10 mg/day of 
prednisone equivalent, allergy injections, immunoglobulin, interferon, 
immunomodulators, cytotoxic drugs, or other similar or toxic drugs during the preceding 
6-month period prior to vaccine administration ( Day 1). The use of low dose topical, 
ophthalmic, inhaled and  intranasal steroid preparations will be permitted.  
12. Anticipating the need for immunosuppressive treatment within the next 6 months.  
13. Received immunoglobulins and/or any blood or blood products within the 4 months 
before the first vaccine administration or a t any time during the study.  
14. Has any blood dyscrasias or significant disorder of coagulation.  
15. Has any chronic liver disease , including fatty liver . 
16. Has a history of alcohol abuse or other recreational drug (excluding cannabis) use within 
6 months before th e first vaccine administration.  
17. Has a positive test result for drugs of abuse at screening or before the first vaccine 
administration.  If cannabis  is the only detected drug, inclusion is permitted.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 37 of 116 18. Has any abnormality or permanent body art (e.g., tattoo) that would interfere with the 
ability to observe local reactions at the injection site (deltoid region).  
19. Received or plans to receive a licensed, live vaccine within 4 weeks before or after each 
vaccination.  
20. Received or plans to receive a licensed,  inactivated vaccine within 2 weeks before or 
after each vaccination.  
21. Receipt of any other SARS -CoV -2 or other experimental coronavirus vaccine at any time 
prior to or during the study.  
22. Close contact of anyone known to have SARS -CoV -2 infection within 30 days prior to 
vaccine administration.  
23. History of COVID -19 diagnosis.  
24. On current treatment with investigational agents for prophylaxis of COVID -19. 
25. Current use of any prescription or over -the-counter medications within 7 days prior to 
vaccination , unless app roved by the investigator  or necessary to manage a chronic 
condition . 
26. Plan to travel outside the US (continental US, Hawaii, and Alaska) from enrollment 
through 2 8 days after the last vaccination . 
27. Reside in a nursing home or other skilled nursing facility or have a requirement for 
skilled nursing care.  
28. Non-ambulatory.  
29. For subjects ≥56 years of age, history of chronic smoking within the prior year.  
30. For subjects ≥56 years of age, current smoking or vaping.  
31. For subjects ≥56 years of age, individuals c urrently working with high risk of exposure to 
SARS -CoV -2 (e.g., active health care worker s with direct patient contact , emergency 
response personnel).  
5.2.1 Exclusion of Spec ific Populations  
This is a first -in-human trial in healthy subjects, ≥18 years of age. Because the effect s on the 
fetus are not known, pregnant women will not be eligible for the trial. Women of childbearing 
potential must utilize a highly effective method of contraception and will be required to have a 
negative urine or serum pregnancy test within 24 hours prior to each vaccination. Children will 
not be included in this trial as presently there are no safety or efficacy data in adults. Should the 
outcome of this trial be deemed acceptable, additional trials may be initiated , including those in 
other populations.  
5.3 Inclusion of Vulnerable Subjects  
Not Applicable  
5.4 Lifestyle Considerations  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 38 of 116 During this study subjects  are asked to:  
• Refrain from consuming food or drink containing poppy seeds within 72 hours of the 
screening visit as this could cause a false positive urine drug screen result.  
• Follow  public health guidance on preventing SARS -CoV -2 infection.  
• Subjects must not eat or drink anything hot or cold within 10 minutes prior to taking oral 
temperature.  
5.5 Screen Failures  
After the screening assessments  have been completed, the participating site  PI or qualified 
designee is to review the inclusion  and exclusion criteria and determine the subject’s eligibility 
for the study.  
Only the following information will be collected on screen failures: demographics (age, screen 
number, sex, ethnicity, and rac e) and reason for ineligibility. Subjects who are found to be 
ineligible will be told the reason for ineligibility.  
Individuals who do not meet the criteria for participation in this study (screen failure) because of 
an abnormal clinical laboratory finding  may be rescreened once.  
5.6 Strategies for Recruitment and Retention  
5.6.1 Recruitment  
Potential subjects will learn about the study via IRB -approved recruitment strategies, including 
direct mailing , recruitment from an IRB -approved trial registry a nd local advertisements/flyers . 
Screening will begin with a brief IRB -approved telephone call from study staff. Information 
about the study will be presented to potential subjects and questions about their health and ability 
to comply with the study visit sc hedule will be asked of potential subjects  to presumptively 
determine eligibility. Appointments will be made at the research clinic  for potential subjects who 
are interested in the study for further screening procedures and additional protocol -specific 
information.  
5.6.2 Retention  
Study retention strategies will include education and explanation of the study schedule and 
procedures during screening and enrollment visits and restriction of enrollment to persons who 
can attend all study visits . Participating subjec ts will be reminded of subsequent visits during 
each visit, and study staff will contact subjects prior to appointments. Study staff will contact 
subjects who miss appointments to encourage them to return for completion of safety 
evaluations.  
5.6.3 Compensation Plan for Subjects  
Subjects may be compensated for their participation in this trial. Compensation will be in 
accordance with local IRB requirements, and subject to local IRB approval. Reimbursements 
will be disbursed at specific timepoints during the study  with the amount contingent on 
completing study procedures.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 39 of 116 5.6.4 Costs  
There is no cost to subjects for the research tests, procedures/evaluations or study product while 
taking part in this trial. Procedures and treatment for clinical care may be billed to the subject, 
subject’s insurance or third party.  
6. STUD Y PRODUCT  
6.1 Study Product (s) and Administration  
6.1.1 Study Product  Description  
Product: mRNA -1273  
mRNA -1273 is an LNP dispersion containing an mRNA that encodes for the pre fusion 
stabilized spike protein SARS -CoV -2. mRNA -1273 consists of an mRNA Drug Substance that is 
manufactured into LNPs composed of the proprietary ionizable lipid, SM -102, and 3 
commercially available lipids, cholesterol, DSPC, and PEG2000 DMG. mRNA -1273 has a total 
lipid content of 9.7  mg/mL and is formulated at a concentration of 0.5 mg/mL in 20 mM 
trometamol (Tris) buffer containing 87 mg/mL sucrose and 10.7 mM sodium acetate, at pH 7.5.  
Diluent: 0.9% NaCl for injection, USP  
The USP grade 0.9% NaCl or normal saline for injection is a sterile, nonpyrogenic, isotonic 
solution; each mL contains NaCl 9 mg. It contains no bacteriostatic agent, antimicrobial agent, 
preservatives, or added buffer and is supplied only in single -dose containers. The solution may 
contain hydrochloric acid and/or  sodium hydroxide for pH adjustment (pH 5.3, range 4.5 -7.0). 
This product should be used to dilute the vaccine to the desired concentration.  
6.1.2 Dosing and Administration  
mRNA -1273 (0.5 mg/mL) will be diluted in 0.9% NaCl for injection, USP to obtain 10, 25, 5 0, 
100, and 250 mcg in 0.5 mL dosages. Each dose will be administered via IM injection (0.5 mL) 
into the deltoid muscle on Days 1 and 29. The second dose of vaccine (0.5 mL) will be 
administered preferably in the same arm used for the first dose. The pharm acist will prepare a 
single dose (0.5 mL) for each subject based on cohort assignment.  
Table 7: Dosing and Administration  
Cohort  Product 
Name  Dose  Route  Frequency of 
Administration  
1 mRNA -1273  25 mcg  IM D1, D29  
2 mRNA -1273  100 mcg  IM D1, D29  
3 mRNA -1273  250 mcg  IM D1, D29  
4 mRNA -1273  25 mcg  IM D1, D29  
5 mRNA -1273  100 mcg  IM D1, D29  
6* mRNA -1273  250 mcg  IM D1, D29  
7 mRNA -1273  25 mcg  IM D1, D29  
8 mRNA -1273  100 mcg  IM D1, D29  
9* mRNA -1273  250 mcg  IM D1, D29  
10 mRNA -1273  50 mcg  IM D1, D29  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 40 of 116 Cohort  Product 
Name  Dose  Route  Frequency of 
Administration  
11 mRNA -1273  50 mcg  IM D1, D29  
12 mRNA -1273  50 mcg  IM D1, D29  
13* mRNA -1273  10 mcg  IM D1, D29  
*Cohorts 6, 9 and 13 were not enrolled.  
See the protocol -specific Manual of Procedures ( MOP ) for detailed information on the 
preparation, labeling, storage, and administration of vaccine for each cohort. Vaccine  preparation 
will be performed by the participating  site’s research pharmacist on the same day of vaccine 
administration to the subject.  
Visually inspect the mRNA -1273 upon receipt and prior to use. If the study product(s) appear(s) 
to have been damaged, contaminated or discolored, contain(s) visible particulate matter, or if 
there are any concerns regarding the integrity, do NOT use the af fected study product(s). The 
affected study product(s) must be quarantined at appropriate storage temperature and labeled as 
‘Do Not Use’ (until further notice). The participating site PI or responsible person should 
immediately contact the DMID Product Su pport Team at 
DMIDProductSupportTeam@niaid.nih.gov and DMID Clinical Project Manager for further 
instructions before any additional vaccinations are administered. Based on the information 
collected, DMID and/or the manufacturer will determine whether the a ffected study product(s) 
can be used. If the affected study product(s) cannot be used, the participating site will receive 
specific instructions on how to return the affected study product(s) to the DMID Clinic al 
Material Services ( CMS ) or destroy the affe cted study product(s) on -site. If the mRNA -1273 is 
unusable, study staff will use another vial from the study supply. Replacement vials may be 
requested by contacting DMID. Additional instructions for quarantine and DMID contact 
information are provided in  the protocol -specific MOP.  
The injection dose volume ( 0.5 mL  each)  of vaccine should be withdrawn from the final mixed 
vial(s) or compounding vial (s) containing the prepared dosing solution. The number of 
individual dosing syringes that may be filled from  one mixing vial varies depending on the 
dosage. Doses for multiple subjects may be drawn into individual dosing syringes (0.5 mL each) 
from the same mixing vial within 30 minutes of completion of dosing solution preparation ( 10, 
25, 50, and 100 mcg doses only). Gently invert the final mixed vial(s) or the compounding 
vial(s) 20 times until components are mixed  prior to withdrawing . Do not mix vigorously or 
sonicate or vortex.  
Aseptic technique will be used for the withdrawal and administration of each dose  of vaccine 
using a disposable, sterile needle appropriate in length for each subject and a 1 -mL disposable, 
sterile syringe.  
The expiration time of the dosing syringe containing the prepared mRNA -1273 solution is 4 
hours at room temperature for the 10 mcg  dosage  after the solution is drawn into the dosing 
syringe and 8 hours at room temperature for the 25, 50, 100, and 250 mcg dosages after the 
solution is drawn into the dosing syringe.  
6.1.3 Dose Escalation  
Section  4.1. 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 41 of 116 6.1.4 Dose Modifications  
No dose modifications.  
6.2 Accountability /Handling/Storage/ Preparation  
6.2.1 Acquisition and Accountability  
Product: mRNA -1273  
Will be provided by ModernaTX, Inc. via the DMID CMS.  
Upon request by DMID, mRNA -1273 will be transferred to the following address:  
DMID Clinical Materials Services Contract  
Fisher BioServices  
20439 Seneca Meadows Parkway  
Germantown, MD 20876  
Phone: 240 -477-1350  
Fax: 240 -477-1360  
Email: DMID.CMS@thermofisher.com  
Diluent: 0.9% NaCl for injection, USP  
Will be provided by DMID via the DMID CMS.  
All study products will be shipped to the clinical research site upon request and approval from 
DMID.  
Accountability  
The participating  site PI is res ponsible for study product distribution and disposition and has 
ultimate responsibility for study product accountability. The participating  site PI may delegate to 
the participating site’s research pharmacist responsibility for study product ac countability . The 
participating  site’s research pharmacist will be responsible for maintaining complete records and 
documentation of study product receipt, accountability, dispensation, storage conditions, and 
final disposition of the study product(s). Study product a ccountability records and dispensing 
logs should include, but are not limited to the following: DMID protocol number; name, dosage 
form, strength of the study product; capture vial numbers assigned sequentially by the 
pharmacists as vials/syringes are used  (number uniquely, do not start over at 1 or repeat 
numbers), manufacturer or other source; control, lot number or other identification number; 
expiration or retest date; date of receipt of the study product; quantity received from supplier; 
subject identi fication number ; quantity dispense d as amount or dose per subject ; balance of study 
product currently available ; disposition of study product  if not dispensed to a study subject (e.g. , 
disposed/destroyed or retuned to supplier as per protocol or protocol -specific MOP or as directed 
by DMID) ; date of vaccine preparation/administration, time of vaccine preparation, expiration of 
vaccine preparation ; and amount of vaccine withdrawn for adm inistration. Time of vaccine 
administration to the subject will be recorded on the appropriate data collection form ( DCF ). All 
study product(s), including the amount of mRNA -1273, diluent ( 0.9% NaCl for injection, USP ), 
and vial admixtures, whether adminis tered or not, must be documented on the appropriate study 
product accountability record or dispensing log. The sponsor’s monitoring staff will verify the 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 42 of 116 participating site’s study product accountability records and dispensing logs per the  DMID -
approved  clinical  monitoring plan  (CMP) . 
Once all subject dosing is complete, the pharmacy staff should retain or dispose of used study 
products and complete study product accountability procedures in accordance with site -specific 
standard operating procedures (SOPs) . This applies to : 
• used and unused mRNA -1273 vials  
• used mixing vials  
• mRNA -1273 cartons  
All used supplies noted above may either  be sequestered from the unused supplies and retained 
until study conclusion or until study product accountability has occurred b y the monitor and 
written notification stating retention is no longer required is received , or may be destroyed in 
accordance with site -specific SOPs with a second pharmacy staff member’s observation and 
verification as documented in the pharmacy log . Refe r to the protocol -specific MOP for details 
on storing used mRNA -1273 vials , used 0.9% NaCl  Injection vials and used mixing vials.  
Destruction  
After the study treatment period has ended or as appropriate over the course of the study after 
study product  accountability has been performed, disposition of unused and used mRNA -1273 
vials should occur as noted:  
• Unused and Used mRNA -1273 vials:  
o Should be  destroyed on -site following applicable site procedures or by the site’s 
selected destruction vendor. Following t he site’s procedure for the destruction of 
hazardous material or study product  destruction policy/SOP when destroying used 
and unused items.  
o A certificate of destruction or documentation of destruction should be provided to 
the sponsor and retained in the Pharmacy Binder once completed.  
Used syringes may be destroyed in accordance with site -specific SOPs.  
6.2.2 Formulation, Appearance, Packaging, and Labeling  
Product: mRNA -1273  
mRNA -1273 is provided as a sterile liquid for injection, white to off white dispersion in 
appearance, at a concentration of 0.5 mg/mL in 20 mM Tris buffer containing 87 mg/mL sucrose 
and 10.7 mM sodium acetate, at pH 7.5 . 
Diluent: 0.9% NaCl for injection, USP  
The USP grade 0.9% NaCl or normal saline for injection is a sterile, non pyrogenic, isotonic 
solution; each mL contains NaCl  9 mg. It contains no bacteriostatic agent, antimicrobial agent, 
preservatives, or added buffer and is supplied only in single -dose containers. It is clear in 
appearance , and available in 10 mL vials . 
Each  of the study products will be labeled according to manufacturer specifications and include 
the statement “Caution: New Drug Limited by Federal Law to Investigational Use.”  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 43 of 116 Sterile empty vials (2 -mL or 10 -mL) will be provided with latex -free stoppers.  
6.2.3 Prod uct Storage and Stability  
Product: mRNA -1273  
mRNA -1273 is stored at -70°C ( -60°C to -90°C).  
Stability protocols for mRNA -1273 will include at least 24 -months duration at the intended 
storage temperature (-60°C to -90°C) . 
Stability and compatibility with th e apparatus intended for administration for up to 8 hours after 
preparation were assessed. The prepared doses were stable for clinical in -use for up to 8 hours at 
room temperature  (Note: up to 4 hours at room temperature for 10 mcg doses) . 
Diluent: 0.9% Na Cl for injection, USP  
0.9% NaCl for injection, USP is stored at 20 to 25°C (68 to 77°F) [See USP Controlled Room 
Temperature .] 
The temperature of the storage unit must be manually recorded daily (excluding non -business 
days and holidays, as applicable) and continuously monitored and recorded during the course of 
this trial per site-specific SOPs , and documentation will be maintain ed. If the temperature 
fluctuates outside of the required range, the affected study product(s) must be quarantined at the 
correct storage temperature and labeled as ‘Do Not Use’ (until further notice). The participating  
site’s research pharmacist must aler t the participating site PI and study coordinator, if the 
temperature fluctuates outside of the required range. In the event the temperature fluctuates 
outside of the required range, including accidental deep -freezing or disruption of the cold chain, 
the a ffected study product(s) must not be administered. The participating  site PI or responsible 
person should immediately contact the DMID Product Support Team at 
DMIDProductSupportTeam@niaid.nih.gov for further instructions before any additional 
vaccinations are administered. Based on the information collected, DMID and/or the 
manufacturer will determine whether the affected study product(s) can be used. If it cannot be 
used, the participating site will receive specific instructions on how to return the affect ed study 
product(s) to the DMID CMS or destroy it on -site. Additional instructions for quarantine and 
DMID contact information are provided in the protocol -specific MOP.  
mRNA -1273 must be stored in a secure area with limited access (pharmacy staff only), a nd must 
be stored frozen at -60°C to -90°C. The freezer should have an automated temperature recording 
and alert system. There must be an available back -up freezer. The freezers must be connected to 
a back -up generator ; or alternate plan in the event of a power failure . The pharmacy must have in 
place a 24 -hour alert system that allows for rapid response in case of freezer malfunctioning. In 
addition, vaccine accountability study staff (e.g., pharmacy staff) are required to keep a 
temperature log to establish a record of compliance with these storage conditions. Only vaccine 
accountability study staff (e.g., pharmacy staff) should have access to the product used in this 
study. The participating site is respo nsible for reporting any mRNA -1273 that was not 
temperature controlled during shipment or during storage to the pharmacy staff. Such mRNA -
1273 will be retained for inspection by the pharmacy staff  and disposed of according to approved 
methods.  
6.2.4 Preparation  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 44 of 116 Refer to the  protocol -specific MOP for details about preparation . 
6.3 Measures to Minimize Bias: Randomization and Blinding  
6.3.1 Treatment Assignment Procedures  
Per International Council for Harmonisation of Technical Requirements for Pharmaceuticals for 
Human Use (ICH) guideline E6: GCP, screening records will be kept at the participating site to 
document the reason why an individual was screened, but failed tria l entry criteria. The reasons 
why individuals failed screening will be recorded in the Statistical and Data Coordinating 
Center’s (SDCC) Advantage eClinicalSM (Electronic Data Capture System).  
Once consented and upon entry of demographic data and confirmat ion of eligibility for this trial, 
the subjects will be enrolled. Enrollment will proceed in a staged fashion. Sentinel subject dosing 
will begin with 4 subjects in cohort 1 (25 mcg). The 4 sentinel subjects for cohort 2 (100 mcg) 
will be enrolled no earli er than one day after enrollment of the last of the 4 sentinel subjects in 
cohort 1. If no halting rules have been met after the 8 sentinel subjects have completed Day 5, 
then full enrollment will proceed first with the remaining subjects in cohort 1, foll owed by the 
remaining subjects in cohort 2 without interruption. If no halting rules have been met after all 
subjects in cohort 2 have completed Day 8, then dosing of 4 sentinel subjects will begin in cohort 
3. If no halting rules have been met after the 4  sentinel subjects in cohort 3 have completed Day 
5, then full enrollment of cohort 3 will proceed.  
If no halting rules have been met after all subjects in cohorts 1 and 2 have completed Day 8, 
dosing will begin for cohorts 4 (25 mcg; 56 -70 years of age) a nd 5 (100 mcg; 56 -70 years of 
age). If no halting rules have been met after all subjects in cohorts 4 and 5 have completed Day 
8, dosing will begin for cohorts 7 (25 mcg; ≥71 years of age) and 8 (100 mcg; ≥71 years of age).  
Based on the interim immunogenic ity data available as of May 15, 2020, enrollment into cohorts 
6 and 9 (250 mcg; 56 -70 years of age and ≥71 years of age) will be deferred in order to explore 
lower dosages. Therefore, enrollment of cohorts 10 -12 (50 mcg; 18 -55 years of age, 56 -70 years 
of age and ≥71 years of age) will be prioritized. Subjects will be enrolled simultaneously in 
cohorts 10 -12; there will be no staging. To further explore dosage sparing, cohort 13 (10 mcg 
dose; 18 -55 years of age) may be enrolled. A decision regarding the en rollment of cohorts 6, 9 
and 13 will be made after review of interim immunogenicity data from cohorts 1 -5, 7, 8, and 10 -
12. 
If no halting rules have been met after all subjects in cohorts 5 and 8 have completed Day 8, 
dosing will begin concurrently for coh orts 10 -12. If no halting rules have been met after all 
subjects in cohorts 3, 7 and 8 have completed Day 8, dosing may begin for cohort 6, if enrolled. 
If no halting rules have been met after all subjects in cohort 6 have completed Day 8, dosing may 
begin  for cohort 9, if enrolled.  
6.3.2 Randomization and Blinding  
This is an open -label study  with sequential group enrollment so randomization and blinding will 
not be utilized.  
6.3.3 Blinding and Masking Procedures  
Not Applicable  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 45 of 116 6.4 Study Intervention Compliance  
Each dose of study product will be administered by a member of the clinical research team  that is 
qualified and licensed to administer the study product . Administration and date, time, and 
location of injection will be recorded on the appropriate DCF . 
6.5 Concomita nt Therapy  
Information about prior medications, including hormonal contraceptives, taken by the subject in 
the 30 days prior to providing informed consent will be recorded on the appropriate DCF . 
Concomitant medications include all medications (prescriptio n, over the counter, supplements, 
and vaccines received outside of the study) taken by the subject  from the time the informed 
consent is signed through Day 394 . At each study visit following dosing , including  telephone 
calls, subjects will be queried about  new concomitant medications and changes to existing 
medications.  
Medications that might interfere with the evaluation of the investigational product should not be 
used by the subject during the study -reporting period (12 months after the second  vaccinatio n) 
unless clinically indicated as part of the subject’s health care.  
In the event medical conditions dictate the use of medications, subjects are encouraged to obtain 
adequate care, comply with the course of therapy as prescribed by their physician, and in form the 
study Investigator as soon as practical. Any drug or vaccine used or received by the subject 
during the trial should be recorded on the appropriate  DCF . 
6.5.1 Rescue Medicine  
Not Applicable  
6.5.2 Non-Research Standard of Care  
Not Applicable  
7. STUDY  INTERVENTION  DISCONTINUATION  AND  
SUBJECT  DISCONTINUATION/WITHDRAWAL  
7.1 Halting Criteria and Discontinuation of Study Intervention  
7.1.1 Halting Criteria  
The study will be paused if any of the following events occur:  
1- Any subject experiences a n SAE after admini stration of the vaccine  that is considered 
related to vaccine . 
2- Any subject experiences laryngospasm, bronchospasm or anaphylaxis within 24 hours 
after administration of vaccine that is considered related to vaccine.  
3- Any subject experiences ulceration, absc ess or necrosis at the injection site that is 
considered related to vaccine administration.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 46 of 116 4- Two (2) or more subjects experience an allergic reaction such as generalized urticaria 
(defined as occurring at  three or  more body parts) within 72 hours after admi nistration of 
vaccine that is considered related to vaccine . 
5- Three (3) or more subjects experience a Grade 3 AE ( unsolicited and/or clinical 
laboratory  abnormality ), in the same Preferred Terms based on the Medical Dictionary 
for Regulatory Activities ( MedDRA ) coding, that lasted at least 48 hours after 
administration of the vaccine and is considered  related to the vaccine.  Clinical laboratory 
abnormalities are not subject to the time window.  
Study product administration and enrollments may resume only after review of the AEs that 
caused the pause result s in a recommendation to permit further study product administration and 
enrollments.  
7.1.2 Sentinel Halting Criteria  
If any of the following events occur to the sentinel subjects, the study will be paused:  
1- Any subject experiences ulceration, abscess or necrosis at the injection site.  
2- Any subject experiences laryngospasm, bronchospasm or anaphylaxis within 24 hours 
after administration of vaccine.  
3- Any subject experiences generalized urticaria (defined as occurring at three or more body 
parts) within 72 hours after administration of vaccine.  
4- Any subject experiences an SAE (except for accident or trauma) after administration of 
the vaccine that is conside red related to the vaccine.  
5- Any 2 subjects in the same cohort experience the same Grade 3 Solicited Local AE or 
Systemic AE, (excluding measured grades of erythema and edema/ induration alone) that 
lasted at least 48 hours within 7 days after administration  of the vaccine . 
6- Any 2 subjects experience the same  Grade 3 AE (unsolicited and/or clinical laboratory 
abnormality), in the same Preferred terms based on the MedDRA coding, that lasted at 
least 48 hours after administration of the vaccine and is considered related to the vaccine. 
Clinical l aboratory abnormalities are not subject to the time windo w. 
7.1.3 Criteria for Continuation of Dosing and Redosing  
In the event a halting rule is met:  
• an unscheduled safety analysis by the SMC will be required for approval of further 
enrollment , and  
• further administration of the vaccine, including a second dose, is suspended for ALL 
subjects until an assessment by the SMC takes place.  
7.1.3.1  Withdrawal Criteria for Second  Study Vaccination  
Prior to receiving the second vaccination, subjects  will be reassessed. The following events 
constitute contraindications to any further  administration of vaccines. If any of these events 
occur during the study, the subject  must not receive the second vaccin ation  but will be 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 47 of 116 encouraged to continue study participation for safety and immun ogenicity evaluation s through 
12 months after their last vaccination.  
• Withdrawal of consent.  
• As deemed necessary by the participating  site PI or appropriate sub -investigator for non -
compliance or other reasons.  This may include previously undisclosed or new conditions 
that meet exclusion criteria.  
• Any clin ically significant medical condition that, in the opinion of the participating site 
PI or appropriate sub -investigator , poses an additional risk to the subject  if he/she 
continues to participate in the study . 
• Anaphylaxis or unexpected systemic hypersensiti vity reaction following the 
administration of the first vaccin ation . 
• Any SAE judged to be related to vaccine . 
• Pregnancy . 
• Subject is lost to follow -up. 
• New information becomes available that makes further participation unsafe.  
• Termination of this trial.  
7.1.3.2  Delay of Study Vaccination  
If any of these events occur at the time scheduled for vaccination, the subject  may be vaccinated 
at a later date, within the window specified in the SOA , or the subject  may be withdrawn from 
dosing at the discretion of the participating site PI or appropriate sub -investigator : 
• Acute moderate or severe infection with or without fever at the time of vaccination . 
• Fever, defined as oral temperature ≥38.0°C (100.4°F) at the time of vaccination . 
Subjects  with a minor illness without fe ver, as assessed by the participating site PI or appropriate 
sub-investigator , can be administered vaccines. Subjects  with an oral temperature of 38.0°C 
(100.4°F) or higher  will be re -contacted within the window specified in the SOA  and re -
evaluated for eligibility.  
7.1.4 Follow -up for Subjects that Discontinued Study Intervention  
Discontinuation of study intervention  does not require discontinuation from the study, and the 
remain ing study procedures should be completed as indicated by the SOA . If a clinically 
significant finding is identified , including, but not limited to , changes from baseline , after 
enrollment, the participating site PI  or qualified designee will determine if a ny change in subject  
management is needed. Any new clinically relevant finding will be reported as an AE.  
The data to be collected at the time of study intervention discontinuation should include the 
following:  
• Clinical s afety laboratory evaluations . 
• Complete physical examination . 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 48 of 116 • Vital signs (BP,  heart rate  [HR], oral temperature) . 
• Immunogenicity evaluations . 
7.2 Subject  Withdrawal from the Study  and Replacement  
Subjects  are free to withdraw from participation in the study at any time upon request, withou t 
any consequence.  
A study subject will be discontinued from participation in the study if any of the following 
reasons occur prior to initial dosing:  
• Request by the subject to terminate participation . 
• Vaccine is not administered . 
A subject may be removed from the study for the following reasons post initial dosing; however, 
whenever possible the subject should be followed for safety and immunogenicity evaluations per 
protocol:  
• Subject becomes pregnant before receiving the second do se of vaccine . 
• Study non -compliance to protocol requirements that in the opinion of the participating 
site PI or appropriate sub -investigator  poses an increased risk (e.g. , missing safety labs) 
or compromises the validity of the data.  
• Lost to follow -up. 
• If the subject  met an exclusion criterion for participation in the study (either newly 
developed or not previously recognized) that precludes further study participation . 
• Request of primary care provider; the IRB, FDA, or NIAID . 
• Medical disease or condition, or new clinical finding(s) for which continued 
participation, in the opinion of the participating site PI or appropriate sub -investigator 
might compromise the safety of th e subject, interfere with the subject ’s successful 
completion of this study, or interfere with the evaluation of responses . 
• If any AE, clinical laboratory abnormality or situation occurs such that continued 
participation in the study would not be in the be st interest of the subject . 
• The occurrence of a n SAE . 
If the subject agrees, every attempt will be made to follow all AEs through resolution  or 
stabilization . 
Subjects who withdraw, or are withdrawn from this study, or are lost to follow -up after signing 
the informed consent form (ICF) and administration of the study product will not be replaced.  
Subjects who withdraw, or are withdrawn from this study, or are lost to follow -up after signing 
the ICF but before administration of the study product may be repla ced. 
The reason for subject  discontinuation or withdrawal from the study will be recorded on the 
appropriate DCF . 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 49 of 116 7.3 Lost to Follow -Up 
A subject  will be considered lost to follow -up if he or she fails to appear for a follow -up 
assessment . Extensive effort (i.e., generally three documented contact attempts via telephone 
calls, e -mail, etc., made on separate occasions) will be made to locate or recall the  subject , or at 
least to determine the  subject’s  health status. These efforts will be docu mented in the subject ’s 
study file . 
8. STUDY  ASSESSMENTS  AND  PROCEDURES  
8.1 Screening and  Immunogenicity Assessments  
8.1.1 Screening Procedures  
There is a small amount of risk to subjects who report that they are in good health but have an 
unknown health problem at the time of screening. Screening assessments can occur u p to 42 days 
before the subject’s first vaccination  (Day 1 ) and  may occur in o ne or two visits . At the first visit, 
and prior to any other study -related activities, t he participating  site PI or appropriate sub -
investigator  will provide the subject with detailed study information and will obtain written 
informed consent.  
Some or all of the following assessments are performed during the screening visit to determine 
eligibility requirements as specified in the inclusion and exclusion criteria:  
• Obtain medical history . 
• Review pre -study medications and therapies up to 30 days prior to the start of screening 
and record on the appropriate DCF . 
• Review of adult vaccinations , including any other SARS -CoV -2 or other experimental 
coronavirus vaccines . 
• Measure vital signs (HR, BP, and oral temperature) and height and weight for 
determination of BMI.  
• Perform full physical examination  which  will include assessments of the following 
organs and organ systems: skin, head, ears, eyes, nose, and throat ( HEENT ), neck, lungs, 
heart, liver, spleen, ab domen, extremities, lymph nodes (axillary and cervical), and 
nervous system.  
• Review of birth control history with female subjects.  
• Counsel subjects to use adequate birth control methods required during the trial to avoid 
pregnancy . 
• Obtain blood and urine for clinical screening laborator y evaluations : 
o Hematology  
▪ WBCs  
▪ Hgb 
▪ PLTs  
o Chemistry (fasting or non -fasting)  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 50 of 116 ▪ ALT  
▪ AST  
▪ ALP  
▪ T. Bili  
▪ Lipase  
▪ Cr 
▪ PT 
▪ PTT 
o Serology  
▪ Hepatitis B surface antigen  
▪ Hepatitis C virus antibody  
▪ HIV types 1 and 2 antigen/antibody  
o Serum pregnancy test (in women of childbearing potential)  
o Urine drug screen  
• Review inclusion and exclusion criteria . 
Clinical screening l aboratory  evaluations  will be performed locally by the site laboratory . The 
volume of venous blood to be collected for these evaluations is presented in Table 8. 
The overall eligibility of the subject to participate in the study will be assessed once all screening 
values are available. The screening process can be suspended prior to complete assessmen t at 
any time if exclusions are identified by the study team.  
Study subjects who qualify for inclusion will be contacted and scheduled for enrollment and first 
vaccination within the window for enrollment.  
If a physiologic parameter, e.g., vital signs or clinical laboratory value , is outside of the protocol -
specified range, then the measurement may be repeated once if, in the judgment of the 
participating  site PI or appropriate sub -investigator , the abnormality is the result of an acute, 
short -term, rapidly  reversible condition (e.g., stress, anxiety or “white coat syndrome”)  or other 
source of error . A physiologic parameter may also be repeated if there is a technical problem 
with the measurement caused by malfunctioning, or an inappropriate measuring devic e (i.e., 
inappropriate -sized BP cuff).  
A subject may be re -screened if there is a transient disease status (e.g., subject complained of a 
“cold or fever” and met a temporary delaying enrollment criterion of acute illness or fever), or if 
a protocol eligibi lity criterion that is not met at the initial time of screening, will be met by 
rescreening at a later date (e.g., a medication taken within exclusionary window at the time of 
first screening that would not be within exclusionary window at a later rescreen ). 
No subject s may be screened more than twice due to a screening failure result as defined above.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 51 of 116 Subjects  will be provided the results of abnormal clinical laboratory test values or abnormal 
clinical findings necessitating follow -up at the discretion of the participating  site PI or 
appropriate sub -investigator . Research laboratory results will not be provided to the subject . 
8.1.2 Screening Procedures for Leukapheresis  
For those subjects consented for leukapheresis, s creening procedures , including screening 
laboratory evaluations,  will be performed  locally prior to the leukapheresis procedure . Refer to 
the protocol -specific MOP for details on the leukapheresis procedure.  
8.1.3 Immunogenicity Evaluations  
Serological Immunogenicity Assays : 
The fo llowing serological immunogenicity assays will be performed:  
• IgG ELISA to the SARS -CoV -2 S (spike) protein.  
• IgM and IgA ELISA to the SARS -CoV -2 S (spike) protein.  
• Neutralization assay using a SARS -CoV -2 pseudovirus.  
• Neutralization assay using a live wild-type SARS -CoV -2. 
Preparation of blood samples and shipping instructions for serological immunogenicity assays 
are outlined in the protocol -specific MOP. Inability (e.g., loss of IV access) to collect all baseline 
samp les on Day 1 will not exclude the subject from further participation in this study as long as a 
minimum of baseline serum for serological immunogenicity assays is collected.  
Cellular Immunology Assays : 
This trial will also investigate T cell immune responses using multiparametric flow cytometry.  
Preparation of blood samples and shipping instructions for cellular immunology assays are 
outlined in the  protocol -specific MOP.  
The volume of venous blood to be collected for immunogenicity evaluations is pr esented in 
Table  8. 
8.1.4 Samples for Genetic/Genomic Analysis  
8.1.4.1  Genetic/ Genomic Analysis  
Stored PBMC s, including leukocyte samples obtained by leukapheresis , may be used in 
secondary research for sequencing of DNA from B cells to characterize B cell receptors and 
monoclonal antibodies.  The DNA data may be used to synthesize antigen -specific antibodies to 
characterize antibody binding. Secondary r esearch samples may also be used for other genomic 
analysis , including, but not limited to,  single nucleotide polymorphisms (SNP) arrays , human 
leukocyte antigen ( HLA ) typing,  transcriptomic analysis, evaluat ion of  the immune response to 
the vaccine , and/o r evaluation of any AE from the vaccine.  
8.1.4.2  Genetic Privacy and Confidentiality  
Any genetic data generated will be kept private . Informed consent permitting data sharing will be 
part of the consent process. Subjects will be informed that the evolution of geno mic technology 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 52 of 116 and analytical methods raises the risk of re -identification, even when specimens are de -
identified.  No data that may identify specific subjects will be kept with the genetic data.  
8.1.4.3  Management of Results  
All genetic testing in this protocol wi ll be performed for research only and  is not performed in a 
Clinical Laboratory Improvement Amendments ( CLIA ) certified laboratory. Therefore, results 
will not be shared with the subjects.  
8.2 Safety and Other Assessments  
Study procedures are specified in the SOA . A study clinician , licensed to make medical 
diagnoses and listed on the Form FDA 1572 as the participati ng site PI or appropriate sub-
investigator, will be responsible for all study -related medical decisions.  
• Medical history : 
o A complete medical history will be obtained by interview of subjects at the 
screening visit. Subjects will be queried regarding a hist ory of significant medical 
disorders of the head, ears, eyes, nose, throat, mouth, cardiovascular system, 
lungs, gastrointestinal tract, liver, pancreas, kidney, urologic system, nervous 
system, blood, lymph nodes, endocrine system, musculoskeletal system,  skin, and 
genital/reproductive tract. A history of any allergies, cancer, immunodeficiency, 
psychiatric illness, substance abuse, and autoimmune disease will be solicited.  
o At all subsequent visits an interim medical history will be obtained by interview 
of subjects and any changes since the previous clinic visit or telephone call will be 
noted. The interim medical history should include an assessment for new medical 
conditions and symptoms suggestive of Protocol Specified AESIs, MAAEs and 
NOCMCs.  
• Physical examination : 
o A full physical examination will be performed at the screening visit and a 
symptom -directed (targeted) physical examination will be performed if indicated 
at all other timepoints specified  in the SOA . 
▪ A full physical examination will include assessments of the following 
organs and organ systems: skin, HEENT, neck, lungs, heart, liver, spleen, 
abdomen, extremities, lymph nodes (axillary and cervical), and nervous 
system.  
▪ Height and weight will be measured, and BMI  calculated, at the screening 
visit only.  
o A symptom -directed (targeted) physical examination will be performed if 
indicated at all other timepoints specified  in the SOA . 
▪ Targeted physical examinations should also include an assessment for 
signs suggestive of Protocol Specified A ESIs, MAAEs and NOCMCs. 
Interim or unscheduled physical examinations will be performed at the 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 53 of 116 discretion of the participating  site PI or appropriate sub -investigator , if 
necessary, to evaluate AEs or abnormal clinical laboratory test results.  
o Reactogenicit y assessments of solicited AEs occurring from the time of each 
vaccination through 7 days post each vaccination , will include an assessment of 
injection site reactions –erythema, edema/ induration  and pain, as well as systemic 
reactions –fever, fatigue, chill s, myalgia (exclusive of the injection site), 
arthralgia, headache, and nausea. Pre -administration reactogenicity assessments 
will be performed immediately prior to each  vaccination to establish baseline, 
then the vaccination will be given.  
o Subjects will be observed in the clinic for at least 60 minutes post each 
vaccination. The vaccination site will be examined, post -administration 
reactogenicity assessments will be performed, and any AEs/SAEs will be 
recorded on the appropriate DCF  prior t o discharge from the clinic. The 
vaccination site will also be examined on Day s 8 and 36. 
• Vital signs : Vital sign measurements will include systolic and diastolic BP, HR, and oral 
temperature. Vital signs will be measured at timepoints specified  in the SOA . On Day s 1 
and 29, vital sign measurements will be collected prior to  vaccine administration. Vital 
signs assessed on Day 1 prior to the first vaccination will be considered as baseline. 
Subjects must not eat or drink anything hot or cold within 10 minute s prior to taking oral 
temperature.  
• Clinical laboratory evaluations : 
o Fasting is not required before collection of clinical laboratory evaluations . 
o Serum  pregnancy test will be performed locally by the site laboratory  at the 
screening visit , and urine or serum pregnancy test will be performed locally by the 
site laboratory  within 24 hours prior to  each vaccination  on Day s 1 and 29 , and as 
needed at interim or unscheduled visits for all women of childbearing potential. 
Results must be confirmed as negative prior to enrollment  on Day 1 and 
administration of each vaccination.  
o Serology: hepatitis B surface antigen, hepatitis C virus antibody, and HIV types 1 
and 2 antigen/ antibody at the screening  visit only . 
o Urine  drug scr een for drugs of abuse  (components per the standard panel at the 
site laboratory ) at the screening visit only . 
o Clinical screening laboratory evaluations  (WBC s, Hgb, PLT s, ALT, AST, ALP, 
T. Bili, Cr, Lipase, PT, and PTT) will be collected at the screening visit.  
▪ Clinical screening laboratory evaluations will be performed locally by the 
site laboratory. The volume of venous blood to be collected for clinical 
screening laboratory evaluations is presented in Table 8. 
o Clinical safety laboratory evaluations  (WBC s, Hgb, PLT s, ALT, AST, ALP, T. 
Bili, Cr , and Lipase ) collected immediately prior to the first vaccination will serve 
as the baseline  (Day 1) , and will be repeated on Day s 8, 29 and 3 6. 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFI DENTIAL  Page 54 of 116 ▪ Clinical safety laboratory evaluations will be performed locally by the site 
laboratory. The volume of venous blood to be collected for clinical safety 
laboratory evaluations is presented in Table 8. Inability (e.g., loss of IV 
access) to collect all baseline samples on Day 1 will not exclude the 
subject from further participation in this study as long as a minimum of 
baseline clinical safety laboratory evaluations is collected.  
o Blood and urine will be collected at timepoints specified  in the SOA . 
• Memory aid: 
o All subjects will complete a Memory Aid from the time of each vaccination 
through 7 days post each vaccination  (Days 1-8 for the first vaccination , and Days 
29-36 for the second vaccination) . Memory Aids will be reviewed with the 
subjects for any AEs (solicited injection site and systemic reactions , as well as 
unsolicited AEs), SAEs and concomitant medications during telephone calls on 
Days 2, 3, 30 , and 31 and at clinic visits on Day s 8 and 36. 
• Telep hone call: 
o Subjects will be contacted by telephone to query for safety events. AEs that have 
occurred since the previous clinic v isit or telephone call will be solicited. Based 
on the information collected, subjects may be asked to return to the clinic for 
evaluation.  
• Leukapheresis  (only for those subjects consented for leukapheresis) : 
o To support development of diagnostics, therapeutics and vaccines, a subset of 
subjects enrolled in cohorts 2, 3, 5, 10, and 11 may undergo leukapheresis to 
collect additional samples for secondary research. If enrollment in cohort 6 
proceeds, a subset of subjects in this cohort may  also undergo leukapheresis.  
o Leukapheresis is an outpatient procedure during which leukocytes will be 
selectively harvested; red cells and other blood components will be returned to the 
subject. In a typical leukapheresis procedure, approximately 1 -3 x109cells can be 
isolated with only minimal loss of red blood cells. No sedation is required. The 
procedure will be done by trained site staff and will be done using devices and 
procedures that conform to standard guidelines and SOPs.  
o For those subjects consented for leukapheresis, screening procedures, including 
screening laboratory evaluations, will be performed locally prior to the 
leukapheresis procedure.  
o Refer to  the protocol -specific MOP for details on the leukapheresis procedure .
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 55 of 116 Table 8: Venipuncture Volumes  
1 Inability  (e.g., loss of IV access ) to collect all baseline samples on Day 1 will not exclude the subject from further participation in this study as long as a m inimum of baseline clinical safety 
laboratory evaluations  and serum for serological immunogenic ity assays are collected.  
2 These blood volumes are not included in the blood volume totals. Blood volume depends upon day of early termination visit.  
3 Only for those subjects consented for leukapheresis.  These blood volumes are not included in the blood volume totals.  
4  Visits 09 -14 windows should be based off the actual Visit 06 date.  Procedures  
Screening  
Visit 00, Day -42 to -1 
Enrollment/Baseline  
Visit 01, Day 1  
Visit 02, Day 2  
1 day post Dose 1  
Visit 03, Day 3  
2 days post Dose 1  
Visit 04  
Day 8 +/ - 1 day  
Visit 05  
Day 15 +/ - 2 day s 
Visit 06  
Day 29 +/ - 2 days 
Visit 07, Day 30  
1 day post Dose 2  
Visit 08, Day 31  
2 days post Dose 2  
Visit 094 
Day 36 +/ - 1 day 
Visit 104 
Day 43 +/ - 2 days  
Visit 114 
Day 57 +/ - 2 days 
Visit 11Af 
Day 71 -7/+ 21 days  
Visit 124 
Day 119 +/ - 7 days  
Visit 134 
Day 209 +/ - 7 days  
Final Study Visit 144,5 
Day 394 +/ -14 days  
Early Termination Visit  
Total Volume  of 
Blood Drawn (mL)  
Vaccination   X     X            
Clinical Laboratory 
Evaluations1 28 8   8  8   8        60 
Serum for Serological 
Immunogenicity Assays1  16    16 16   16 16 16  16 16 16 162 144 
PBMCs for Cellular 
Immunology Assays   80    40 16   16 40 16  40 40  162 or 
402 288 
Serum for Secondary Research   16    8 8   8 8 8  8 8 8 82 80 
Serum for Product Assay 
Development   16    8 8   8 8 8  8 8 8 82 80 
Leukocytes for Secondary 
Research  
(subset of subjects)              623      
Per Visit Blood Volume 
Total (mL)  28 136   8 72 56   56 72 48  72 72 32 - 652 
Cumulative Blood Volume 
(mL) (prior 56 days)   164   172 244 300   356 428 312  72 72 32   
Running Blood Volume 
Total (mL)  28 164   172 244 300   356 428 476  548 620 652 -  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 56 of 116 5 Subjects who participate  in the optional third mRNA -1273 vaccination substudy  will exit the Schedule of Activities for the main study between Visit 13 and the close of the 
window for Visit 14 and will not have Visit 14 , instead will have Visit 14A and subsequent substudy visits. See Section 12, Appendix A  for the Schedule of Activities for the 
optional third mRNA -1273 vaccination substudy . 
 
 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 57 of 116 8.2.1 Procedures to be Followed in the Event of Abnormal Clinical Laboratory Test 
Values or Abnormal Clinical Findings  
If a physiologic parameter, e.g., vital signs, or clinical laboratory value , is outside of the 
protocol -specified range, then the measurement may be repeated once if, in the judgment of the 
participating site PI or appropriate sub -investigator , the abnormality is the result of an acute, 
short -term, rapidly reversible condition (e.g., stress, anx iety or “white coat syndrome”) or other 
source of error. A physiologic parameter may also be repeated if there is a technical problem 
with the measurement caused by malfunctioning, or an inappropriate measuring device (i.e., 
inappropriate -sized BP cuff).  
All abnormal clinical findings or abnormal clinical laboratory test s values that occur post 
vaccination will be considered  AEs. 
8.3 Adverse Events and Serious Adverse Events  
8.3.1 Definition of Adverse Event (AE)  
AE means any untoward medical occurrence associated with the use of an intervention in 
humans, whether or not considered intervention -related (21 CFR 312.32 (a)). An AE can 
therefore be any unfavorable and unintended sign (including an abnormal clinical laboratory 
finding), symptom or disease temporally associated with the use of medicinal (investigational) 
product.  
Any medical condition that is present at the time that the subject is screened will be considered 
as baseline and not reported as an AE. However,  if the severity of any pre -existing medical 
condition increases, it should be recorded as an AE.  
AEs can be further divided into solicited AEs and unsolicited AEs. Solicited AEs are those for 
which the study team will specifically query the subject  whethe r they occurred. Unsolicited AEs 
are those events that the subject report occurring without being queried about the specific event.  
All AEs will be assessed for severity and relationship to study intervention ( Section 8.3.3 ). 
Reporting of all AEs, solicited and unsolicited, will occur during the period from study product 
administration on Day 1 through 28 days after the second  vaccin ation . After  Day 57 through the 
end of study on Day 394 , only SAEs , Protocol Specified AESIs, MAAEs , and NOCMCs  will be 
reported  as AEs. 
All AEs, solicited and unsolicited, will be captured on the appropriate DCF . Information to be 
collected for AEs includes event description, date of on set, assessment of severity, relationship to 
study product and alternate etiology (assessed only by those with the training and authority to 
make a diagnosis and listed on the Form FDA 1572 as the participating site PI or appropriate 
sub-investigator ), dat e of resolution, seriousness , and outcome. AEs occurring during the study -
collection and reporting period will be documented appropriately regardless of relationship.  
AEs will be followed t o resolution  or stabilization . 
8.3.1.1  Solicited Adverse Events  
Solicited AEs are anticipated local and systemic AEs for which consistent collection of 
information is desired. Study c linicians will follow and collect resolution information for any 
reactogenicity symptoms that are not resolved within 7 days.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 58 of 116 Solicited AEs (i.e., reactogenicity) will be collected using a memory aid  and recorded on the 
appropriate DCF  from the time of each vaccination through  7 days post each vaccination  (Days 
1-8 for the first vaccination, and Days 29 -36 for the second vaccination) . 
For this study , solicited AEs will be:  
• Injection site Pain 
• Injection site Erythema  
• Injection site Edema /Induration  
• Headache  
• Fatigue  
• Myalgia  
• Arthralgia  
• Nausea  
• Fever  
• Chills  
8.3.1.2  Unsolicited Adverse Events  
All AEs spontaneously reported by the subject and/or in response to an open question from study 
staff or revealed by observation, physical examination or other diagnostic procedures must be 
recorded on the appropriate DCF . 
Unsolicited AEs of all severities will be reported from the time of study product administration 
through Day 57.  
After Day 57, only  SAEs (as detailed in Section 8.3.2 ), Protocol Specified AESIs, MAAEs , and 
NOCMCs will be reported  through the  end of the study (Day 394) . 
8.3.1.3  Possible  Adverse Events Assoc iated with Leukapheresis  
For those subjects consented for leukapheresis, t he possible  adverse events associated with  the 
leukapheresis procedure are: 
• Site of needle placement: pain, bruising and discomfort in the arms . 
• Vasovagal episodes, characterized by transient hypotension, dizziness, nausea, and rarely 
syncope . 
• Temporary decrease (1 -2 days) in red blood cell count . 
• Blood loss  secondary to machine malfunction . 
• Toxicity -associated anticoagulant resulting in a sour taste in the mouth, mil d muscle 
cramps and/or tingling sensation around the mouth, feet or hands . 
The risks of the leukapheresis procedure are minimal and are generally confined to the period of 
the actual study visit itself. In this protocol, AEs that are non -serious will not b e routinely 
recorded in the study database.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 59 of 116 Only SAEs that occur during or within 24 hours after the leukapheresis study visit will be 
recorded in the study database.  
8.3.1.4  Special Reporting of Adverse Events  
Not Applicable  
8.3.2 Definition of Serious Adverse Event (SAE)  
An SAE is defined in 21 CFR 312.32 as follows: “An AE or suspected adverse reaction is 
considered serious if, in the view of either the participating site PI or appropriate sub -investigator  
or the sponsor, it results in any of the following outcomes:  
• Death,  
• a life -threatening AE, 
• inpatient hospitalization or  prolongation of existing hospitalization,  
• a persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions,  
• or a congenital anomaly/birth defect.  
Important medical events that may not result in death, be lif e-threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical judgment, they 
may jeopardize the patient or subject and may require medical or surgical intervention to prevent 
one of the outcomes listed in this def inition. Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias 
or convulsions that do not result in inpatient hospitalization, or the development of drug 
dependency or drug abuse.”  
“Life -threatening” refers to an AE that at occurrence represents an immediate risk of death to a 
subject. An event that may cause death if it occurs in a more severe form is not considered life -
threatening. Similarly, a hospital admission for an elective procedure is not considered a n SAE.  
All SAEs, as with any AE, will be assessed for severity and relationship to study intervention . 
All SAEs will be recorded on the appropriate SAE DCF . 
All SAEs will be followed through resolution or stabilizat ion by a study clinician,  licensed to 
make medical diagnoses and  listed on the Form FDA 1572 as the participating  site PI or 
appropriate s ub-investigator.  
All SAEs will be reviewed and evaluated by DMID and will be sent to the SMC ( for periodic 
review unle ss related) and IRB/IEC.  
8.3.3 Suspected Unexpected Serious Adverse Reactions (SUSAR)  
A SUSAR is any SAE where a causal relationship with the study product is at least reasonably 
possible but is not listed in the Investigator ’s Brochure  (IB), Package Insert, and /or Summary of 
Product Characteristics.  
8.3.4 Classification of an Adverse Event  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 60 of 116 The determination of seriousness, severity and causality will be made by an on -site investigator 
who is qualified (licensed) to diagnose AE information, provide a medical evaluation  of AEs and 
classify AEs based upon medical judgment. This includes , but is not limited to , physicians, 
physician assistants and nurse practitioners.  
8.3.4.1  Severity of Adverse Event s 
All AEs or SAEs will be assessed for severity, according to the toxicity grading scales in the 
FDA “Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in 
Preventive Vaccine Clinical Trials” . 
For AEs not included in the protocol -defined gr ading system, the following guidelines will be 
used to describe severity.  
• Mild (Grade 1) : Events that are usually transient and may require only minimal or no 
treatment or therapeutic intervention and generally do not interfere with the subject’s 
usual activities of daily living.  
• Moderate (Grade 2) : Events that are usually alleviated with additional specific 
therapeutic intervention. The event interferes with usual activities of daily living, causing 
discomfort but poses no significant or permanent  risk of harm to the research subject . 
• Severe (Grade 3) : Events interrupt usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention. Severe events are 
usually incapacitating.  
AEs character ized as intermittent require documentation of onset and duration of each episode. 
The start and stop date of each reported AE will be recorded on the appropriate DCF . Changes in 
the severity of an AE will be documented to allow an assessment of the duratio n of the event at 
each level of intensity.  
8.3.4.2  Relationship to Study Intervention  
For each reported adverse reaction, the participating site PI or qualified designee must assess the 
relationship of the event to the study product using the following guideline s: 
• Related  – The AE is known to occur with the study intervention, there is a reasonable 
possibility that the study intervention caused the AE, or there is a temporal relationship 
between the study intervention and event. Reasonable possibility means that th ere is 
evidence to suggest a causal relationship between the study intervention and the AE.  
• Not Related  – There is not a reasonable possibility that the administration of the study 
intervention caused the event, there is no temporal relationship between th e study 
intervention and event onset, or an alternate etiology has been established.  
8.3.5 Time Period and Frequency for Event Assessment and Follow -Up 
For this study:  
• solicited AEs will be collected from Day s 1-8 (7 days post first vaccination) and Days 
29-36 (7 days post second vaccination) . 
• unsolicited AEs will be collected from Day s 1-57. 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 61 of 116 • SAEs, Protocol Specified AESIs, MAAEs , and NOCMCs  will be collected from Day 1 
through the end of the study  (Day 394).  
8.3.6 Adverse Event Repo rting  
8.3.6.1  Investigators Reporting of AEs 
Information on all AEs should be recorded on the appropriate DCF . All clearly related signs, 
symptoms and results of diagnostic procedures performed because of an AE should be grouped 
together and recorded as a single diagnosis. If the AE is a clinical laboratory abnormality that is 
part of a clinical condition or synd rome, it should be recorded as the syndrome or diagnosis 
rather than the individual clinical laboratory abnormality. Each AE will also be described in 
terms of duration (start and stop date), severity, association with the study product, action(s) 
taken, a nd outcome.  
8.3.7 Serious Adverse Event Reporting  
8.3.7.1  Investigators Reporting of SAEs  
Any AE that meets a protocol -defined criterion as an SAE must be submitted immediately 
(within 24 hours of site awareness) on an SAE form to the DMID Pharmacovigilance Group, at 
the following address:  
DMID Pharmacovigilance Group  
Clinical Research Operations and Management Support (CROMS)  
6500 Rock Spring Dr. Suite 650  
Bethesda, MD 20817, USA  
SAE Hot Line: 1 -800-537-9979 (US) or 1 -301-897-1709 (outside US) 
SAE FAX Number: 1 -800-275-7619 (US) or 1 -301-897-1710 (outside US)  
SAE Email Address: PVG@dmidcroms.com  
In addition to the SAE form, select SAE data fields must also be entered into the SDCC system. 
Refer to  the protocol -specific MOP for details regard ing this procedure.  
Other supporting documentation of the event may be requested by the DMID Pharmacovigilance 
Group and should be provided as soon as possible. The DMID Medical Monitor will review and 
assess the SAE for regulatory reporting and potential impact on study subject safety and protocol 
conduct.  
At any time after completion of the study, if the participating site PI or appropriate sub -
investigator becomes aware of an SAE that is suspected to be related to study product, the 
participating site PI or appropriate sub -investigator will report the event to the DMID 
Pharmacovigilance Group.  
8.3.7.2  Regulatory Reporting of SAEs  
Following notification from the participating site PI or appropriate sub -investigator, DMID, as 
the IND sponsor, will report any SUSAR in an IND safety report to the FDA and will notify all 
participating site PIs (i.e., all PIs to whom the sponsor is providing drug under its IND(s) or 
under any PI’s IND(s) ) of potential serious risks from clinical studies or any other source, as 
soon as p ossible. DMID will report to the FDA any unexpected fatal or life -threatening 
suspected adverse reaction as soon as possible, but in no case later than 7 calendar days after the 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 62 of 116 sponsor’s initial receipt of the information. If the event is not fatal or lif e-threatening , the IND 
safety report will be submitted within 15 calendar days after the sponsor determines that the 
information qualifies for reporting as specified in 21 CFR Part 312.32.  Relevant follow -up 
information to an IND safety report will be sub mitted as soon as the information is available. 
Upon request from FDA, DMID will submit to the FDA any additional data or information that 
the agency deems necessary, as soon as possible, but in no case later than 15 calendar days after 
receiving the reque st. 
SAEs that are not SUSARs will be reported to the FDA at least annually in a summary format 
which includes all SAEs . 
8.3.8 Reporting Events to Subjects  
Subjects  will be informed of any AEs or SAEs that occur as part of their participation in this 
trial.  
8.3.9 Adverse Events of Special Interest  (AESIs)  
Adverse Events of Special Interest (AESI s) represent any events for which additional data 
(besides the standard AE data) are desired. These may be at the request of the regulatory agency, 
industry partner or DMID,  and driven by a regulatory requirement, or known or potential risk 
from the product or class. Non -structured data similar to SAEs will be collected for AESI s. 
AESI s encompass the following terms:  
• Protocol Specified AESIs:   
o All suspected cases of myocardit is or pericarditis should be recorded . For 
reporting purposes, a subject  who displays signs/symptoms consistent with 
myocarditis or pericarditis  should be reported as a potential case of myocarditis or 
pericarditis.  
• NOCMCs  – defined as any new ICD diagnosi s (per current International Statistical 
Classification of Diseases and Related Health Problems) that is applied to the subject 
during the course of the study, after receipt of the study agent, that is expected to 
continue for at least 3 months and require s continued health care intervention.  
• MAAEs  – defined as hospitalization, an emergency room visit or an otherwise 
unscheduled visit to or from medical personnel for any reason.  
All AESI s are assessed, recorded, and followed as described above under AEs. AESIs that meet 
SAE criteria will be reported on an SAE form within 24 hours to the DMID Pharmacovigilance 
Group, at the following address:  
DMID Pharmacovigilance Group  
Clinical Research Operations and Management Support (CROMS)  
6500 Rock Spring Dr. Suite 650  
Bethesda, MD 20817, USA  
SAE Hot Line: 1 -800-537-9979 (US) or 1 -301-897-1709 (outside US)  
SAE FAX Number: 1 -800-275-7619 (US) or 1 -301-897-1710 (outside US)  
SAE Email Address: PVG@dmidcroms.com  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 63 of 116 In addition,  for documentation and medical assessment  purposes AESIs that do not meet SAE 
criteria will also be reported on an SAE form  within the period for AE reporting to the DMID 
Pharmacovigilance Group ; however, the narrative will indicate that the AESI did not meet SAE 
criteria.  
8.3.10  Reporting of Pregnancy  
Pregnancy is not an AE. However, any pregnancy that occurs during study participation (through 
Day 394) should be reported to the sponsor on the appropriate DCF . Pregnancy should be 
followed to outcome.  
8.4 Unanticipated Problems  
8.4.1 Definition of Unanticipated Problems (U Ps) 
The Department of Health and Human Services (DHHS)  OHRP considers unanticipated 
problems involving risks to subjects  or others to include, in general, any incident, experience, or 
outcome that meets all of the following criteri a: 
▪ Unexpected in terms of nature, severity, or frequency given (a) the research procedures 
that are described in the protocol -related documents, such as the IRB -approved research 
protocol and informed consent document; and (b) the characteristics of the subject  
population being studied;  
▪ Related or possibly related to participation in the research (“possibly related” means there 
is a reasonable possibility that the incident, experience, or outcome may have been 
caused by the procedures involved in the resear ch); and  
▪ Suggests that the research places subjects  or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or 
recognized.  
8.4.2 Unanticipated Problem Reporting  
To satisfy the requirement for pr ompt reporting, UPs will be reported using the following 
timeline:  
▪ UPs that are SAEs will be reported to the IRB and to the SDCC/study sponsor within 24 
hours of the participating site PI  or appropriate sub -investigator  becoming aware of the 
event  per the above describe d SAE reporting process . 
▪ UPs that are SAEs will be collected from Day 1 through the end of the study (Day 394).  
▪ Any other UP will be reported to the IRB and to the SDCC/study sponsor within 3 days  
of the participating site PI  or appropriate sub -investigator  becoming aware of the 
problem.  
▪ UPs that are not SAE s will be collected from Days 1 -57. 
8.4.3 Reporting Unanticipated Problems to Subjects  
Subjects will be informed of any UPs that occur as part of their partic ipation in this trial.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 64 of 116 9. STATISTICAL  CONSIDERATIONS  
9.1 Statistical Hypotheses  
This is a phase I , open -label, dose -ranging clinical trial and is not designed to test a specific 
hypothesis. Rather, it is intended to obtain preliminary estimates in healthy adults of the safety, 
reactogenicity, and immunogenicity of mRNA -1273.  
9.2 Sample Size Determination  
Rare AEs are not demonstrable in a clinical study of this size; however, the probabilities of 
observing one or more AEs given various true event rates are presented in Table 9. With the 
assumption that all enrolled subjects will likely complete immunizations and safety visits in this 
relatively short duration study, the following statistical considerations apply. With 15 subjects in 
each dose group  (cohorts 1 -3,10,13), the chance of observing at least one AE of probability 20% 
or more is approximately 97%. Therefore, if no AEs of a given type occur in a dose group 
(cohorts 1 -3,10,13 ), we can be relatively confident that they will occur in fewer than 20% of 
people once the vaccine is implemented. With 60 subjects across the se four dosing cohorts  (1-
3,10) , the chance of observing at least one AE of probability 5% or more is at least 9 5%. 
Therefore, if no AEs of a given type occur across the combined doses, we can be very confident 
that any dosage -independent event will occur in fewer than 5% of people once the vaccine is 
implemented.  If Cohort 13 is enrolled and there are 75 subjects across five dosing cohorts (1 -
3,10,13), the chance of observing at least one AE of pr obability 5% or more is at least 97.9%. 
Therefore, if no AEs of a given type occur across the combined doses, we can be very confident 
that any dosage -independent event will occur in fewer than 5% of people once the vaccine is 
implemented. With 10 subjects  in each dose group  (cohorts 4 -9,11-12), the chance of observing 
at least one AE of probability 20% or more is approximately 89.3%. Therefore, if no AEs of a 
given type occur in a dose group  (cohorts 4 -9,11-12), we can be relatively confident that they 
will occur in fewer than 20% of people once the vaccine is implemented  in the older population . 
With 30 subjects across each of the two older subject dosing cohorts  (i.e., cohorts 4 ,5,11  and 
7,8,12 ), the chance of observing at least one AE of probability 5 % or more is at least 78.5%. 
Therefore, if no AEs of a given type occur across the combined doses, we can be very confident 
that any dosage -independent event will occur in fewer than 5% of older people once the vaccine 
is implemented.  If Cohorts 6 and 9 ar e enrolled and there are 40 subjects across each of the two 
older subject dosing cohorts (i.e., cohorts 4,5,6,11 and 7,8,9,12), the chance of observing at least 
one AE of probability 5% or more is at least 87.1%. Therefore, if no AEs of a given type occur 
across the combined doses, we can be very confident that any dosage -independent event will 
occur in fewer than 5% of older people once the vaccine is implemented.  
Table 9: Probability of Observing an Adverse Event for V arious Event Rates  
N “True ” 
Event 
Rate  Probability of 
Observation 
(%) N “True ” 
Event 
Rate  Probability of 
Observation 
(%) N “True” 
Event 
Rate  Probability 
of 
Observation 
(%) 
15 0.1%  1.5 
60 0.1%  5.8 
75 0.1%  7.2 
0.5%  7.2 0.5%  26.0 0.5%  31.3 
1.0%  14.0 1.0%  45.3 1.0%  52.9 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 65 of 116 N “True ” 
Event 
Rate  Probability of 
Observation 
(%) N “True ” 
Event 
Rate  Probability of 
Observation 
(%) N “True” 
Event 
Rate  Probability 
of 
Observation 
(%) 
2.0%  26.1 2.0%  70.2 2.0%  78.0 
3.0%  36.7 3.0%  83.9 3.0%  89.8 
4.0%  45.8 4.0%  91.4 4.0%  95.3 
5.0%  53.7 5.0%  95.4 5.0%  97.9 
10.0%  79.4 10.0%  99.8 10.0%  >99.9  
15.0%  91.3 15.0%  >99.9 15.0%  >99.9  
20.0%  96.5 20.0%  >99.9  20.0%  >99.9  
 
N “True” 
Event 
Rate  Probability of 
Observation 
(%) N “True” 
Event 
Rate  Probability of 
Observation 
(%) N “True” 
Event 
Rate  Probability 
of 
Observation 
(%) 
10 0.1%  1.0 
30 0.1%  3.0 
40 0.1%  3.9 
0.5%  4.9 0.5%  14.0 0.5%  18.2 
1.0%  9.6 1.0%  26.0 1.0%  33.1 
2.0%  18.3 2.0%  45.5 2.0%  55.4 
3.0%  26.3 3.0%  59.9 3.0%  70.4 
4.0%  33.5 4.0%  70.6 4.0%  80.5 
5.0%  40.1 5.0%  78.5 5.0%  87.1 
10.0%  65.1 10.0%  95.8 10.0%  98.5 
15.0%  80.3 15.0%  99.2 15.0%  99.8 
20.0%  89.3 20.0%  99.9 20.0%  >99.9  
9.3 Populations for Analyses  
The Safety Analysis population for the  main study  includes all subjects who received one dose of 
vaccine. Analyses for the primary safety population will include safety reported through the end 
of the main study . A modified primary safety population analysis will also be performed that 
excludes safety da ta collected after subjects receive either the third mRNA -1273 vaccination in 
the optional substudy or non -study EUA vaccine, if applicable . 
The modified intent -to-treat ( mITT) population includes all subjects who received one dose of 
vaccine and contribut ed both pre - and at least one post -vaccination venous blood samples for 
immunogenicity testing for which valid results were reported.  
In the final analysis, protocol deviations  will be reviewed to determine which protocol deviations 
may affect the analysis . The per protocol (PP) population will then be defined – and this includes 
all subjects in the mITT subset with the following exclusions:  
• Data from all available visits for subjects found to be ineligible at baseline.  
• Data from all visits subsequent for the protocol deviations  that are considered to affect 
the science . 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 66 of 116 • Data from any visit that occurs substantially out of window.  
9.4 Statistical Analyses  
Interim analyses of safety, reactogenicity, and immunologic response data may be done, as 
needed.  
The final analysis will be performed after the final data lock (through Day 394) and clinical 
study report (CSR) completed when all primary safety endpoint data and all secondary 
immunogenicity endpoint data are available  and received by the SDCC . Any avai lable data from 
the exploratory immunogenicity endpoints may also be included  in the CSR . Remaining  
exploratory immunogenicity endpoint data may be included in an addendum to the CSR, 
publication of manuscript(s), or other report(s).  Abbreviated analysis p lans that describe planned 
analyses to facilitate dissemination of study data for public health reasons, including  manuscript 
publication(s) , will be developed by the SDCC. A full statistical analysis plan (SAP)  will be 
developed by the SDCC and finalized prior to the primary data lock.  
9.4.1 General Approach  
Unless otherwise noted in the SAP, continuous variables will be summarized using the following 
descriptive statistics: n (non -missing sample size), mean, standard deviation, median, maximum 
and minimum. The frequency and percentages (based on the non -missing sample size) of 
observed levels will be reported for all categorical measures.  
9.4.2 Analysis of the Primary Endpoint(s)  
Section 9.4.4  describes the analyses of Safety which is the primary endpoint of this protocol.  
9.4.3 Analysis of the Secondary Endpoint(s)  
Summaries and analysis of immunogenicity data will be presented for the mITT population. If 
there are protocol deviations  which may affect the analysis , a per -protocol (PP) analysis may 
also be performed.  
Seroconversion is defined as a 4 -fold increase in a ntibody titer over baseline.  
Seroconversion rates , GMFR  and GMT for SARS -CoV -2 as measured by IgG ELISA will be 
calculated at Day s 1 (GMT only)  and 57 by cohort and will be summarized graphically. 
Seroconversion rates , GMFR  and GMT will be presented with their corresponding 95% 
confidence interval (CI) estimates at each timepoint and overall peak GMT, and the pair -wise 
differences between serocon version rates by cohort will be summarized by study day along with 
95% CIs. 
9.4.4 Safety Analyses  
Summaries and analysis of safety data will be presented for the Safety Analysis Population.  
Solicited AEs will be summarized by severity for each day post vaccinati on (Days 1 -8) and as 
the maximum severity over all 8 days. Additionally, solicited AEs will be analyzed by taking the 
most severe response over the follow -up period, dichotomizing into a binary variable (none 
versus mild, moderate, or severe) and using sta ndard techniques, such as exact confidence 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 67 of 116 intervals (CI), to summarize the proportion of subjects reporting each symptom, any application 
site symptom, and any systemic symptom.  
Unsolicited non -serious AEs will be collected from the time of first vaccinat ion through 28 days 
after the second  vaccination. Unsolicited AEs will be coded by MedDRA for preferred term and 
system organ class (SOC). SAEs , Protocol Specified AESIs, MAAEs , and NOCMC s will be 
collected from the time of first vaccination through the end of the study (Day 394) . The numbers 
of SAEs and MAAEs will be reported by detailed listings showing the event description, 
MedDRA preferred term and SOC, relevant dates (vaccinations and  AEs), severity, relatedness, 
and outcome for each event. Non -serious unsolicited AEs will be summarized as number and 
percentage of subjects reporting at least one event in each MedDRA preferred term and SOC, 
cross tabulated by severity and relationship t o study product. Additionally, the proportion of 
subjects and exact 95% CIs of AEs in aggregate and by MedDRA categories will be computed.  
Clinical laboratory data will be summarized by severity for each visit, and as the maximum over 
all post -vaccination visits. Graphical presentations may include box plots and shift plots.  
9.4.5 Baseline Descriptive Statistics  
Summaries of demographic variables such as age, sex, ethnicity, and race will be presented by 
cohort and overall. Summaries of baseline clinical laborato ry values will be presented by cohort 
and overall.  
9.4.6 Planned Interim and Early Analyses  
Data may be disseminated to public health officials and partners as needed  and included in 
publications and presentations to inform the global scientific community . Early  analyses will 
include safety and immunogenicity as described in Sections 9.4.6.1 , 9.4.6.2  and 9.4.6.3 . Further, 
the protocol team will review data periodically to confirm no halting criteria have been met as 
described in Section 10.1.6.1 . 
Cumulative safety information, study status, and primary endpoint results may be published,  
presented at a public forum , or presented as summaries aggregated by study arm at the discretion 
of the sponsor while the main  study is ongoing. Any ad -hoc analyses , jointly developed by the 
SDCC and/or  the VRC , other participating laboratories  and ModernaTX, Inc. , will be executed 
by the SDCC as needed. None of the interim analyses will include any formal statistical 
hypothesis testing; therefore, p value adjustment  will not be made to any analyses.  
9.4.6.1  Interim Safety Analyses  
Given the need for rapid review and dissemination of study data for public health reasons, AEs 
and SAEs maybe reviewed as necessary outside of SMC reviews.  The SMC will not need to 
meet (unless halting rules are met ), and materials will be provided electronically. Documentation 
of review and any concerns noted will be solicited electronically.  
The SMC will review cumulative AE data after all subjects in cohorts 1 and 2 have completed 
Day 8. In addit ion, cumulative AE data will be provided to the SMC after all subjects in cohorts 
3, 4, 5, 7, and 8 have completed Day 8 . Cumulative AE data will also be provided to the SMC 
after all subjects in all cohorts have completed Day 57. Documentation of review a nd any 
concerns noted will be solicited electronically.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 68 of 116 9.4.6.2  Interim Immunogenicity Review  
For public health reasons there will be several immunogenicity reviews. The following reviews 
are anticipated  once data are available:  
• Sentinel subjects in cohorts 1 and 2, ELISA IgG data through  Day 29; 
• All subjects in cohorts 1 and 2, ELISA IgG data through Day 29 ; 
• Sentinel subjects in cohort 3, ELISA IgG data through  Day 29; 
• All subjects in cohort 3, ELISA IgG data through Day 29 ; 
• All subjects in cohorts 4, 5, 7 and 8, ELISA IgG data through Day 29;  
• All subjects in cohorts 10 -12, ELISA IgG data through Day 29 ; 
• All subjects in cohort 13, ELISA IgG data through Day 29 (if cohort is enrolled);  
• All subjects in cohorts 6 and 9, ELISA IgG  data through Day 29  (if cohorts are enrolled) ; 
• Sentinel  subjects  in cohorts 1 and 2, ELISA IgG data through Day 57;  
• All subjects in cohorts 1 and 2, ELISA IgG data through Day 57;  
• Sentinel  subjects  in cohort 3, ELISA IgG data through Day 57;  
• All subjects in cohort 3, ELISA IgG data through Day 57 ; 
• All subjects in cohorts 4, 5, 7 and 8, ELISA IgG data through Day 57;  
• All subjects in cohorts 10 -12, ELISA IgG data through Day 57 ; 
• All subjects in cohort 13, ELISA IgG data through Day 57 (if cohort is enrolled)  
• All subjects in cohorts 6 and 9, ELISA IgG data through Day 57  (if cohorts are enrolled) . 
• Additional data review of immunogenicity may be performed to inform public health 
decisions.  
Data may be disseminated to public health officials and partner s as needed  and included in 
publications and presentations to inform the global scientific community . 
9.4.6.3  Interim Immunogenicity and Safety Review  
Interim analys es of safety, reactogenicity, and immunologic response data may be done , as 
needed . 
9.4.7 Sub-Group Analyses  
The protocol does not define any formal subgroup analyses, and the study is not adequately 
powered to perform subgroup analyses.  
9.4.8 Tabulation of Individual Subject  Data  
In general, all data will be listed, sorted by cohort and subject, and  when appropriate by visit 
number within subject.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 69 of 116 9.4.9 Exploratory Analyses  
Summaries and analysis of immunogenicity data will be presented for the mITT population. If 
there are protocol deviations  which may affect the analysis , a PP analysis may also be 
performed.  
Seroconversion is defined as a 4 -fold increase in antibody titer over baseline.  
Seroconversion rates, GMFR and GMT for SARS -CoV -2 as measured by IgG, IgA and IgM 
ELISA, neutralization assay using SARS -CoV -2 pseudovirus and neutralization assay u sing a 
live wild-type SARS -CoV -2 will be calculated for specified timepoints by cohort and will be 
summarized graphically. Seroconversion rates, GMFR and GMT will be presented with their 
corresponding 95% CI estimates at each timepoint and overall peak GMT , and the pair -wise 
differences between seroconversion rates by cohort will be summarized by study day along with 
95% CI.  
Summaries and analysis of cellular assay data will be presented for the mITT population. If there 
are protocol deviations  which may af fect the analysis , a PP analysis may also be performed.  
The magnitude, phenotype and percentage of cytokine producing S  protein -specific T cells will 
be summarized at each timepoint by vaccination group.  
10. SUPPORTING  DOCUMENTATION  AND  OPERATIONAL  
CONSIDERATI ONS  
10.1 Regulatory, Ethical, and Study Oversight Considerations  
This study will be conducted in conformity with the principles set forth in The Belmont Report: 
Ethical Principles and Guidelines for the Protection of Human Subjects of Research (US 
National Comm ission for the Protection of Human Subjects of Biomedical and Behavioral 
Research; April 18, 1979), and the federal policy for the Protection of Human Subjects codified 
in 45 CFR Part 46, 21 CFR Part 50 (Protection of Human Subjects), and the ICH E6(R2).  
An OHRP -registered IRB will review and approve this protocol, associated informed consent 
documents, recruitment material s, and handouts or surveys intended for the subjects, prior to the 
recruitment, screening and enrollment of subjects. The IRB review sha ll be in accordance with 
45 CFR 46 and 21 CFR 50, 21 CFR 56 ( IRBs), and other federal, state, and local regulations and 
policies, as applicable.  
Each institution engaged in this research will hold an OHRP -approved FWA.  
Any amendments to the protocol or informed consent documents  will be approved by the IRB 
before they are implemented. IRB review and approval will occur at least annually throughout 
the duration of the study. The participating site PI  will notify the IRB of deviations from the 
protocol and re portable SAEs, as applicable to the IRB policy.  
DMID must receive the documentation that verifies IRB  approval for this protocol, informed 
consent documents and associated documents , prior to the recruitment, screening and enrollment 
of subjects, and any I RB approvals for continuing review or amendments as required by the 
DMID.  
10.1.1  Informed Consent Process  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 70 of 116 Informed consent is a process that is initiated prior to an individual agreeing to participate in a 
trial and continuing throughout the individual’s trial pa rticipation. Investigators or designated 
research staff will obtain a subject’s informed consent in accordance with the requirements of 45 
CFR 46, 21 CFR 50 and 21 CFR 56 for FDA -regulated studies, state and local regulations and 
policy, and ICH E6 GCP before any study  procedures or data collection are performed. The 
participating  site PI  or other study staff may obtain oral or written information for the purpose of 
screening, recruiting, or determining the eligibility of prospective subjects without the informed 
consen t of the prospective subject if the process is approved by the IRB.  
At the first study visit, informed consent will be obtained and documented before any study 
procedures are performed. Subjects will receive a concise and focused presentation of key 
information about the clinical trial, verbally and with a written consent form. The key 
information about the purpose of the study, the procedures and experimental aspects of the study, 
study interventions/products, risks and discomforts, the expected dura tion of the subject’s 
participation in the trial, any expected benefits to the subject, and alternative treatments and 
procedures that may be available to the subject. The explanation will be organized and presented 
in lay terminology and language that fac ilitates understanding why one might or might not want 
to participate.  
Subjects will receive an explanation as to whether any compensation and any medical treatments 
are available if injury occurs, and, if so, what they consist of, or where further informa tion may 
be obtained. Subjects will be informed of the anticipated financial expenses, if any, to the subject 
for participating in the trial, as well as any anticipated prorated payments, if any, to the subject 
for participating in the trial. They will be informed of whom to contact (e.g., the participating  site 
PI) for answers to any questions relating to the research project. Information will also include the 
foreseeable circumstances and/or reasons under which the subject’s participation in the trial may  
be terminated. The subjects will be informed that participation is voluntary and that they are free 
to withdraw from the study for any reason at any time without penalty or loss of benefits to 
which the subject is otherwise entitled.  Subjects will be allo wed sufficient time to consider 
participation in this research trial and have the opportunity to discuss this trial with their family, 
friends or legally authorized representative, or think about it prior to agreeing to participate.  
Subjects will be inform ed that records identifying the subject will be kept confidential, and, to 
the extent permitted by the applicable laws and/or regulations, will not be made publicly 
available. If the results of the trial are published, the subject’s identity will remain co nfidential. 
Subjects will be informed, even if identifiers are removed, that information collected from this 
research and/or specimens may be used for  secondary  research , including the sharing of 
deidentified data . 
Subjects will be informed that the monito r(s), auditors(s), IRB, NIAID, and regulatory 
authority(ies) will be granted direct access to the subject’s original medical records for 
verification of clinical trial procedures and/or data without violating the confidentiality of the 
subject, to the exte nt permitted by the applicable laws and regulations, and that, by signing a 
written ICF, the subject is authorizing such access.  
ICFs will be IRB -approved,  and subjects will be asked to read and review the consent form. 
Subjects must sign the ICF prior to starting any study procedures being done specifically for this 
trial. Once signed, a copy of the ICF will be given to the subject for their records.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 71 of 116 New information will be communicated by the participating  site PI to subjects who consent to 
participate in  this trial in accordance with IRB requirements. The informed consent document 
will be updated, and subjects will be re -consented per IRB requirements, if necessary.  
10.1.1.1  Requirements for Permission by Parents/Guardians and Assent by Children (in 
case of a mino r) 
Not Applicable  
10.1.1.2  Other Informed Consent Procedures  
The rights and privacy of human subjects who participate in genomic or phenotypic research 
studies will be protected at all times. The consent process, including relevant language in the 
ICF, will provide an explanation of the potential risks to the individual study subjects and their 
families. Clinical metadata, genomic, or other datasets or a subset of the clinical and other 
metadata that may potentially identify human subjects will not be r eleased in unrestricted 
databases. Subjects will be informed that the evolution of genomic technology and analytical 
methods raises the risk of re -identification, even when specimens are de -identified.  
Subjects will be asked for consent to collect addition al blood, the use of residual specimens, and 
the sharing of genetic information and samples for secondary research. This extra/residual blood 
and corresponding serum, plasma and PBMCs will be used as back -up specimens for PP defined 
assays or designated fo r secondary research use and stored indefinitely at a designated storage 
facility.  
Subject s will be asked to consent specifically to genetic testing, including DNA sequencing. 
DNA sequencing data will be kept private. DNA data may be used to produce commer cial 
antibody -based therapeutics. Subjects will not share in profits or commercial rights to those 
products.  
To support development of diagnostics, therapeutic s and vaccines, a subset of subjects enrolled 
in cohorts 2 , 3, 5, 10, and 11, and possibly cohort  6, if enrolled,  will also be asked to consent for 
leukapheresis to collect additional samples for secondary research , which will be stored 
indefinitely at a designated storage facility . 
If subjects  choose not to provide permission for extra  blood and secondary research use, they 
will not be eligible for enrollment into the study. However, consent for leukapheresis is not 
required for study participation.  
Collection of extra/residual samples during the course of the study will help facilitate rapid 
follow -on analyses, if warranted, to provide more comprehensive scientific insights into the 
impact (safety and immunological) of the vaccine  on the host response to vaccination. To 
maintain statistical power in follow -on analyses it is important that ex tra blood collection and 
secondary research use be included in as many subjects as possible, due to the limited sample 
size per treatment arm , with the exception of leukapheresis . 
The stored samples will be labeled with barcodes to maintain confidentiality. Research  with 
identifiable samples and data may occur as needed, however, subject confidentiality will be 
maintained as described for this protocol and with IRB approval.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 72 of 116 Samples designated for secondary research use may be used for additional immunological 
assess ments that may include but are not limited to antibody epitope mapping, B and T cell 
repertoire determination, non -traditional immune assay development, determination of innate 
immune factors and the ability of vaccine -induced antibodies to cross -react to different proteins 
and virus strains. These blood samples might be used in new or different immunological 
laboratory tests, to provide information for the development of new vaccines  or therapeutics , or 
for the studies of nCoV or other infections. Secondar y research using DNA may also be 
warranted to understand genetic factors involved in vaccination failures.  
Samples will not be sold for commercial profit.  Although the results of any future research may 
be patentable or have commercial profit, subjects will have no legal or financial interest in any 
commercial development resulting from any future research.  
There are no direct benefits to the subject for ex tra specimens collected or from the secondary 
research. No results from secondary research will be entered into the subject’s medical record.  
Incidental findings will not be shared with the subject, including medically actionable incidental 
findings, unle ss required by law.  
Risks are associated with the additional volume of blood collected, such as anemia. Risks for 
loss of privacy and confidentiality are described below.  
Subjects may withdraw permission to use samples for secondary use at any time. They w ill need 
to contact the participating  site and the samples will be removed from the study repository after 
this study is completed and documentation will be completed that outlines the reason for 
withdrawal of permission for secondary use of samples. Subje cts who withdraw consent before 
the last visit will not have the extra  blood drawn for secondary use. 
Human Genetic Testing  
The research staff will seek the subjects’ consent for extra and residual specimens to be stored 
and used for secondary research , including genetic research,  evaluating human genomic and 
phenotypic markers . The rights and privacy of human subjects who participate in genomic or 
phenotypic research studies will be protected at all times.  
The consent process will include an explanation of  the potential risks to the individual subjects 
and their families associated with data submitted to an NIH data repository and subsequent 
sharing. Data that may potentially identify human subjects will not be released in unrestricted 
databases. Subjects w ill be informed that the evolution of genomic technology and analytical 
methods raises the risk of re -identification, even when specimens are de -identified. The consent 
will include whether individual subject data will be shared through a NIH controlled ac cess data 
repository. Data for genomic or phenotypic research will be submitted to a controlled access data 
repository, therefore, informed consent permitting the data sharing must be documented, even if 
the specimens are de -identified.  
10.1.2  Study Termination  and Closure  
In Section 7, Study Intervention Discontinuation and Subject  Discontinuation/Withdrawal, 
describes the temporary halting of the study.  
This study may be prematurely terminated if there is sufficient reasonable cause, including , but 
not limited to:  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 73 of 116 • Determination of unexpected, significant, or unacceptable risk to subjects  
• Results of interim analysis  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or not evaluable  
• Regulatory authorities  
If the study is prematurely terminated, the PI will promptly inform study subjects  and t he IRB as 
applicable. Study subjects  will be contacted, as applicable, and be informed of changes to study 
visit schedule. The PI will assure appropriate follow -up for the subjects, as necessary.  
The sponsor will notify regulatory authorities as applicable . 
10.1.3  Confidentiality and Privacy  
Subject confidentiality is strictly held in trust by the participating investigators, their staff, and 
the sponsor(s) and their agents. This confidentiality is extended to cover clinical information 
relating to subjects , test results of biological samples and genetic tests, and all other information 
generated during participation in the study. No identifiable information concerning subjects  in 
the study will be released to any unauthorized third party. Subject confidentiality w ill be 
maintained when study results are published or discussed in conferences.  
The study monitor, other authorized representatives of the sponsor, representatives of the IRB, 
and/or regulatory agencies may inspect all documents and records required to be maintained by 
the participating site PI , including , but not limited to, medical records (office, clinic, or hospital) 
and pharmacy records for the subjects  in this study. The participating site will permit access to 
such records.  
All source records , includ ing electronic data , will be stored in secured systems in accordance 
with institutional policies and federal regulations.  
All study data and research specimens that leave the participating site (including any electronic 
transmission of data) will be identi fied only by a coded number that is linked to a subject through 
a code key maintained at the participating  site. Names or readily identifying information will not 
be released unless DMID approves and it aligns with the consent form, or according to laws for 
required reporting.  
Because it may be possible to re -identify de -identified genomic data, even if access  to data is 
controlled and data security standards are met, confidentiality cannot be guaranteed, and re -
identified data could potentially be used to discriminate against or stigmatize subjects , their 
families, or groups. In addition, there may be unknown risks.  
As this research is funded by the NIH, it is covered by NIH policy which effectively issues the 
research a Certificate of Confidentiality  (COC) . By this policy, researchers cannot be forced to 
disclose or provide, in any Federal, State, or local civ il, criminal, administrative, legislative, or 
other proceeding, the name of such individual or any such information, document, or 
biospecimen that contains identifiable, sensitive information about the individual and that was 
created or compiled for purpos es of the research, unless such disclosure or use is made with the 
consent of the individual to whom the information, document, or biospecimen pertains.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 74 of 116 The Certificate cannot be used to resist a demand for information from personnel of the United 
States G overnment that is used for auditing or evaluation of federally funded projects, like this 
study, or for information that must be released in order to meet the requirements of the FDA.  
A COC  does not prevent subject s from voluntarily releasing information a bout themselves or 
their involvement in this research. If any person or agency obtains a written consent to receive 
research information, then the researchers may not use the Certificate to withhold that 
information.  
The COC  does not prevent the researcher s from reporting , without the subject’s consent, 
information that would identify the subject as a subject  in the research project in the case of 
matters that must be legally reported , including child and elder abuse, sexual abuse, or wanting 
to harm themse lves or others.  
The release of individual private information or specimens for other research will only occur if 
consent was obtained from the individual to whom the information, document, or biospecimen 
pertains, or that the release is in compliance with applicable Federal regulations governing the 
protection of human subjects in research.  
10.1.4  Secondary Use of Stored Specimens and Data  
Secondary Human Subject Research is the re -use of identifiable data or identifiable 
biospecimens that were collected from some other ‘‘primary’’ or ‘‘initial’’ activity, such as the 
data and samples collected in this protocol. This section will detail the samples and data 
available for secondary research. Any use of the sample or data,  however, will be presented in a 
separate protocol and require separate IRB approval.  
10.1.4.1  Samples for Secondary Research  
The following types of  samples will be stored and used for  secondary research:  
• Residual Research Sample : Any leftover Primary Research Sample after the laboratory 
testing specified in this protocol is completed will be stored for future studies with the 
subject’s consent.  
• Repository Research Sample : Samples will be collected with the subject ’s consent in this 
protocol with the intent to store for additional research (i.e. , samples collected beyond 
those needed for primary research) and will be used in future studies.  Amendments to this 
protocol with additional ass ays may use repository research samples . 
Samples will be stored indefinitely at a DMID -designated storage facility. Each sample will be 
encoded (labeled) only with a barcode and a unique tracking number to protect subject 
confidentiality. Secondary research with coded samples and data may occur, however, subject 
confidentiality will be maintained as described for this protocol. An IRB review of the secondary 
research using coded specimens is required.  
Residual/Repository Research Samples, u pon written request and approval from DMID  and any 
approvals required by the site or network , may be shared for secondary research with 
investigators at the participating site, with researchers at other Infectious Disease Clinical 
Research Consortium ( IDCR C) sites or other institutions, or company -designated research 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 75 of 116 laboratories. The samples will not be sold or used directly for production of any commercial 
product. DMID will authorize shipment from the DMID CMS.  
Reports from secondary research will not be  kept in the subjects’ health records or shared with 
subjects, unless required by law. Reports will not be sent to the specimen repository.  
The subject’s decision can be changed at any time by notifying the study doctors or nurses in 
writing. To participat e in this study , subjects must consent for storage of samples for secondary 
use. If the subject subsequently changes his/her decision, the samples will be destroyed if the 
samples have not been used for research or released for a specific research project.  
10.1.4.2  Data Sharing for Secondary Research  
Data from this study  may be used for secondary research. All of the individual subject  data 
collected during this study  will be made available after de -identification. The SAP and Analytic 
Code will also be made availab le. Data will be available immediately following publication, with 
no end date. Upon written request, with provision of a methodologically sound proposal, and 
approval from DMID and any approvals required by the site or network , data may be shared for 
secondary research with investigators /researchers . The data will be available for only the purpose 
outlined in the approved proposal.  
For access to genomic data in the NIH designated controlled access database, an investigator (or 
data requestor) must submit a  Data Access Request which certifies adherence to the NIH 
Security Best Practices for Controlled -Access data subject to the NIH Genomic Data Sharing 
(GDS ) Policy.  
The participating  site PI  may request removal of data on individual study subjects from NIH data 
repositories in the event that a research subject withdraws or changes his or her consent. 
However, some data that have been distributed for approved research use cannot be retrieved.  
10.1.5  Key Roles and Study Governance  
This study is sponsored by DMID. Decisions related to th is study will be made by the protocol 
team, which includes representatives from the participating site (PI), DMID (sponsor), VRC, and 
ModernaT X, Inc. Key Roles are noted  in the protocol -specific MOP.  
10.1.6  Safety Oversight  
10.1.6.1  Protocol Team Oversight  
The protocol team will meet at the following timepoints to review AE data and to ensure no 
halting  rules have been met:  
• after the four 25 mcg (cohort 1) and the four 100 mcg (cohort 2) sentinel subjects have 
completed Day 5 . 
• after the full cohorts 1 and 2 have completed Day 8 . 
• after the four 250 mcg (cohort 3) sentinel subjects have completed Day 5 . 
• after the full cohorts 1  and 2 have completed Day 29 (prior to beginning Dose 2 
vaccinations in cohort 3) . 
• after the full cohort 3 has completed Day 8.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 76 of 116 • after the full cohorts 4 and 5 have completed Day 8.  
• after the full cohorts 7 and 8 have completed Day 8.  
• after the full cohort 6, if enrolled,  has completed Day 8.  
10.1.6.2  Safety Monitoring Committee  (SMC)  
The SMC is an independent group of at least 2-3 experts that monitors subject safety and advises 
DMID. SMC members will be separate and independent of study staff participating in this trial 
and should not have scientific, financial, or other conflicts of interest related to this trial. The 
SMC will c onsist of members with appropriate expertise to contribute to the interpretation of 
data from this trial. A quorum will consist of a simple majority.  
The SMC will hold an organizational meeting prior to enrollment. At this meeting, the SMC will 
review the charter, protocol, ICF, IB, and safety report template s. 
Given the frequency and urgency to review data, the SMC will not need to meet (unless halting  
rules are met ), and materials will be provided electronically . Documentation of review and any 
concerns n oted will be solicited electronically . 
The SMC will review cumulative AE data after all subjects in cohorts 1 and 2 have completed 
Day 8. In addition, cumulative AE data will be provided to the SMC after all subjects in cohorts 
3, 4, 5, 7, and 8 have compl eted Day 8. Cumulative AE data will also be provided to the SMC 
after all subjects in all cohorts have completed Day 57. Documentation of review and any 
concerns noted will be solicited electronically.  
The SMC does not need to meet for dose escalation to 2 50 mcg (cohort s 3, 6 and 9 ) or for 
initiation of the optional third mRNA -1273 vaccination substudy . 
The SMC will meet w hen trial or optional third mRNA -1273 vaccination substudy halting 
criteria are met , or as requested by the sponsor or PI.  
Ad hoc reviews will occur when trial halting criteria are met, or as requested by the sponsor or 
PI. 
The SMC will have a final review meeting at the end of the trial, defined as the end of the 
optional third mRNA -1273 vaccination substudy . 
Procedures for S MC reviews/meetings will be defined in the SMC charter. The SMC will review 
applicable data , including, but not limited to, enrollment, demographics, dosing  data,  clinical  
laboratory data , and safety data , at scheduled timepoints during this trial as defin ed in the SMC 
charter.  
Additional data may be requested by the SMC, and interim statistical reports may be generated 
as deemed necessary and appropriate by DMID. As an outcome of each review/meeting, the 
SMC will make a recommendation as to the advisability of proceeding with st udy product  
administration, and to continue, modify, or terminate this trial.  
10.1.7  Clinical Monitoring  
Clinical site monitoring is conducted to ensure that the rights and well -being of trial subjects  are 
protected, that the reported trial data are accurate, com plete, and verifiable. Clinical Monitoring 
also ensures conduct of the trial is in compliance with the currently approved protocol/  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 77 of 116 amendment(s), ICH, GCP , and with applicable regulatory requirement(s) and sponsor 
requirements. Clinical monitoring will also verify that any critical study procedures are 
completed following specific instructions in the protocol -specific MOP . 
Monitoring for this study will be performed by DMID. Details of clinical site monitoring are 
documented in a CMP. The CMP describes in detail who will conduct the monitoring, at what 
frequency monitoring will be done, at what level of detail monitoring will be performed, and the 
distributi on of monitoring reports. Monitoring visits will include, but are not limited to, review 
of regulatory files, accountability records, electronic case report forms ( eCRFs ), ICFs, medical 
and laboratory reports, site study intervention storage records, train ing records, and protocol and 
GCP compliance. Site monitors will ha ve access to each participating  site, study staff and all 
study documentation according to the DMID -approved CMP . Study monitors will meet with all 
participa ting site PIs to discuss any pro blems and outstanding issues and  will document site visit 
findings and discussions.  
10.1.8  Quality Control (QC) and Quality Assurance  (QA)  
To ensure the reliability of study data, the participating site will develop a Clinical Quality 
Management Plan (CQMP). The CQMP will describe : 
• routine internal quality control (QC) and QA activities  
o for the purposes of measuring, documenting and reporting study conduct, protocol 
adherence, human subjects’ protections, and reliability of the protocol -driven data 
collected;  
o independent of sponsor site monitoring.  
• a process for addressing data quality issues (i.e., collecting, recording), and reporting 
findings in a timely manner); systemic issues (i.e., protocol conduct, non -compliance, 
human subject protections), and  implementation and evaluation of Corrective and 
Preventative Action Plan (CAPA) procedures.  
10.1.9  Data Handling and Record Keeping  
10.1.9.1  Data Collection and Management Responsibilities  
Data collection is the responsibility of the study staff at the participati ng site under the 
supervision of the  participating  site PI. The participating site PI must maintain complete and 
accurate source documentation.  
Clinical research data from source documentation , including, but not limited to, AEs/SAEs, 
concomitant medications, med ical history, physical assessments, and clinical laboratory data , 
will be entered by the participating site into eCRFs via a 21 CFR Part 11 -compliant internet data 
entry system provided by the SDCC . The data system includes password protection and internal 
quality checks, such as automatic range checks, to identify data that appear inconsistent, 
incomplete, or inaccurate. AEs and concomitant medications will be coded according to the most 
current ve rsions of MedDRA and WhoDrug, respectively.  
The SDCC  for this study will be responsible for data management, quality review, analysis, and 
reporting of the study data.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 78 of 116 The IND sponsor is responsible for review of data collection tools and processes, and re view of 
data and reports.  
AEs will be coded according to the MedDRA dictionary version  23.0 or higher . 
A separate study specific Study Data Standardization Plan (SDSP) appendix will be developed 
which describes the technical recommendations for the submiss ion of human study data and 
related information in a standardized electronic format throughout product development.  
At the end of the study, a copy of all datasets , including annotated CRFs  and data dictionary , will 
be provided to DMID.  
10.1.9.2  Study Record Retention  
Study -related records, including the regulatory file, study product accountability records, consent 
forms, subject source documents and electronic records , should be maintained for a period of 2 
years following the date a marketing application is  approved for the investigational product for 
the indication for which it is being investigated; or, if no application is to be filed or if the 
application is not approved for such indication, until 2 years after the investigation is 
discontinued and FDA i s notified. These documents should be retained for a longer period, 
however, if required by local policies or regulations. No records will be destroyed without the 
written consent of DMID. Consent forms with specimen retention linked to identifiable 
specim ens will be maintained for as long as the specimens remain in identifiable format, and a 
minimum of three years after use of the identifiable specimens in nonexempt human subject 
research.  
10.1.9.3  Source Records  
Source data are all information in original records (and certified copies of original records) of 
clinical findings, observations, or other activities in a clinical trial necessary for the 
reconstruction and evaluation of the trial. Source data should be attributable, legible, 
contemporaneous, original, acc urate, a nd complete. Each participating  site will maintain 
appropriate medical and research records for this trial, in compliance with ICH GCP, regulatory, 
and institutional requirements. Data recorded in the eCRF derived from source documents should 
be co nsistent with the data recorded on the source documents.  
Interview of subjects is sufficient for obtaining medical history. Solicitation of medical records 
from the subject’s primary care provider is not required.  
10.1.10  Protocol Deviations  
A protocol deviation i s any non -compliance with the clinical trial protocol, any process that is 
noted in the protocol and refers to details in the  protocol -specific  MOP or GCP requirements , or 
any critical study procedures with specific instructions in ancillary documents referenced in the 
protocol such as a protocol -specific MOP . 
The non -compliance may be either on the part of the subject, the participating site PI  or the study 
staff. Follo wing a deviation(s), corrective actions should be developed by the participating site 
and implemented promptly. All individual protocol deviations will be addressed in subject study 
records.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 79 of 116 It is the responsibility of the participating  site PI and study s taff to use continuous vigilance to 
identify and report deviations within five working days of identification of the protocol 
deviation, or within five working days of the scheduled protocol -required activity. All deviations 
must be promptly reported to DM ID per the protocol deviation reporting procedures. Protocol 
deviations must be sent to the local IRB/IEC per their guidelines. The participating site PI and 
study staff  are responsible for knowing and adhering to their IRB requirements. A completed 
copy o f the DMID Protocol Deviation Form must be maintained in the Regulatory File, as well 
as in the subject ’s chart if the deviation is subject specific.  
10.1.11  Publication and Data Sharing Policy  
Analyses will be conducted as data become available while the study is  ongoing at the discretion 
of the sponsor. Analyses of data will be available for publication to inform the scientific 
community. Data will be available immediately following publication, with no end date, with 
data sharing at the discretion of the PI. Pub lication of manuscripts may occur at the discretion of 
the sponsor in accordance with DMID’s Expanded Distribution of Clinical  Research Endpoint 
Data Policy.  
10.1.12  Human Data Sharing Plan  
This study will be conducted in accordance with the following publication and data sharing 
policies and regulations:  
• NIH Public Access Policy, which ensures that the public has access to the published 
results of NIH funded research. It requires scientists to submit final peer -reviewed journal 
manuscripts that arise from NIH fund s to the digital archive PubMed Central upon 
acceptance for publication.  
10.1.13  Genomic Data Sharing  (GDS)  Plan  
This study will comply with the NIH GDS  Policy, which applies to all NIH -funded research that 
generates large -scale human or non -human genomic data, as  well as the use of these data for 
subsequent research. Large -scale data include genome -wide association studies (GWAS), SNP 
arrays, and genome sequence, transcriptomic, epigenomic, and gene expression data.  
10.1.14  Publication  
At intervals throughout the study at the discretion of the sponsor and following completion of the 
study, the lead PI is expected to publish the results of this research in a scientific journal. This 
study will adhere to the following publication and data sharing policies and regulat ions:  
• NIH Public Access Policy, which ensures that the public has access to the published 
results of NIH funded research. As such, the final peer -reviewed journal manuscripts will 
be accessible to the public on PubMed Central no later than 12 months after publication.  
10.1.15  Conflict of Interest Policy  
The independence of this study from any actual or perceived influence, such as by the 
pharmaceutical industry, is critical. Therefore, any actual conflict of interest of persons who have 
a role in the design, conduct, analysis, publication, or any aspect of this trial will be disclosed 
and managed. Furthermore, persons who have a perceived conflict of interest will be required to 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 80 of 116 have such conflicts managed in a way that is appropriate to their participation in  the design and 
conduct of this trial. DMID has established policies and procedures for all study team members 
to disclose all conflicts of interest and will establish a mechanism for the management of all 
reported dualities of interest.  
10.2 Additional Conside rations  
10.2.1  Research Related Injuries  
For any potential research related injury, the participating site PI or designee will assess the 
subject. Study staff will try to reduce, control and treat any complications from this trial. 
Immediate medical treatment may  be provided by the participating site , such as giving 
emergency medications to stop immediate allergic reactions to the vaccine . As needed, referrals 
to appropriate health care facilities will be provided to the subject. The participating site PI 
should t hen determine if an injury occurred as a direct result of the tests or treatments that are 
done for this trial.  
If it is determined by the participating  site PI that an injury occurred to a subject as a direct result 
of the tests or treatments that are don e for this trial, then referrals to appropriate health care 
facilities will be provided to the subject. Study staff will try to reduce, control and treat any 
complications from this trial. Immediate medical treatment may be provided by the participating 
site, such as giving emergency medications to stop immediate allergic reactions to the vaccine. 
No financial compensation will be provided to the subject by NIAID, NIH , the vaccine 
manufacturer , or the participating site for any injury suffered due to partic ipation in this trial.  
For this protocol, the study vaccine,  mRNA -1273 , manufactured by ModernaTX, Inc. is covered 
under the PREP Act, as described in Section 2.1.1 . 
10.3 Abbreviations  
Table 10: Abbreviations  
2019 -nCov  2019 -novel Coronavirus  
AE Adverse Event  
AESI  Adverse Event of Special Interest  
ALP  Alkaline Phosphatase  
ALT  Alanine Transaminase  
AST  Aspartate Transaminase  
BMI  Body Mass Index  
BP Blood Pressure  
°C Degrees Celsius  
CAPA  Corrective and Preventative Action Plan  
CFR  Code of Federal Regulations  
CI Confidence Interval  
CICP  Countermeasures Injury Compensation Program  
CLIA  Clinical Laboratory Improvement Amendments  
CMP  Clinical Monitoring Plan  
CMS  Clinical Material Services  
CMV  Cytomegalovirus  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 81 of 116 COC  Certificate of Confidentiality  
COPD  Chronic Obstructive Pulmonary Disease  
CoV  Coronavirus  
COVID -19 Coronavirus Disease 2019  
Cr Creatinine  
CRF  Case Report Form  
CROMS  Clinical Research Operations and Management Support  
CSR  Clinical Study Report  
CQMP  Clinical Quality Management Plan  
DCF  Data Collection Form  
DHHS  Department of Health and Human Services  
DMID  Division of Microbiology and Infectious Diseases  
DNA  Deoxyribonucleic Acid  
DSPC  1,2-distearoyl -sn-glycero -3-phosphocholine  
EC Ethics Committee  
eCRF  Electronic Case Report Form  
eGFR  Estimated Glomerular Filtration Rate  
ELISA  Enzyme -Linked Immunosorbent Assay  
EUA  Emergency Use Authorization  
°F Degrees Fahrenheit  
FDA  Food and Drug Administration  
FWA  Federal Wide Assurance  
GCP  Good Clinical Practice  
GDS  Genomic Data Sharing  
GLP  Good Laboratory Practices  
GMFR  Geometric Mean Fold Rise  
GMT  Geometric Mean Titer  
GWAS  Genome -Wide Association Studies  
hDPP4  Dipeptidyl Peptidase 4  
HEENT  Head, Ears, Eyes, Nose, and Throat  
Hgb Hemoglobin  
HIV Human Immunodeficiency Virus  
HKU1  Human Coronavirus HKU1  
HLA  Human Leukocyte Antigen  
hMPV  Human Metapneumovirus  
HR Heart Rate  
HRSA  Health Resources and Services Administration  
IB Investigator’s Brochure  
ICD International Classification of Diseases  
ICF Informed Consent Form  
ICH International Council for Harmonisation  
IDCRC  Infectious Disease Clinical Research Consortium  
IDE Investigational Device Exemption  
IEC Independent or Institutional Ethics Committee  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 82 of 116 IgA Immunoglobulin A  
IgG Immunoglobulin G  
IgM Immunoglobulin M  
IM Intramuscular  
IND Investigational New Drug Application  
IRB Institutional Review Board  
IV Intravenous  
kg Kilogram  
LNP  Lipid Nanoparticle  
m Meter  
MAAE  Medically -Attended Adverse Event  
mcg Microgram  
MedDRA  Medical Dictionary for Regulatory Activities  
MERS  Middle East Respiratory Syndrome  
mg Milligrams  
MI Myocardial Infarction  
min Minute  
mITT  Modified Intent -To-Treat  
mL Milliliter  
mm Hg  Millimeter of Mercury  
MOP  Manual of Procedures  
mRNA  Messenger Ribonucleic Acid  
N Number (typically refers to subjects)  
NaCl  Sodium Chloride  
nCoV  Novel Coronavirus  
NDA  New Drug Application  
Neut  Neutralizing  
NIAID  National Institute of Allergy and Infectious Diseases  
NIH National Institutes of Health  
NOAEL  No-Observed -Adverse -Effect -Level  
NOCMC  New -Onset Chronic Medical Condition  
OHRP  Office for Human Research Protections  
PBMC  Peripheral Blood Mononuclear Cell  
PEG  Polyethylene Glycol  
PHI Protected Health Information  
PI Principal Investigator  
PIV3  Parainfluenza Virus Type 3  
PLT Platelet  
PP Per Protocol  
PREP  Act Public Readiness and Emergency Preparedness Act  
PT Prothrombin Time  
PTT Partial Thromboplastin Time  
QA Quality Assurance  
QC Quality Control  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 83 of 116 RNA  Ribonucleic Acid 
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SARS  Severe Acute Respiratory Syndrome  
SARS -CoV  SARS Coronavirus  
SARS -CoV -2 SARS Coronavirus 2  
SDCC  Statistical and Data Coordinating Center  
SDSP  Study Data Standardization Plan  
SMC  Safety Monitoring Committee  
SNP Single Nucleotide Polymorphisms  
SOA  Schedule of Activities  
SOC  System Organ Class  
SOP Standard Operating Procedure  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
T. Bili  Total Bilirubin  
Th T helper  
UP Unanticipated Problem  
US United States  
USP United States Pharmacopeia  
VRC  Vaccine Research Center  
WBC  White Blood Cell  
WHO  World Health Organization  
WIV1  Chinese Horseshoe Bat Coronavirus WIV1  
 
10.4 Protocol Amendment History  
Table 11: Protocol Amendment History  
Version , Date  Section  Description of Change  Brief Rationale  
2.0,  
March 13, 
2020  Throughout  Administrative . Advanced version and date . 
Throughout  Clarifications and modifications 
to resolve inconsistencies . To address Pre -IND, IND 
non-hold and PI comments . 
Sect. 1.1, 
Page 7  Updated COVID -19 case 
counts .  
Sect. 2.1, 
Page 14  Updated COVID -19 status .  
Sect. 4.1, 
Page  22 Enrollment will occur at up to 
three  one domestic clinical 
research  sites. Revised language to add 
clinical research sites. 
Sect. 1.2, 
Table 4 and 
Sect. 8.2, 
Table 9  Adjusted visit windows .  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 84 of 116 Version , Date  Section  Description of Change  Brief Rationale  
Sect. 5.1, 
Page 26  Added Inclusion Criteri on #16: 
The subject  must agree to 
refrain from donating blood or 
plasma during the study 
(outside of this study).  Moved from Exclusion 
Criteri on #22. 
Sect. 5.2,  
Page 28  Revised Exclusion Criterion 
#21: 
Close contact of anyone known 
to have SARS -CoV -2 infection 
within 30 days prior to vaccine 
administration.  Increased duration from 2 
weeks to 30 days from 
known contact.  
Sect. 5.2,  
Page 28  Deleted Exclusion Criterion 
#22: 
Has traveled to 
countries/region s with known 
widespread community 
transmission of SARS -CoV -2 
(e.g., China, regions in Italy, 
South Korea, Iran, or other 
countries based on the most 
updated epidemiology at the 
time of study enrollment) 
within 30 days before the first 
vaccination.  Addresse d in revision to 
Exclusion Criterion #21 . 
Sect. 5.4, 
Page 29  Revised lifestyle considerations .  
Sect. 6.1.2, 
Page 31  Revised dosing and 
administration instructions .  
Sect. 6.2.1,  
Page 33  Revised product destruction and 
storage instructions .  
Sect. 7.1,  
Page 36  Revised halting and sentinel 
halting criteria . 
Halting Criterion #5 revised:  
Three (3) or more subjects 
experience a Grade 3 AE 
(unsolicited  systemic and/or 
clinical laboratory abnormality), 
in the same Preferred Terms 
based on the Medical 
Dictionary for Regulatory 
Activities (MedDRA) coding, 
that lasted at least 48 hours after  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 85 of 116 Version , Date  Section  Description of Change  Brief Rationale  
administration of the vaccine 
and is considered related to the 
vaccine.  
Sect. 7.1.3,  
Page 37  Revised dosing and redosing 
criteria   
Sect.  8.1.2,  
Page 42  Added research laboratory 
location and contact 
information   
Sect. 8.2, 
Table 9  Adjusted blood volumes .  
Sect. 8.3.9  Clarified AESIs reporting .  
Sect. 2.1.1  Added P REP Act.  
3.0,  
March 30, 
2020  Throughout  Administrative.  Advanced version and date.  
Sect. 2.1.1  Revised PREP Act language.  To address Office of General 
Counsel comments.  
Sect. 5.1 
and 5.2  Refine d eligibility criteria.  To address PI comments . 
Sect. 8.1.3  Removed previous Table 8: 
Testing Laboratories.  Details moved to protocol -
specific MOP.  
Throughout  Included  cohorts >55 years of 
age. To rapidly assess clinical 
safety of novel vaccines in 
this vulnerable population as 
early as possible, based on 
currently available 
information and clinical 
experience suggesting that 
older adults may be at higher 
risk for severe illness from 
COVID -19. 
Throughout  Included  leukapheresis for a 
subset of subjects . To support development of 
diagnostics, therapeutics and 
vaccines . 
4.0,  
May 20, 2020  Throughout  Administrative.  Advanced version and date.  
Sect. 2.1  Updated SARS -CoV -2 case 
counts , deaths  and status.  To be current as of May 14, 
2020.  
Sect. 2.1  Updated animal data.  To include additional 
immune response data in 
mice.  
Sect. 2.2.1,  
Risks of 
mRNA -
1273  Included animal data.  To add non -GLP toxicity 
data in rats.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 86 of 116 Version , Date  Section  Description of Change  Brief Rationale  
Sect. 2.2.1,  
Risks of 
mRNA -
1273  Included preliminary safety data 
from this ongoing phase I 
clinical trial.  To advise study design 
changes.  
Sect. 2.2.1,  
Risks of  
mRNA -
1273  Updated non SARS -CoV -2 
clinical studies.  To be consistent with 
updated IB v2.0, 18 May 
2020.  
Sect. 2.2.1,  
Risks of 
mRNA -
1273  Deleted duplicate paragraph on 
risks.  Same text already included 
in this section.  
Sect. 2.2.1,  
Risks of 
mRNA -
1273  Updated enhanced 
immunopathology data in 
animals.  To include immune response 
data in mice.  
Throughout 
and Sect. 
4.1. Included 10 and 50 mcg dosage 
cohorts and updated the number 
of cohorts and subjects.  To further explore dose -
ranging.  
Throug hout 
and Sect. 
4.1 Revised timing and added 
conditions for enrollment of 
cohorts 6 and 9.  Based on preliminary safety 
data from this ongoing phase 
I clinical trial.  
Throughout 
and Sect. 
4.1 Includ ed timing and added 
conditions for enrollment of 
cohorts 10 -13. To be consistent with study 
design changes.  
Throughout 
and Sect. 
4.1 Updated/included timing of 
early and Day 57 data reviews 
for cohorts, 6 and 9 -13.  To be consistent with study 
design chang es. 
Throughout 
and Sect. 
4.1 Revised cohorts eligible for 
leukapheresis.  To be consistent with study 
design changes.  
Sect. 5  Updated estimated time from 
initiation of enrollment to 
complete enrollment in this 
clinical trial from 
approximately 12 to 16 weeks.  To compensate for the 
inclusion of additional 
cohorts.  
Sect. 5.1  Updated Inclusion Criteria for 
BMI and Systolic BP.  Per Letter of Amendment  
dated April 10, 2020 . 
Sect. 5.1.1  Updated Leukapheresis 
Inclusion Criteria for cohorts 
eligible for leukapheresis.  To be consistent with study 
design changes.  
Sect. 5.2  Updated Exclusion Criteria for 
chronic kidney disease eGFR 
value, as well as for subjects 
≥56 years of age - history of Per Letter of Amendment  
dated April 10, 2020 . 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 87 of 116 Version , Date  Section  Description of Change  Brief Rationale  
chronic smoking, current 
smoking or vaping and 
individuals curren tly working 
with high risk of exposure to 
SARS -CoV -2. 
Throughout 
and Sect. 
6.1.2, 
Table 7  Updated dosing and 
administration to include 10 and 
50 mcg dosage cohorts.  To further explore dose -
ranging and be cons istent 
with study design changes.  
Sect. 6.1.2  Added/updated the expiration 
time of the dosing syringe 
containing the prepared mRNA -
1273 solution to 4 hours at 
room temperature for the 10 
mcg dosage after the solution is 
drawn into the dosing syringe 
and 8 hours at room 
temperature for the 25, 50, 100, 
and 250 mcg dosages after the 
solution is drawn into the 
dosing syringe.  To be consistent with 
updated pharmacy manual.  
Sect. 6.2.1  Updated study product 
accountability and destruction 
instruct ions for used and unused 
mRNA -1273 vials, used mixing 
vials and mRNA -1273 cartons.  To allow for study product 
accountability and 
destruction in accordance 
with site -specific SOPs and 
with second verification as 
well as documentation to 
include a certificat e of 
destruction or document of 
destruction.  
Sect. 6.2.3  Added stability of prepared 10 
mcg doses – up to 4 hours at 
room temperature.  To be consistent with 
updated pharmacy manual.  
Sect. 6.3.1  Updated/added Treatment 
Assignment Procedures for 
cohorts 6 and 9 -13. To be consistent with study 
design changes.  
Throughout  Changed participant(s) to 
subject(s).  To be consistent.  
Sect. 9.2  Updated Sample Size 
Determination . To be consistent with study 
design changes.  
Sect. 9.4.6  Added “ other parti cipating 
laboratories ” to the list of those 
involved in jointly developing 
ad-hoc analyses.  To be consistent with current 
practice.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 88 of 116 Version , Date  Section  Description of Change  Brief Rationale  
Sect. 
9.4.6.1 and 
10.1.6.2.  Updated Interim Safety 
Analyses to clarify: 
“Cumulative AE data will also 
be provided to the SMC  after all 
subjects in all cohorts have 
completed Day 36.”  To be consistent with study 
design changes and current 
practice.  
Sect. 
9.4.6.3  Updated Interim 
Immunogenicity and Safety 
Review for additional separate 
interim analyses through Day 
57 to be conducted as needed.  To be consistent with study 
design changes and current 
practice.  
Sect.10.1.1
4 Updated Publication with: “ At 
intervals throughout the study at 
the discretion of the sponsor 
and…” To allow for additional 
publications of results in 
scientific journals before the 
completion of the study.  
Throughout 
and Sect. 
10.3,  
Table 10  Updated abbreviations.   
Sect. 11  Updated references.   
Protocol 
Summary  Updated anticipated duration of 
entire study from 18 to 20 
months (from start of screening 
to last subject last visit).  To compensate for the 
inclusion of additional 
cohorts.  
5.0,  
December 4, 
2020  Throughout  Administrative.  Advanced version and date.  
Protocol 
Summary  50 mcg dosage added.  Inadvertently not included in 
previous amendment.  
Protocol 
Summary 
and Sect. 3  “3” dosages changed to “5”.  Inadvertently not included in 
previous amendment.  
Protocol 
Summary, 
Sect. 3, 4.1, 
8.1.3, 
8.1.4.1, and 
9.4.9  Exploratory objective, 
endpoints and supportive text 
for B cell analyses removed.  To be considered for 
secondary research instead of 
primary research.  
Sect. 6.4  Changed “entered into the 
electronic case report form 
eCRF)” to “recorded on the 
appropriate DCF.”  Administrative.  
Sect. 9.4, 
9.4.6.2 and 
9.4.6.3  Interim I mmunogenicity and 
Safety Review revised.  To align with what was or 
will be done in the study.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 89 of 116 Version , Date  Section  Description of Change  Brief Rationale  
Sect. 9.4  Summary of Statistical 
Analyses (interim and final 
analyses as well as final data 
lock timing) and CSR plans 
revised.  To align with what was or 
will b e done in the study.  
Sect. 
9.4.6.1 and 
10.1.6.2  SMC meeting plan for Interim 
Safety Analyses revised.  To align with what was done 
in the study.  
Sect. 
10.1.1. and 
10.1.1.2  Consenting specifically to 
genetic testing, including DMD 
sequencing removed from 
primary research and added to 
secondary research.  Genetic testing will not be 
included as primary research. 
No change to ICF needed, 
because genetic testing is 
already included as 
secondary research and not 
included as primary research 
in the ICF. 
Sect. 
10.1.6.2  Number of SMC members 
changed from “3” to “2 -3”. To align with what was done 
in the study.  
Sect. 
10.1.6.2  Clarified that SMC materials 
will be provided electronically.  To align with what was done 
in the study.  
Sect. 
10.1.6.2  Removed “The SMC will 
review blinded aggregate data 
in the open session of the SMC 
meetings.”  To align with what was done 
in this open -label study.  
Sect. 10.1.7  Abbreviation for electronic case 
reports forms added.  Administrative.  
6.0,  
January  28, 
2021  Throughout  Administrative.  Advanced version and date.  
Throughout  *Cohorts 6, 9 and 13 were not 
enrolled.  Updates to the study . 
Throughout  OneUp to one  Administrative.  
Throughout  lastsecond  Administrative.  
Throughout  Based on interim 
immunogenicity and 
reactogenicity data, Cohorts 6, 
9 and 13 were not enrolled.  Updates to the study.  
Throughout  main study  Administrative.  
Protocol 
Summary, 
Study 
Design  Added text.  Updates to the study, 
including ad ded the Optional 
Third mRNA -1273 
Vaccination SubStudy.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 90 of 116 Version , Date  Section  Description of Change  Brief Rationale  
Protocol 
Summary, 
Study 
Duration  The duration of the optional 
third mRNA -1273 vaccination 
substudy  is anticipated to be 12 
months from the last subject 
vaccinated with the third 
mRNA -1273 vaccination . Added the Optional Third 
mRNA -1273 Vaccination 
SubStudy.  
Protocol 
Summary, 
Subject 
Duration  The duration for each individual 
subject in the optional th ird 
mRNA -1273 vaccination 
substudy  is approximately 26 
months (from first contact to 
last visit).  Added the Optional Third 
mRNA -1273 Vaccination 
SubStudy.  
Protocol 
Summary, 
Safety  See Section 12, Appendix A for 
halting rules for the optional 
third mRNA -1273 vaccination 
substudy.  Added the Optional Third 
mRNA -1273 Vaccination 
SubStudy.  
Protocol 
Summary, 
Safety  The SMC does not need to meet 
for dose escalation or for 
initiation of the optional third 
mRNA -1273 vaccination 
substudy . Added the Optional Third 
mRNA -1273 Vaccination 
SubStudy.  
Sect. 1.2 , 
Table 4  g) Subjects who participate in 
the optional third mRNA -1273 
vaccination substudy will exit 
the Schedule of Activities for 
the main study between Visit 13 
and the close of the window for 
Visit 14 and will not have Visit 
14, instead will have Visit 14A 
and subsequent substudy visits. 
See Section 12, Appendix A for 
the Schedule of Activities for 
the optional third mRNA -1273 
vaccination substudy.  Added the Optional Third 
mRNA -1273 Vaccination  
SubStudy.  
Sect. 2.2.1, 
Risks of 
mRNA -
1273  Added and deleted  text. Updates to the study and 
added new information.  
Sect. 2.2.2  As outlined in Section 12.2, 
data from the Phase 3 placebo -
controlled clinical trial of 
mRNA -1273 (COVE) suggests 
94.1% efficacy of the vaccine 
when administered at 100 mcg Updates to the study and 
added new information.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 91 of 116 Version , Date  Section  Description of Change  Brief Rationale  
versus placebo against SARS -
CoV -2 infection when assessed 
on November 25, 2020 (Baden 
LR et al, 2020). The efficacy of 
other doses of mRNA -1273 
(e.g., 25, 50, or 250 mcg) is not 
known. Although declines in 
binding and neutralizing 
antibodies are observed over 
time, 100 mcg of mRNA -1273 
has the potential to provide 
durable humoral immunity 
(Widge AT e t al, 2020).  
Sect. 4.4  Added new section.  Optional Third mRNA -1273 
Vaccination SubStudy.  
Sect. 8.2, 
Table 8  5 Subjects who participate in the 
optional third mRNA -1273 
vaccination substudy will exit 
the Schedule of Activities for 
the main study between Visit 13 
and the close of the window for 
Visit 14 and will not have Visit 
14, instead will have Visit 14A 
and sub sequent substudy visits. 
See Section 12, Appendix A for 
the Schedule of Activities for 
the optional third mRNA -1273 
vaccination substudy.  Added the Optional Third 
mRNA -1273 Vaccination 
SubStudy.  
Sect. 9.3  The Safety Analysis population 
for the main study  includes all 
subjects who received one dose 
of vaccine.  Analyses for the 
primary safety population will 
include safety reported through 
the end of the main study. A 
modified primary safety 
population analysis will also be 
performed that excludes safety 
data collected after subjects 
receive either the third mRNA -
1273 vaccination in the optional 
substudy or non -study EUA 
vaccine, if applicable. Updated for main study and 
substudy.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 92 of 116 Version , Date  Section  Description of Change  Brief Rationale  
Sect. 
10.1.6.2  The SMC does not need to meet 
for dose escalation to 250 mcg 
(cohorts 3, 6 and 9) or for 
initiation of the optional third 
mRNA -1273 vaccination 
substudy.  
The SMC will meet when trial 
or optional third mRNA -1273 
vaccination substudy halting 
criteria are met, or as requested 
by the sponsor or PI.  
Ad hoc reviews will occur when 
trial halting criteria are met, or 
as requested by the sponsor or 
PI. 
The SMC will have a final 
review meeting at the end of the  
study trial, defined as the end of 
the optional third mRNA -1273 
vaccination substudy.  Added the O ptional Third 
mRNA -1273 Vaccination 
SubStudy.  
Sect. 10.3, 
Table 10  Abbreviations for emergency 
use authorization  (EUA)  and 
polyethylene glycol  (PEG)  
added . Administrative.  
Sect. 11  Added references.  Updates to the study.  
Sect. 12, 
Appendix 
A Added ne w section.  Optional Third mRNA -1273 
Vaccination SubStudy.  
7.0,  
July 30 , 2021  Throughout  Administrative.  Advanced version and date.  
Throughout  Added protocol specified 
adverse events of special 
interest ( AESIs ). Myocarditis and pericarditis  
classified as protocol 
specified AESIs  to address 
Manufacturer surveillance 
request. . 
Protocol 
Summary, 
Safety  Deleted: See Section 12, 
Appendix A for halting rules for 
the optional third mRNA -1273 
vaccination substudy.  No special halting rules for 
the Optional Third mRNA -
1273 Vaccination Substudy . 
Sect. 2.2.1  Myocarditis and pericarditis  
added to the risks of mRNA -
1273.  Per updated Moderna 
COVID -19 EUA Vaccine  
Fact Sheet.  
 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 93 of 116 11. REFERENCES  
 
1. Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., 
Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., McDermott, A. B., Flach, B., 
Lin, B. C., Doria -Rose, N. A., O'Dell, S., Schmidt, S. D., Corbett , K. S., Swanson, P. A., 2nd, 
Padilla, M., Neuzil, K. M., … mRNA -1273 Study Group (2020). Safety and Immunogenicity 
of SARS -CoV -2 mRNA -1273 Vaccine in Older Adults.  The New England Journal of 
Medicine,  383(25), 2427 –2438. https://doi.org/10.1056/NEJMoa2028 436. 
 
2. Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., 
Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Kehtan, S., Segall, N., Solis, J., 
Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P ., … COVE Study Group 
(2020). Efficacy and Safety of the mRNA -1273 SARS -CoV -2 Vaccine.  The New England 
Journal of Medicine, 10.1056/NEJMoa2035389. Advance online publication. 
https://doi.org/10.1056/NEJMoa2035389 . 
 
3. Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., 
Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R. W., 
Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweeney, D. A., Short, W. 
R., Touloumi, G., … AC TT-1 Study Group Members (2020). Remdesivir for the Treatment 
of Covid -19 - Final Report.  The New England Journal of Medicine,  383(19), 1813 –1826. 
https://doi.org/10.1056/NEJMoa2007764 . 
 
4. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC,  Poon RW, Tsoi 
HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, 
Yuen KY. 2020. A familial cluster of pneumonia associated with the 2019 novel coronavirus 
indicating person -to-person transmission: a study of a family cluster. T he Lancet. Jan 24. pii: 
S0140 -6736(20)30154 -9. doi: 10.1016/S0140 -6736(20)30154 -9. 
 
5. Chen, P., Nirula, A., Heller, B., Gottlieb, R. L., Boscia, J., Morris, J., Huhn, G., Cardona, J., 
Mocherla, B., Stosor, V., Shawa, I., Adams, A. C., Van Naarden, J., Custer , K. L., Shen, L., 
Durante, M., Oakley, G., Schade, A. E., Sabo, J., Patel, D. R., … BLAZE -1 Investigators 
(2020). SARS -CoV -2 Neutralizing Antibody LY -CoV555 in Outpatients with Covid -19. The 
New England Journal of Medicine, NEJMoa2029849. Advance online p ublication. 
https://doi.org/10.1056/NEJMoa2029849 . 
 
6. Chen, Yingzhu, Shuai Lu, Hao Jia, Yao Deng, Jianfang Zhou, Baoying Huang, Yueyang Yu, 
Jiaming Lan, Wenling Wang, Yongliang Lou, Kun Qin, and Wenjie Tan. 2017. 'A novel 
neutralizing monoclonal antibody tar geting the N -terminal domain of the MERS -CoV spike 
protein', Emerging Microbes &Amp; Infections, 6: e37.  
 
7. Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu -Barnum, S., Gillespie, 
R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., Dinnon, K. H., Elbashir, S. 
M., Shaw, C. A., Woods, A., Fritch, E. J., Martinez, D. R., Bock, K. W., Minai, M., Nagata, 
B. M., Hutchinson, G. B., … Graham, B. S. (2020). SARS -CoV -2 mRNA vaccine design 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 94 of 116 enabled by prototype pathogen preparedness.  Natu re, 586(7830), 567 –571. 
https://doi.org/10.1038/s41586 -020-2622 -0. 
 
8. Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu -Barnum, S., Werner, A. P., 
Flach, B., O'Connell, S., Bock, K. W., Minai, M., Nagata, B. M., Andersen, H., Martinez, D. 
R., Noe, A. T., Douek, N., Donaldson, M. M., Nji, N. N., Alvarado, G. S., Edwards, D. K., 
Flebbe, D. R., … Graham, B. S. (2020). Evaluation of the mRNA -1273 Vaccine against 
SARS -CoV -2 in Nonhuman Primates.  The New England Journal of Medicine,  383(16), 
1544 –1555. https://doi.org/10.1056/NEJMoa2024671 . 
 
9. Corti, Davide, Jincun Zhao, Mattia Pedotti, Luca Simonelli, Sudhakar Agnihothram, Craig 
Fett, Blanca Fernandez -Rodriguez, Mathilde Foglierini, Gloria Agatic, Fabrizia Vanzetta, 
Robin Gopal, Christopher J. Langri sh, Nicholas A Barrett, Federica Sallusto, Ralph S. Baric, 
Luca Varani, Maria Zambon, Stanley Perlman, and Antonio Lanzavecchia. 2015. 
'Prophylactic and postexposure efficacy of a potent human monoclonal antibody against 
MERS coronavirus', Proceedings of t he National Academy of Sciences, 112: 10473 -78. 
 
10. Garg, S., Kim, L., Whitaker, M., O'Halloran, A., Cummings, C., Holstein, R., Prill, M., Chai, 
S. J., Kirley, P. D., Alden, N. B., Kawasaki, B., Yousey -Hindes, K., Niccolai, L., Anderson, 
E. J., Openo, K. P.,  Weigel, A., Monroe, M. L., Ryan, P., Henderson, J., Kim, S., … Fry, A. 
(2020). Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory -
Confirmed Coronavirus Disease 2019 - COVID -NET, 14 States, March 1 -30, 2020.  MMWR. 
Morbidity and mortality weekly report,  69(15), 458 –464. 
https://doi.org/10.15585/mmwr.mm6915e3 . 
 
11. Hartley,  G.E., Edwards E.S.J, Aui P.M., et al. Rapid generation of durable B cell memory to 
SARS -CoV -2 spike and nucleocapsid proteins in COVID -19 and convalescence. Science 
Immunology 2020;5:eabf8891.  
 
12. Ibarrondo, F. J., Fulcher, J. A., Goodman -Meza, D., Elliott, J., Hofmann, C., Hausner, M. A., 
Ferbas, K. G., Tobin, N. H., Aldrovandi, G. M., & Yang, O. O. (2020). Rapid Decay of Anti -
SARS -CoV -2 Antibodie s in Persons with Mild Covid -19. The New England Journal of 
Medicine,  383(11), 1085 –1087. https://doi.org/10.1056/NEJMc2025179 . 
 
13. Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., 
McCullough, M. P., Chappell, J. D. , Denison, M. R., Stevens, L. J., Pruijssers, A. J., 
McDermott, A., Flach, B., Doria -Rose, N. A., Corbett, K. S., Morabito, K. M., O'Dell, S., 
Schmidt, S. D., Swanson, P. A., 2nd, Padilla, M., … mRNA -1273 Study Group (2020). An 
mRNA Vaccine against SARS -CoV-2 - Preliminary Report.  The New England Journal of 
Medicine,  383(20), 1920 –1931. https://doi.org/10.1056/NEJMoa2022483 . 
 
14. Johnson, Reed F., Ulas Bagci, Lauren Keith, Xianchun Tang, Daniel J. Mollura, Larry 
Zeitlin, Jing Qin, Louis Huzella, Christopher J. Bartos, Natasha Bohorova, Ognian Bohorov, 
Charles Goodman, Do H. Kim, Michael H. Paulty, Jesus Velasco, Kevin J. Whaley, Joshua 
C. Johnson, James Pettitt, Britini L. Ork, Jeffrey Solomon, Nicholas Oberlander, Quan Zhu, 
Jiusong Sun, Michael R. Holbrook, Gen e G. Olinger, Ralph S. Baric, Lisa E. Hensley, Peter 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 95 of 116 B. Jahrling, and Wayne A. Marasco. 2016. '3B11 -N, a monoclonal antibody against MERS -
CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of 
MERS -CoV Jordan -n3/2012', Virolog y, 490: 49 -58. 
 
15. Kalil, A. C., Patterson, T. F., Mehta, A. K., Tomashek, K. M., Wolfe, C. R., Ghazaryan, V., 
Marconi, V. C., Ruiz -Palacios, G. M., Hsieh, L., Kline, S., Tapson, V., Iovine, N. M., Jain, 
M. K., Sweeney, D. A., El Sahly, H. M., Branche, A. R.,  Regalado Pineda, J., Lye, D. C., 
Sandkovsky, U., Luetkemeyer, A. F., … Beigel, J. H. (2020). Baricitinib plus Remdesivir for 
Hospitalized Adults with Covid -19. The New England Journal of Medicine, 
NEJMoa2031994. Advance online publication. https://doi.org /10.1056/NEJMoa2031994 . 
 
16. Kim, Y., H. Lee, K. Park, S. Park, J. H. Lim, M. K. So, H. M. Woo, H. Ko, J. M. Lee, S. H. 
Lim, B. J. Ko, Y. S. Park, S. Y. Choi, D. H. Song, J. Y. Lee, S. S. Kim, and D. Y. Kim. 2019. 
'Selection and Characterization of Monoclonal Antibodies Targeting Middle East Respiratory 
Syndrome Coronavirus through a Human Synthetic Fab Phage Display Library Panning', 
Antibodies (Basel). Jul 31;8(3). pii: E42. doi: 10.3390/antib8030042.  
 
17. Lumley, S. F., O'Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., 
Marsden, B. D., Cox, S., James, T., Warren, F., Peck, L. J., Ritter, T. G., de Toledo, Z., 
Warren, L., Axten, D., Cornall, R. J., Jones, E. Y., Stuart, D. I., Screaton, G., Ebner, D., … 
Oxford University Hospitals Staff Te sting Group (2020). Antibody Status and Incidence of 
SARS -CoV -2 Infection in Health Care Workers.  The New England Journal of Medicine, 
NEJMoa2034545. Advance online publication. https://doi.org/10.1056/NEJMoa2034545 . 
 
18. Martin, J. E., M. K. Louder, L. A. Hol man, I. J. Gordon, M. E. Enama, B. D. Larkin, C. A. 
Andrews, L. Vogel, R. A. Koup, M. Roederer, R. T. Bailer, P. L. Gomez, M. Nason, J. R. 
Mascola, G. J. Nabel, B. S. Graham, and V. R. C. Study Team. 2008. 'A SARS DNA vaccine 
induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I 
clinical trial', Vaccine, 26: 6338 -43. 
 
19. Modjarrad, K., C. C. Roberts, K. T. Mills, A. R. Castellano, K. Paolino, K. Muthumani, E. L. 
Reuschel, M. L. Robb, T. Racine, M. D. Oh, C. Lamarre, F. I. Z aidi, J. Boyer, S. B. 
Kudchodkar, M. Jeong, J. M. Darden, Y. K. Park, P. T. Scott, C. Remigio, A. P. Parikh, M. 
C. Wise, A. Patel, E. K. Duperret, K. Y. Kim, H. Choi, S. White, M. Bagarazzi, J. M. May, 
D. Kane, H. Lee, G. Kobinger, N. L. Michael, D. B. Wei ner, S. J. Thomas, and J. N. Maslow. 
2019. 'Safety and immunogenicity of an anti -Middle East respiratory syndrome coronavirus 
DNA vaccine: a phase 1, open -label, single -arm, dose -escalation trial', Lancet Infect Dis, 19: 
1013 -22. 
 
20. Pallesen, Jesper, Nianshu ang Wang, Kizzmekia S. Corbett, Daniel Wrapp, Robert N. 
Kirchdoerfer, Hannah L. Turner, Christopher A. Cottrell, Michelle M. Becker, Lingshu 
Wang, Wei Shi, Wing -Pui Kong, Erica L. Andres, Arminja N. Kettenbach, Mark R. Denison, 
James D. Chappell, Barney S.  Graham, Andrew B. Ward, and Jason S. McLellan. 2017. 
'Immunogenicity and structures of a rationally designed prefusion MERS -CoV spike antigen', 
Proceedings of the National Academy of Sciences, 114: E7348 -E57.  
 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 96 of 116 21. Polack, F. P., Thomas, S. J., Kitchin, N., Ab salon, J., Gurtman, A., Lockhart, S., Perez, J. L., 
Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., 
Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Jr, Hammitt, L. L., Türeci, Ö., 
…C4591001 Clinical Trial Group (2020). Safety and Efficacy of the BNT162b2 mRNA 
Covid -19 Vaccine.  The New England Journal of Medicine,  383(27), 2603 –2615. 
https://doi.org/10.1056/NEJMoa2034577 . 
 
22. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, 
Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, 
Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, 
Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized 
Patients with Covid -19 - Preliminary Report. The New England Journal of Medicine . 2020 
Jul 17:NEJMoa2021436. doi: 10.1056/NEJMoa2021436. Epub ahead of print. PMID: 
32678530;  PMCID: PMC7383595.  
 
23. Slaoui, M., & Hepburn, M. (2020). Developing Safe and Effective Covid Vaccines - 
Operation Warp Speed's Strategy and Approach.  The New England Journal of 
Medicine,  383(18), 1701 –1703. https://doi.org/10.1056/NEJMp2027405 . 
 
24. Wang, Lingsh u, Wei Shi, M. Gordon Joyce, Kayvon Modjarrad, Yi Zhang, Kwanyee Leung, 
Christopher R. Lees, Tongqing Zhou, Hadi M. Yassine, Masaru Kanekiyo, Zhi -yong Yang, 
Xuejun Chen, Michelle M. Becker, Megan Freeman, Leatrice Vogel, Joshua C. Johnson, 
Gene Olinger, Jo hn P. Todd, Ulas Bagci, Jeffrey Solomon, Daniel J. Mollura, Lisa Hensley, 
Peter Jahrling, Mark R. Denison, Srinivas S. Rao, Kanta Subbarao, Peter D. Kwong, John R. 
Mascola, Wing -Pui Kong, and Barney S. Graham. 2015. 'Evaluation of candidate vaccine 
approac hes for MERS -CoV', Nature Communications, 6: 7712.  
 
25. Wang L, Shi W, Chappell JD, Joyce MG, Zhang Y, Kanekiyo M, Becker MM, van 
Doremalen N, Fischer R, Wang N, Corbett KS, Choe M, Mason RD, Van Galen JG, Zhou T, 
Saunders KO, Tatti KM, Haynes LM, Kwong PD, Mo djarrad K, Kong WP, McLellan JS, 
Denison MR, Munster VJ, Mascola JR, Graham BS. 2016. ‘Importance of Neutralizing 
Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory 
Syndrome Coronavirus Spike Glycoprotein To Avoid Neutr alization Escape’, J Virol. 2018 
Apr 27;92(10). pii: e02002 -17. doi: 10.1128/JVI.02002 -17. 
 
26. Widge, A. T., Rouphael, N. G., Jackson, L. A., Anderson, E. J., Roberts, P. C., Makhene, M., 
Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., McD ermott, A. B., Flach, B., 
Lin, B. C., Doria -Rose, N. A., O'Dell, S., Schmidt, S. D., Neuzil, K. M., Bennett, H., Leav, 
B., Makowski, M., … mRNA -1273 Study Group (2021). Durability of Responses after 
SARS -CoV -2 mRNA -1273 Vaccination.  The New England Journal  of Medicine,  384(1), 80 –
82. https://doi.org/10.1056/NEJMc2032195 . 
 
27. Widjaja, Ivy, Chunyan Wang, Rien van Haperen, Javier Gutiérrez -Álvarez, Brenda van 
Dieren, Nisreen M. A. Okba, V. Stalin Raj, Wentao Li, Raul Fernandez -Delgado, Frank 
Grosveld, Frank J. M.  van Kuppeveld, Bart L. Haagmans, Luis Enjuanes, Dubravka Drabek, 
and Berend -Jan Bosch. 2019. 'Towards a solution to MERS: protective human monoclonal 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 97 of 116 antibodies targeting different domains and functions of the MERS -coronavirus spike 
glycoprotein', Emergin g Microbes & Infections, 8: 516 -30. World Health Organization 
(WHO). https://www.who.int . Accessed May 15, 2020.  
 
28. Yu, Xiaojuan, Senyan Zhang, Liwei Jiang, Ye Cui, Dongxia Li, Dongli Wang, Nianshuang 
Wang, Lili Fu, Xuanlin Shi, Ziqiang Li, Linqi Zhang, and Xinquan Wang. 2015. 'Structural 
basis for the neutralization of MERS -CoV by a human monoclonal antibody MERS -27', 
Scientific Reports, 5: 13133.  
 
  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 98 of 116 12. APPENDIX  A: OPTIONAL  THIRD  MRNA -1273  
V ACCINATION  SUBSTUDY  
All aspects of the main study apply to th is substud y unless otherwise specified in Section 12, 
Appendix A . 
12.1 Overview  
All subjects in this clinical trial were scheduled to receive two mRNA -1273 vaccinations, 28 
days apart, at dosages of 25, 50, 100, or 250 mcg ( see Table 1), with the last scheduled follow -up 
visit occurring at 365 days after the second vaccination (see Table 4). During the course of the 
main study , interim efficacy data from a Phase 3 placebo -controlled clinical trial of mRNA -1273 
(COVE) , administered as 2 doses of 100 mcg given 28 days apart, demonstrated vaccine efficacy 
of 94.1% (95% CI: 89.3%, 96.8%) for the prevention of symptomatic, confirmed COVID -19 
(Baden, LR, et al. 2020). After review of the in terim safety and efficacy data from that clinical 
trial, the FDA granted on December 18, 2020 an Emergency Use Authorization (EUA) for the 
mRNA -1273 vaccine in adults 18 years of age and older.  
To potentially enhance and extend the duration of protection p rovided by the 2 -dose vaccination 
schedule of mRNA -1273 administered in the main study, and to gain an understanding of the 
immune responses to a third dose of mRNA -1273, subjects in the main study may participate in 
an optional third mRNA -1273 vaccination  substudy, detailed in Section 12, Appendix A . 
Substudy subjects will receive a third mRNA -1273 vaccin ation, administered via an IM injection 
at a dosage of 100 mcg/0.5  mL, given six to twelve months after receipt of their second 
vaccination in the main study. Substudy subjects will be followed for safety, reactogenicity, and 
immunogenicity endpoints throu gh 12 months post third vaccination ( Substudy Day 366). 
To be eligible to participate in the substudy, subjects must have received both the first and 
second mRNA -1273 vaccinations in the main study. Other eligibility criteria are specified in 
Appendix A . Subjects who received only one mRNA -1273 vaccination in the main study will be 
advised to receive an FDA authorized or approved COVID -19 vaccine, according to the 
recommended schedule, when ava ilable to them outside of this trial, unless they have a 
contraindication to COVID -19 vaccines that are available.  
Subjects who elect not to participate in the optional third mRNA -1273 vaccination substudy or 
are not eligible for the substudy will continue  to be followed according to the Schedule of 
Activities for the main study ( see Table 4) with the Final Study Visit 14 occurring at Day 394 
(±14 days).  
Dosing for the optional third mRNA -1273 vaccination substudy  is found in Table 13. 
Schedule of assessments for the optional third mRNA -1273 vaccination substudy is found in 
Table 14. 
Statistical Considerations for the optional third mRNA -1273 vaccination substudy  are found in  
Section 12.11 . 
12.2 Background and Scientific Rationale  
See Section 2.1 for additional background information.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 99 of 116 In December 2019 the Wuhan Municipal Health Committee identified an outbreak of viral 
pneumonia that was ultimately identified as a novel pathogen named SARS -CoV -2. The disease 
caused by SARS -CoV -2 is called Coronavirus disease 2019 (COVID -19). On January 30, 2020, 
the International Health Regulations Emergency Committee of the World Health Organization 
(WHO) declared the COVID -19 outbreak a Public Health Emergency of International Concern. 
On January 31, 2020, the US Department of Health and Human Services declared a public health 
emergency in the United States. On March 11, 2020 the WHO declared COVID -19 a pandemic. 
As of January 1 0, 2021,  the Center for Systems Science and Engineering (CSSE) at Johns 
Hopkins University (systems.jhu.edu) reports a global tally of 89,960,893 cases and 1,931,083  
deaths and a total of 22,227,722 cases and  373,331 deaths in the United States.  Morbidity and 
mortality ha ve dispr oportionately affected older adults, and racial and ethnic minority 
populations  (Garg S et al, 2020) . 
Despite success in developing a novel antiviral  – remdesivir  (Beigel JH et al, 2020) , use of 
steroids and other novel immunomodulators  (Kalil AC et al, 20 20; Recovery Collaborative 
Group et al, 2020) , and use of monoclonal antibodies  (Chen P et al, 2020)  for prevention and 
treatment of SARS -CoV -2 infection and COVID -19 disease , mortality remains substantial.  
Therefore, there is an urgent public health need for vaccines against SARS -CoV -2. Currently, 
there are over 170 vaccines in preclinical development and 60 vaccines that have entered into 
clinical trials  (https://www.who.int/publications/m/item/draft -landscape -of-covid -19-candidate -
vaccines) . In the US, 2 mRNA vaccines [Moderna (mRNA -1273), Pfizer -BioNTech 
(BNT162b2)]  received FDA EUA in December 2020.  
Studies of mRNA -1273 have been conducted in both mice and nonhuman primates (rhesus 
macaques)  (Corbett KS et al,  N Engl J Med 2020) . A single dose of mRNA -1273 in mice elicited 
robust S protein binding antibody titers, but with no virus neutralization activity observed  
(Corbett KS et al, Nature 2020) . Mice from this study were challenged with mouse -adapted 
SARS -CoV -2 virus, and preliminary results indicate that mRNA -1273 -induced immunity is 
protective after challenge. Similarly, rhesus macaques also had a dose -dependent response to 
vaccination  (Corbett KS et al, N Engl J Med 2020) . The mRNA -1273 vaccine candidate ind uced 
antibody levels exceeding those in human convalescent -phase serum. Vaccination induced type 1 
helper T  cell (Th1) –biased CD4 T  cell responses and low or undetectable Th2 or CD8 T  cell 
responses. Viral replication was not detectable in BAL fluid by day  2 after challenge in seven of 
eight animals in both vaccinated groups. No viral replication was detectable in the nose of any of 
the eight animals in the 100 -μg dose group by day 2 after challenge, and limited inflammation or 
detectable viral genome or an tigen was noted in lungs of animals in either vaccine group.  
This phase I clinical trial is evaluating safety and immunogenicity of variable doses of 
Moderna’s mRNA -1273 in healthy adults across the age spectrum (≥18 years of age). Cohorts 
now include subjects who received two doses of 25, 50, and 100 mcg in all 3 age ranges, and 250 
mcg in those 18 -55 years of age. A total of 120 subjects  have been enrolled to assess the safety, 
reactogenicity, and immunogenicity of the mRNA -1273. To date, no serious adver se events have 
occurred, and no safety concerns have been identified  (Jackson LA et al, 2020; Anderson EJ et 
al, 2020; Widge AT et al, 2020) . Dose -dependent reactogenicity has occurred, with 
reactogenicity generally being greater with the second dose. This  was typically mild -moderate in 
severity, and usually resolved within a few days. The second 250 mcg dose had increased 
reactogenicity in the 18 -55 year old cohort and given high binding and neutralizing antibodies 
with lower doses, a dose of 50 or 100 mcg was chosen for the Phase 2 placebo -controlled, dose-
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 100 of 116 confirmation clinical trial of mRNA -1273 (Jackson LA et al, 2020) . Binding and neutralizing 
antibodies, and T cell responses were dose -dependent  (Jackson LA et al, 2020; Anderson EJ et 
al, 2020) . Responses at 1 month after the second dose were generally greater than those observed 
in sera of patients convalescing from CO VID-19. A CD4 cytokine response occurred particularly 
among type 1 helper T  cells.  
Although declines in binding and neutralizing antibodies are observed by 3 months after the 
boost dose, recipients that had received 100 mcg of mRNA -1273 still had binding a nd 
neutralizing antibody titers that were similar to or exceeded that of convalescent sera  (Jackson 
LA et al, 2020; Anderson EJ et al, 2020; Widge AT et al, 2020) . Data through 6 months after the 
boost dose are pending.  
A Phase 2 placebo -controlled , dose -confirmation clinical trial of mRNA -1273 ([STUDY_ID_REMOVED]) 
is being conducted in adults using a prime -boost regimen of 50 mcg, 100 mcg, or placebo in 18 -
<55 year old and ≥55 year old subjects . This trial is ongoing, but publicly available data are 
limited.  
A Ph ase 3 placebo -controlled clinical trial of mRNA -1273 ([STUDY_ID_REMOVED], the COVE study) 
was initiated at almost 100 sites in the United States that enrolled 30,420 adults and administered 
two doses of either 100 mcg of mRNA -1273 or placebo (saline)  (Baden LR et  al, 2020) . Risks to 
subjects receiving mRNA -1273 were primarily mild to moderate injection site reactions, 
particularly pain. Delayed injection -site reactions (those with onset on or after day 8) were noted 
in 244 subjects  (0.8%) after the first dose and in 68 subjects (0.2%) after the second dose. 
Systemic reactions were transient and included fever, fatigue, chills, headache, myalgias, and 
arthralgias. Solicited systemic adverse events occurred more often in the mRNA -1273 group 
than in the placebo group after both the first dose (54.9%, vs. 42.2%) and the second dose 
(79.4%, vs. 36.5%). The severity of the solicited systemic events increased after the second dose 
in the mRNA -1273 group, with an increase in proportions of grade 2 events (from 16.5% after 
the first dose to 38.1% after the second dose) and grade 3 events (from 2.9% to 15.8%). Solicited 
systemic adverse events in the mRNA -1273 group lasted a mean of 2.6 days and 3.1 days after 
the first and second doses, respectively. Both solicited injection -site and systemic adverse events 
were more common among younger subjects (18 to <65 years of age) than among older subjects 
(≥65 years of age). Serious adverse events were rare, and the incidence was similar in the two 
groups. The frequency of grade 3 adve rse events in the placebo group (1.3%) was similar to that 
in the vaccine group (1.5%), as were the frequencies of medically attended adverse events (9.7% 
vs. 9.0%) and serious adverse events (0.6% in both groups). Hypersensitivity reactions were 
reported in 1.5% and 1.1% of subjects in the vaccine and placebo groups, respectively.  
In the primary efficacy analysis of the Phase 3 placebo -controlled clinical trial of mRNA -1273 
(COVE) , 196 cases of COVID -19 were diagnosed: 11 cases in the vaccine group (3.3 pe r 1000 
person -years; 95% CI, 1.7 to 6.0) and 185 cases in the placebo group (56.5 per 1000 person -
years; 95% CI, 48.7 to 65.3), indicating 94.1% efficacy of the mRNA -1273 vaccine (95% CI, 
89.3 to 96.8%; P<0.001) for the prevention of symptomatic SARS -CoV -2 infection as compared 
with placebo. Findings were similar across key secondary analyses, including assessment starting 
14 days after dose 1. Thirty subjects in the trial had severe COVID -19; all 30 were in the placebo 
group (indicating vaccine efficacy ag ainst severe COVID -19 of 100% [95% CI, could not be 
estimated to 1.0]), and one death among these subjects was attributed to COVID -19. The vaccine 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 101 of 116 efficacy to prevent COVID -19 was consistent across subgroups stratified by demographic and 
baseline character istics.  
It has been observed that antibodies may decline in patients previously infected with mild SARS -
CoV -2 and that reinfection can occur (although perhaps infrequently symptomatic)  (Ibarrondo FJ 
et al, 2020; Lumley SF et al, 2020) . T cells and memory B  cells are established after initial 
infection and remain present through 6 months after initial infection  (Hartley GE et al, 2020) . 
Additionally, the correlate or correlates of protection against COVID -19-related disease are not 
known, although active inv estigations are underway. Samples obtained from the Phase 3 clinical 
trials may provide insight into the correlate or correlates of protection.  
The durability of the immune response to mRNA -1273 remains uncertain beyond 3 months after 
the second vaccinatio n (Widge AT et al, 2020) . Immune responses after vaccination in general 
are known to wane, sometimes to the point where wild -type disease can occur. Since immunity 
after natural SARS -CoV -2 infection is not lifelong and no correlate of protection has been 
identified yet, a study to  assess the safety, reactogenicity, and immunogenicity of a third dose of 
mRNA -1273 is warranted. Additionally, some subjects in this trial  have received less (25 and 50 
mcg) than the 100 mcg dosage utilized in the Phase 3 placebo -controlled clinical trial  of mRNA -
1273 (COVE)  that resulted in the EUA for mRNA -1273. These subjects could directly benefit 
from an additional vaccination that might boost their serological and cellular responses. Since T 
cells and memory B cells are established after initial infe ction through at least 6 months, it is 
likely that SARS -CoV -2 revaccination will result in robust serological responses, even among 
those that received less than the authorized dose (e.g., 25 mcg, 50 mcg) of mRNA -1273.  
12.2.1  Justification for Dose  
It is not know n whether a third mRNA -1273 vaccination will elicit immune responses or enhance 
immunity elicited by the 2-dose vaccination schedule of mRNA -1273 administered in the main 
study . If such responses can be induced , the optimal number of dose s and interval between 
vaccination s is also not known. The EUA was granted for the 2 -dose 100 mcg regimen evaluated 
in the Phase 3 placebo -controlled clinical trial of mRNA -1273 ([STUDY_ID_REMOVED], the COVE 
study) , and 100 mcg is the dos age likely to be used in the future if a dditional mRNA -1273 
vaccination s are recommended. Therefore, the 100 mcg dos age was selected for  evaluation in  
this substudy.  
12.3 Risk/Benefit Assessment  
12.3.1  Known Potential Risks  
The potential risks of participating in this substudy are those associated with having blood 
drawn, IM injection, possible reactions to mRNA -1273, and breach of confidentiality. These and 
additional risks are described in Section 2.2.1 . 
A third vaccination of mRNA -1273 has not been evaluated in humans. The risks are expected to 
be similar to the risks associated with the first and second mRNA -1273 vaccinations in the main 
study but it is possible that there may be unanticipated risks with the third mRNA -1273 
vaccination.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 102 of 116 In a prior Phase 1 dose -ranging study of CMV vaccines ( mRNA -1647 and mRNA -1443) with 
doses administered at 0, 1, and 6 m onths ([STUDY_ID_REMOVED]), no safety issues were identified after 
the late third dose of mRNA vaccine (at 6 months after initial dose).  
12.3.2  Known Potential Benefits  
As outlined in Section 12.2, data from the Phase 3 placebo -controlled clinical trial  of mRNA -
1273 (COVE) suggests 94.1% efficacy of the vaccine when administered at 100 mcg versus 
placebo against SARS -CoV -2 infection when assessed on November 25, 2020  (Baden LR et al, 
2020) . The efficacy of other doses of mRNA -1273 (e.g., 25, 50, or 250 mcg) is not known. 
Although declines in binding and neutralizing antibodies are observed over time, 100 mcg of 
mRNA -1273 has the potential to provide durable humora l immunity  (Widge AT et al, 2020) . 
Administration of a third dose of 100 mcg of mRNA -1273 vaccine might boost cellular 
responses and binding and neutralizing antibody titers in prior mRNA -1273 recipients. This 
could provide a boost in immune responses in subjects that received a lower vaccine dose (i.e., 
25 mcg, 50 mcg) than that used in the Phase 3 placebo -controlled clinical trial  of mRNA -1273  
(COVE) . Additionally, this third mRNA -1273 vaccination of prior 100 mcg or 250 mcg 2-dose 
recipients could boost the immune responses directed against the Spike protein of SARS -CoV -2. 
It is unknown as to whether a third mRNA -1273 vaccination will provide additional protection 
against SARS -CoV -2 infection.  
There is potential benefit to society as a result of  informati on gained from participation in this 
optional third mRNA -1273 vaccination substudy . Data on the safety and immunogenicity of a  
third mRNA -1273 vaccination  of mRNA -1273 could provide key insights to inform the response 
to the ongoing threat imposed by the S ARS -CoV -2 pandemic.  
12.4 Objectives and Endpoints  
Table 12: Objectives and Endpoints (Outcome Measures)  
OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
Primary   
• To evaluate the safety and reactogenicity 
of a third  mRNA -1273 vaccination, at a 
dosage of 100 mcg.  • Frequency and grade of each solicited 
local and systemic reactogenicity AE 
during a 7 -day follow -up period post third  
mRNA -1273 vaccination . 
• Frequency and grade of any unsolicited 
AEs during the 28 -day follow -up period 
post third  mRNA -1273 vaccination . 
• Frequency of any SAEs, Protocol 
Specified AESIs, NOCMCs , and MAAEs 
from  Substudy Day 1 to Substudy Day 
366. 
Secondary   
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 103 of 116 OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
• To evaluate the immunogenicity as 
measured by IgG ELISA to the SARS -
CoV -2 S (spike) protein following a third 
mRNA -1273 vaccination , at a dos age of 
100 mcg,  at all timepoints after the third 
mRNA -1273 vaccination . • GMT of antibody at each timepoint  after 
the third mRNA -1273 vaccination . 
• Percentage of subjects who seroconverted, 
defined as a 4 -fold change in antibody 
titer from the pre -third mRNA -1273 dose  
baseline (Substudy Day 1) at each post -
vaccination timepoint and pre -first 
mRNA -1273  dose baseline ( Main Study 
Day 1).  
• The GMFR in IgG titer from the pre -third 
mRNA -1273 dose  baseline  (Substudy Day 
1) at each post -vaccination timepoint and 
pre-first mRNA -1273 dose baseline (Main 
Study Day 1).  
Exploratory   
• To evaluate the immunogenicity as 
measured by pseudovirus neutralization  
and other viral neutrali zation  assays  
following a third mRNA -1273 
vaccination , at a dos age of 100 mcg.  • GMT of Neut antibody at each timepoint  
after the third mRNA -1273 vaccination . 
• Percentage of subjects who seroconverted, 
defined as a 4 -fold change in Neut 
antibody titer from the pre -third mRNA -
1273 dose  baseline  (Substudy Day 1)  at 
each post-vaccination timepoint and pre-
first mRNA -1273 dose baseline (Main 
Study Day 1) . 
• The GMFR Ne ut antibody titer from the 
pre-third mRNA -1273 dose  baseline 
(Substudy Day 1) at each post-vaccination 
timepoint and pre -first mRNA -1273 dose 
baseline (Main Study Day 1) . 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 104 of 116 OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
• To evaluate the immunogenicity as 
measured by live SARS -CoV -2 
neutralization following a third mRNA -
1273 vaccination , at a dos age of 100 mcg.  • GMT of Neut antibody at each timepoint  
after third mRNA -1273 vaccination . 
• Percentage of subjects who seroconverted, 
defined as a 4 -fold change in Neut 
antibody titer from the pre -third mRNA -
1273 dose  baseline (Substudy Day 1) at 
each post -vaccination timepoint and pre -
first mRNA -1273 dose baseline (Main 
Study Day 1).  
• The GMFR in  Neut antibody titer from 
the pre -third mRNA -1273 dose  baseline 
(Substudy Day 1) at each post -vaccination 
timepoint and pre -first mRNA -1273 dose 
baseline (Main Study Day 1).  
• To assess, in at least a subset of samples, 
the SARS -CoV -2 S protein -specific T c ell 
responses.  • Magnitude, phenotype, and percentage of 
cytokine producing S protein -specific T 
cells, as measured by flow cytometry at 
timepoints pre - and post -third mRNA -
1273 vaccination . 
• To evaluate using a multiplex assay IgG 
ELISA to SARS -CoV -2 S protein and 
SARS -CoV -2 N protein . For each antigen,  
• GMT of antibody at each timepoint after 
the third mRNA -1273 vaccination . 
• Percentage of subjects who seroconverted, 
defined as a 4 -fold change in antibody 
titer from the pre -third mRNA -1273  dose 
baseline (Substudy Day 1) at each post -
vaccination timepoint and pre -first 
mRNA -1273 dose baseline (Main Study 
Day 1).  
• The GMFR in IgG  titer from the pre -third 
mRNA -1273  dose baseline  (Substudy Day 
1) at each post -vaccination timepoint and 
pre-first mRN A-1273 dose baseline (Main 
Study Day 1) . 
12.5 Study Design  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 105 of 116 This is a substudy to a phase I, open -label, dose -ranging clinical trial to assess a  third  mRNA -
1273 vaccination , administered via an IM injection at a dos age of 100 mcg /0.5 mL, in subjects , 
18 years of age and older, who received both the first and second mRNA -1273 vaccinations  in 
the main study  (see Table 13) and meet all other substudy e ligibility criteria. Th is optional third 
mRNA -1273 vaccination  substudy is designed to assess safety, reactogenicity, and 
immunogenicity through 12 months post third vaccina tion (Substudy Day 366). Subjects who 
pariticpiate in this substudy are from the same three domestic clinical research sites that enrolled 
into the main study . 
Table 13: Treatment Arms and Substudy  Dosing 
Cohort  Sample 
Size** Stratum  
(Years of Age)  First and Second Dose 
in Main Study  Optional Third Dose 
in Substudy  
1 15 18-55 25 mcg mRNA -1273  100 mcg mRNA -1273  
2 15 18-55 100 mcg mRNA -1273  100 mcg mRNA -1273  
3 15 18-55 250 mcg mRNA -1273  100 mcg mRNA -1273  
4 10 56-70 25 mcg mRNA -1273  100 mcg mRNA -1273  
5 10 56-70 100 mcg mRNA -1273  100 mcg mRNA -1273  
6* 10 56-70 250 mcg mRNA -1273  n/a 
7 10 ≥71 25 mcg mRNA -1273  100 mcg mRNA -1273  
8 10 ≥71 100 mcg mRNA -1273  100 mcg mRNA -1273  
9* 10 ≥71 250 mcg mRNA -1273  n/a 
10 15 18-55 50 mcg mRNA -1273  100 mcg mRNA -1273  
11 10 56-70 50 mcg mRNA -1273  100 mcg mRNA -1273  
12 10 ≥71 50 mcg mRNA -1273  100 mcg mRNA -1273  
13* 15 18-55 10 mcg mRNA -1273  n/a 
*Cohorts 6, 9 and 13 were not enrolled.  
***Four subject s did not receive the second dose of mRNA -1273  in the main study . Three 
subjects discontinued due to an AE (hives on lower extremities judged related to the first 
mRNA -1273 vaccination [cohort 1], sore throat [cohort 3], and maculopapular rash [cohort 5]) ; 
the other subject discontinued treatment due to quarantine for a COVID -19 exposure (cohort 1).  
The third mRNA -1273 vaccination will be offered to subjects who received 2 doses of 25 or 50 
mcg (cohorts 1, 4, 7, 10, 11, and 12), which are lower than the EUA  mRNA -1273 dos age of 100 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 106 of 116 mcg, as soon as feasible after their Main Study  Day 209 visit, and also will be offered to subjects 
who received 2 doses of 100 and 250 mcg (cohorts 2, 3, 5, and 8) no later than the close  of the 
window for their originally scheduled Main Study Day 394  visit. 
Subjects who receive the third mRNA -1273  vaccination will exit the Schedule of Activities for 
the main study and will enter the Schedule of Activities for the optional third mRNA -1273 
vaccination substudy (see Table 14). Substudy f ollow -up visits will occur 1, 2 and 4 weeks post 
the third mRNA -1273 vaccination (Substudy Days 8, 15, and 29), as well as 3, 6 and 12 months 
after the third mRNA -1273  vaccination (Substudy Days 91, 181 and 366). Blood will be drawn 
at these substudy visits for immunogenicity assays. As with prior mRNA -1273 vaccinations, 
reactogenicity will be measured by the occurrence of solicited injection site and systemic 
reactions from the tim e of the third mRNA -1273 vaccination through 7 days after the third 
mRNA -1273 vaccination . Unsolicited non -serious AEs will be collected from the time of the 
third mRNA -1273 vaccination through 28 days after the third mRNA -1273 vaccination . SAEs, 
Protocol Specified AESIs, MAAEs , and NOCMCs will be collected from the time of first 
mRNA -1273 vaccination through 12 months after the third mRNA -1273 vaccination . 
Subject s who do not participate in this substudy, including those who are not eligible to 
participate in the substudy due to their prior receipt of an FDA authorized (under an EUA) or 
approved COVID -19 vaccine outside of this clinical trial , will continue, with their permission, to 
be followed according to the Schedule of Activities  for the main study  (see Table 4). 
Interim safety and immunogenicity data from this substudy may be reviewed as need ed, at the 
discretion of the study team,  to inform public healt h decisions  and to assess the adequacy of the 
immune responses in the 25 and 50 mcg dose cohorts  compared with the 100 mcg dose cohort . 
Information from interim data reviews may be disseminated to public health officials and 
partners as needed and included in publications and presentations to inform the global scientific 
community.  
Evaluation of immunogenicity will include quantitation of antibodies to the SARS -CoV -2 S 
protein at  multiple timepoints post  third mRNA -1273 vaccination as measured by ELISA and 
virus neutralization assays. In addition, exploratory studies to characterize T cell responses are 
planned.  
Subjects who participate in the optional third mRNA -1273 vaccination substudy will exit the 
Schedule of Activities for the main study between Visit 13 and the close of the window for Visit 
14 and will not have Visit 14, instead will have Visit 14A and subsequent substudy visits  (see 
Table 14). 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 107 of 116 Table 14: Schedule of Activities  for the Optional Third mRNA -1273 Vaccination Substudy  
Optional Third mRNA -1273 
Vaccination Substudy S chedule Day D1 D8 D15 D29 D91 D181 D366 
SubStudy Visit Window (± number of 
days)  n/a 2d 2d 4d 10d 12d 30d 
Optional Third mRNA -1273 
Vaccination Substudy V isit V14A V15 V16 V17 V18 V19 V20 
Clinical Evaluations and 
Procedures  Tube         
Review eligibility criteria for the 
third mRNA -1273  vaccination   X       
Review medical history and con 
meds   X X X X X X X 
Vital signs  X X X X {X} {X} {X} 
Third mRNA -1273  
Vaccination1  X       
Targeted physical exam  {X} {X} {X} {X} {X} {X} {X} 
Evaluate vaccination site  X X      
Review memory aid    X      
Solicited AEs   X X      
Unsolicited AEs and SAEs  X X X X2 X2 X2 X2 
Pregnancy test (urine)3  X       
Serum for humoral 
immunogenicity assays (mL)  SST 24 24 24 24 24 24 24 
Serum for secondary research 
(mL)  SST 8 8 8 8 8 8 8 
PBMC isolation for cellular 
immunology assays and plasma 
(mL)  NaCit 
CPT 40  30 30 30 30 40 
PBMC isolation and plasma for 
secondary research  NaCit 
CPT 48 40 18 34 34 34 40 
Total volume per visit (mL)   120 72 80 96 96 96 112 
Maximum cumulative blood 
volume4 (mL) (prior 56 days)   192 264 344 440 96 96 112 
{ } Required at this substudy visit only if clinically indicated . 
1) 0.5 mL of the mRNA -1273 vaccine will be injected IM in the deltoid muscle. After the 
injection, subjects will be observed for 60 minutes. The injection site will be evaluated , and 
vital signs obtained , during that period and before the subject leaves the clinic.  
2) After Substudy Day 29  through the end of the substudy ( Subst udy Day 3 66), only SAE s, 
Protocol Specified AESIs, MAAEs , and NOCMCs will be reported  as AEs . 
3) For women of childbearing potential. Must be confirmed as negative prior to the third 
mRNA -1273 vaccination. The visit will also include review of contraceptive/menstrual 
history and pregnancy avoidance counselling.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 108 of 116 4) For purposes of estimating the maximum possible cumulative blood volume over the prior 56 
days, this calculation assume s that the blood draw (72 mL) for Main Study Day 209 occur s 
on the d ay prior to Substudy Day 1 . 
12.6 Eligibility Criteria  
12.6.1  Inclusion Criteria  
A subject must meet all the following criteria to be eligible to participate in this substudy:  
1. Enrolled in th e main study  and received both the first and second mRNA -1273 
vaccinations . 
2. Provides written informed consent for the third mRNA -1273  vaccination.  
3. Agrees to the collection of venous blood per substudy . 
4. Must agree to have samples stored for secondary research.  
5. Women of childbearing potential have had a negative urine pregnancy test within 24 
hours before the third mRNA -1273  vaccination.  
6. Women of childbearing potential1 must agree to use or have practiced true abstinence2 or 
use at least one acceptable primary fo rm of contraception.3,4 
Note: These criteria are applicable to females in a heterosexual relationship and child -
bearing potential (i.e., the criteria do not apply to subject s in a same sex relationship ). 
1Not of childbearing potential – post-menopausal females (defined as having a history of 
amenorrhea for at least one year) or a documented status as being surgically sterile 
(hysterectomy, bilateral oophorectomy, tubal ligation/salpingectomy, or Essure® 
placement).  
2True abstinence is 100 % of time no sexual intercourse (male’s penis enters the female’s 
vagina). (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post -ovulation 
methods] and withdrawal are not acceptable methods of contraception).  
3Acceptable forms of primary con traception include monogamous relationship with a 
vasectomized partner  who has been vasectomized for 180 days or more prior to the 
subject’s first vaccination, intrauterine devices, birth control pills, and 
injectable/implantable/insertable hormonal birth control products.  
4Must use at least one acceptable primary form of contraception for at least 30 days 
prior to the third mRNA -1273 vaccination and for at least 30 days after the third mRNA -
1273 vaccination.  
12.6.2  Exclusion Criteria  
A subject who meets any of the following criteria will be excluded from participation in this 
substudy.  
1. Anaphylaxis or other systemic hypersensitivity reaction following a mRNA -1273 or any 
other vaccination.  
2. Immediate allergic reaction of any severity after mRNA -1273 or any of its c omponents.5 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 109 of 116 5Including polyethylene glycol (PEG)  
3. Immediate allergic reaction of any severity to polysorbate .6 
6Due to potential cross -reactive hypersensitivity with the vaccine ingredient PEG  
4. History of an SAE judged related to mRNA -1273 vaccine.  
5. Female su bject who is breastfeeding or plans to breastfeed from the time of the third 
mRNA -1273  vaccination through 30 days after the third mRNA -1273  vaccination.  
6. Has an acute illness7, as determined by the participating site PI or appropriate sub -
investigator, wit h or without fever [ oral temperature ≥38.0°C (100.4 °F)], within 72 hours 
prior to the third mRNA -1273  vaccination . 
7An acute illness which is nearly resolved with only minor residual symptoms remaining 
is allowable if, in the opinion of the participating site PI or appropriate sub -investigator, 
the residual symptoms will not interfere with the ability to assess safety p arameters as 
required by the substudy . 
7. Has received any approved, authorized or investigational COVID -19 vaccine outside of 
this trial.  
8. Any clinically significant medical condition that, in the opinion of the investigator, poses 
an additional risk to the s ubject from vaccination.  
9. History of documented COVID -19 infection.  
10. Has any medical disease or condition that, in the opinion of the participating site PI or 
appropriate sub -investigator, precludes substudy participation.  
11. Received or plans to receive a lice nsed vaccine, other than a COVID -19 vaccine, within 2 
weeks before or after the third mRNA -1273  vaccination.  
12.7 Study Product  
12.7.1  Study Product Description  
Product: mRNA -1273  
For the optional third mRNA -1273  vaccination substudy, mRNA -1273 is provided by 
ModernaTX, Inc. via the DMID CMS  as a sterile solution for injection in a 10  dose multidose 
vial formulated at a concentration of 0.2mg/mL  in 20 mM Tris buffer containing 87 mg/mL 
sucrose and 4.3 mM acetate, at pH 7.5 and presented in 10R USP Type I borosi licate glass vials 
with PLASCAP vial seal containing a 20 mm FluroTec -coated plug stopper and aluminum flip -
off crimp seals with a nominal fill volume of 6.3 mL/vial . 
There is no preservative in the mRNA -1273 solution. Hence, all ten (10) doses must be 
withdrawn into individual dosing syringes in quick succession, one after the other once the vial is 
breached.  
Dilution is not required  for the third mRNA -1273 vaccination . Each multidose vial contains 
ready -to-use solution and does not require further dilutio n or preparation. It will be administered 
as a single 0.5 mL IM injection of 100 mcg into the deltoid muscle.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 110 of 116 See the protocol -specific MOP for detailed information : 
• 20 (minimum) to 30 (maximum) minutes are required for the mRNA -1273 vials to 
equilibrate to room temperature (20ºC to 25ºC ). 
• A maximum of 30 minutes is allowed between completion of equilibration and 
completion of dosing syringes fill.  
• Ten (10) dosing syri nges must be prepared from each mRNA -1273 vial.  
• All dosing syringes must be filled in quick succession, one after the other.  
• Filled dosing syringes must be held at room temperature (20ºC to 25ºC) and will expire 
(eight) 8 hours after being filled.  
• Withdraw al of mRNA -1273 from the vial into the dosing syringe s should be completed 
within 30 minutes after the vial has equilibrated to room temperature (20ºC to 25ºC ). 
12.7.2  Dose Modifications  
It is unknown whether subjects  in the 25 mcg and 50 mcg cohorts from the mai n study  have been 
optimally primed to respond to the  third mRNA -1273 vaccination . In the event that the responses 
to a third mRNA -1273 vaccination in either or both of those cohorts  are judged to be suboptimal 
in comparison to the response s in the 100 mcg cohorts , the study team will inform the subjects 
and consider a protocol amendment  to administer another mRNA -1273 vaccination  at a dosage 
of 100 mcg.  
12.7.3  Product Storage and Stability  
Product: mRNA -1273  
For the optional third mRNA -1273 vaccination substudy, mRNA -1273 must be stored in a secure 
area with limited access (pharmacy staff only), and must be stored locally under refrigerated 
conditions (2°C to 8°C  [36°F to 46°F) ]. The refrige rator  should have an automated temperature 
recording and alert system. There must be an available back -up refrigerator . The refrigerators  
must be connected to a back -up generator; or alternate plan in the event of a power failure. The 
pharmacy must have in  place a 24 -hour alert system that allows for rapid response in case of 
refrigerator  malfunctioning.  
Prepared doses  should remain at ambient temperatures (20ºC to 25ºC) and should not be shaken 
or allowed to roll during transport. Avoid exposing to direct sunlight while the syringe is in route 
to the injection administration location. If the prepared doses  require tran sportation to a separate 
facility, ensure there are appropriate transport procedures in place. Under all circumstances, the 
time from preparation, transportation and administration of mRNA -1273 must occur within 
maximum (nine) 9 hours from the time the via ls are removed from the refrigerator.  
• A minimum of 20 minutes and a maximum of 30 minutes are allowed for equilibration of 
vial to room temperature (20°C to 25°C ) after removal from refrigerator . 
• A maximum of 30 minutes is allowed between completion of equ ilibration and 
completion of dosing syringes fill. However, all dosing syringes (10) must be filled in 
quick succession once the vial is breached.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 111 of 116 • A maximum of 8 (eight) hours is allowed for holding dosing solution in dosing syringes 
prior to completion of  administration.  
• Note that the multi -dose vial does not contain a preservative and must be discarded 6 
hours after the first penetration of the sterile septum.  
12.8 Concomitant Therapy  
Information about prior medications, including hormonal contraceptives, taken by the subject in 
the 30 days prior to providing informed consent for the substudy will be recorded on the 
appropriate DCF.  
Concomitant medications include all medications (prescription, over the counter, supplements, 
and vaccines rec eived outside of the study) taken by the subject from the time the substudy 
informed consent is signed through Substudy Day 366 . At each substudy visit following  the third 
mRNA -1273 vaccination, subjects will be queried about new concomitant medications an d 
changes to existing medications.  
Medications that might interfere with the evaluation of the investigational product should not be 
used by the subject during the study -reporting period (12 months after the third mRNA -1273 
vaccination ) unless clinically i ndicated as part of the subject’s health care.  
In the event medical conditions dictate the use of medications, subjects are encouraged to obtain 
adequate care, comply with the course of therapy as prescribed by their physician, and inform the 
study Investi gator as soon as practical. Any drug or vaccine used or received by the subject 
during the study -reporting period (12 months after the third mRNA -1273 vaccination)  should be 
recorded on the appropriate DCF.  
12.9 Immunogenicity Evaluations  
Serological Immunogeni city Assays : 
The following serological immunogenicity assays may be performed on specimens collected on 
the day of and following the third mRNA -1273 vaccination : 
• IgG ELISA to the SARS -CoV -2 S (spike) protein(s) and SARS -CoV -2 N protein . 
• Pseudovirus and live SARS -CoV -2 neutralization assays . 
Cellular Immunology Assays : 
This substudy will also investigate T cell immune responses using multiparametric flow 
cytometry.  
The volume of venous blood to be collected  at each substudy visit for immun ogenicity 
evaluations is presented in Table 14. 
12.10  Adverse Events and Serious Adverse Events  
12.10.1  Reporting of Adverse Events  
Reporting of all AEs, solicited and unsolicited, will occur during the period from administration 
of the third mRNA -1273 vaccine on Substudy Day 1 through Substudy Day 29 . 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 112 of 116 Solicited AEs (i.e., reactogenicity) will be collected using a memory aid and record ed on the 
appropriate DCF from the time of the third mRNA -1273 vaccination  through 7 days post third 
mRNA -1273 vaccination ( Substudy Days 1 -8). 
Unsolicited AEs of all severities will be reported from the time of the third mRNA -1273 
vaccinati on on Substudy Day 1 through Substudy Day 29.  
After Substudy Day 29  through the end of the substudy ( Substudy Day 3 66), only SAE s, 
Protocol Specified AESIs, MAAEs , and NOCMCs will be reported  as AEs . 
SAEs, Protocol Specified AESIs, MAAEs , and NOCMCs  will be collected fro m Substudy Day 1 
through the end of the substudy ( Substudy Day 366). 
12.10.2  Reporting of Pregnancy  
Pregnancy is not an AE. However, any pregnancy that occurs during substudy participation  
(through Substudy  Day 366 post third mRNA -1273 vaccination ) should be reported to the 
sponsor on the appropriate DCF. Pregnancy should be followed to outcome.  
12.10.3  Unanticipated Problem Reporting  
To satisfy the requirement for prompt reporting, UPs will be reported using the following 
timeline:  
▪ UPs that are SAEs will b e reported to the IRB and to the SDCC/study sponsor within 24 
hours of the participating site PI or appropriate sub -investigator becoming aware of the 
event per the above describe d SAE reporting process.  
▪ UPs that are SAEs will be collected from Substudy Day 1 through the end of the substudy 
(Substudy Day 366).  
▪ Any other UP will be reported to the IRB and to the SDCC/study sponsor within 3 days 
of the participating site PI or appropriate sub -investigator becoming aware of the 
problem.  
▪ UPs that are not SAEs w ill be collected from Substudy Days 1 -29. 
12.11  Statistical Considerations  
12.11.1  Statistical Hypotheses  
This is a substudy to a phase I, open -label, dose -ranging clinical trial and is not designed to test a 
specific hypothesis. Rather, it is intended to obtain preliminary estimates in healthy adults of the 
safety, reactogenicity, and immunogenicity of a thir d mRNA -1273 vaccination between 6 
months and 12 months post second mRNA -1273  vaccination.  
12.11.2  Sample Size Determination  
Rare AEs are not demonstrable in a clinical study of this size; however, the probabilities of 
observing one or more AEs given various true e vent rates are presented in Table 9 and apply to 
the substudy as well. Statistical assumptions described in Section 9.2 apply to the subst udy as 
well. It is possible that not all subjects will receive a third mRNA -1273 vaccination , assuming 5 
subjects in a cohort receive a third mRNA -1273 vaccination  the chance of observing at least one 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 113 of 116 AE of probability 20% or more is approximately 67%. Ass uming all subjects receive a third 
mRNA -1273 vaccination  the following additional statistical consideration applies. With 120 
subjects across all cohorts the chance of observing at least one AE of probability 3% or more is 
approximately 97%.  
12.11.3  Populations fo r Analyses  
The Safety Analysis population includes all subjects who received the third mRNA -1273 
vaccination . 
The modified intent -to-treat (mITT) population includes all subjects who received of the third 
mRNA -1273 vaccination  and contributed both pre - and at least one post -third mRNA -1273 
vaccination  venous blood samples for immunogenicity testing for which valid results were 
reported.  
In the final analysis, protocol deviations will be reviewed to determine which protocol deviations 
may affect the analysis . The per protocol (PP) population will then be defined – and this includes 
all subjects in the mITT subset with the following exclusions:  
• Data from all available visits for subjects found to be ineligible at the time of the third 
mRNA -1273 vaccination . 
• Data from all substudy visits subsequent for the protocol deviations that are considered to 
affect the science.  
• Data from any substudy visit that occurs substantially out of window.  
12.11.4  Statistical Analyses  
Interim analyses of safety, reactogenicity, and immunologic response data may be done, as 
needed.  
The final substudy analysis will be performed after the final data lock (through  Substudy  Day 
366) and reported as an addendum to the clinical study report (CSR). The addendum will be 
completed when all primary safety endpoint data and all secondary immunogenicity endpoint 
data are available and received by the SDCC. Any available data from the exploratory 
immunogenicity endpoints may also be included in the addendum. Remaining explorator y 
immunogenicity endpoint data may be included in a further addendum to the CSR, publication of 
manuscript(s), or other report(s). Abbreviated analysis plans that describe planned analyses to 
facilitate dissemination of study data for public health reasons , including manuscript 
publication(s), will be developed by the SDCC. A full statistical analysis plan (SAP) will be 
developed by the SDCC and finalized prior to the final data lock.  
12.11.5  General Approach  
Unless otherwise noted in the SAP, continuous variables will be summarized using the following 
descriptive statistics: n (non -missing sample size), mean, standard deviation, median, maximum 
and minimum. The frequency and percentages (based on the non -missing sample size) of 
observed levels will be reported for all categorical measures.  
12.11.6  Analysis of the Primary Endpoint(s)  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 114 of 116 Section  12.11.8  describes the analyses  of Safety which is the primary endpoint of this substudy . 
12.11.7  Analysis of the Secondary Endpoint(s)  
Summaries and analysis of immunogenicity data will be presented for the mITT population. If 
there are protocol deviations which may affect the analysis, a per -protocol (PP) analysis may 
also be performed.  
GMFR and seroconversion analyses will be done using two definitions of baseline. Baseline 1 
will be considered Main Study Day 1 prior to the first mRNA -1273  vaccination (pre -first 
mRNA -1273 dose baseline) and baseline 2 will be considered Substu dy Day 1 prior to the third 
mRNA -1273  vaccination  (pre-third mRNA -1273  dose  baseline).  
Seroconversion is defined as a 4 -fold increase in antibody titer over baseline.  
Seroconversion rates, GMFR and GMT for SARS -CoV -2 as measured by IgG ELISA will be 
calculated at Substudy Days 1, 8, 15, 29, 91, 181 and 366 post  third mRNA -1273 vaccination  by 
cohort and will be summarized graphically. Seroconversion rates, GMFR and GMT w ill be 
presented with their corresponding 95% confidence interval (CI) estimates at each post-
vaccination timepoint and overall peak GMT.  
12.11.8  Safety Analyses  
Summaries and analysis of safety data will be presented for the Safety Analysis Population.  
Solicited AEs will be summarized by severity for each day post third mRNA -1273  vaccination  
(Substudy Days 1 -8) and as the maximum severity over all 8 days. Additionally, solicited AEs 
will be analyzed by taking the most severe response over the follow -up period and using 
standard techniques, such as exact confidence intervals (CI), to summarize the proportion of 
subjects reporting each symptom, any application site symptom, and any systemic symptom.  
Unsolicited non -serious AEs will be collected from the time of the third mRNA -1273 
vaccination through 28 days after the third mRNA -1273 vaccination.  Unsolicited AEs will be 
coded by MedDRA for preferred term and system organ class (SOC). SAEs, Protocol Specified 
AESIs, MAAEs , and NOCMCs will be collected from the time of first mRNA -1273 vaccination 
through 12 months after the third mRNA -1273 vaccination . The numbers of SAEs and MAAEs 
will be reported by detailed listings showing the event description, MedDRA  preferred term and 
SOC, relevant dates (vaccinations and AEs), se verity, relatedness, and outcome for each event. 
Non-serious unsolicited AEs will be summarized as number and percentage of subjects reporting 
at least one event in each MedDRA  preferred term and SOC, cross tabulated by severity and 
relationship to study p roduct. Additionally, the proportion of subjects and exact 95% CIs of AEs 
in aggregate and by MedDRA  categories will be computed.  
Clinical laboratory data will be summarized by severity for each substudy visit, and as the 
maximum over all post -vaccination subst udy visits. Graphical presentations may include box 
plots and shift plots.  
12.11.9  Baseline Descriptive Statistics  
Summaries of demographic variables such as age, sex, ethnicity, and race will be presented by 
cohort and overall. Summaries of baseline clinical  laboratory values will be presented by cohort 
and overall . 
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 115 of 116 12.11.10  Planned Interim and Early Analyses  
Data may be disseminated to public health officials and partners as needed and included in 
publications and presentations to inform the global scientific communi ty.  
Cumulative safety information, study status, and primary endpoint results may be published, 
presented at a public forum, or presented as summaries aggregated by study arm at the discretion 
of the sponsor while the main  study is ongoing. Any ad -hoc ana lyses, jointly developed by the 
SDCC and/or the VRC, other participating laboratories and ModernaTX, Inc., will be executed 
by the SDCC as needed. None of the interim analyses will include any formal statistical 
hypothesis testing; therefore, p value adjus tment will not be made to any analyses.  
12.11.10.1  Interim Safety Analyses  
Given the need for rapid review and dissemination of study data for public health reasons, AEs 
and SAEs maybe reviewed as necessary outside of SMC reviews. T he SMC will not need to 
meet (unless halting rules are met ), and materials will be provided electronically. Documentation 
of review and any concerns noted will be solicited electronically.  
12.11.10.2  Interim Immunogenicity Review  
For public health reasons there may be several immunogenicity revie ws as needed.  
Data may be disseminated to public health officials and partners as needed and included in 
publications and presentations to inform the global scientific community.  
12.11.10.3  Interim Immunogenicity and Safety Review  
Interim analyses of safety, reactogenicity, and immunologic response data may be done, as 
needed.  
12.11.11  Sub-Group Analyses  
The protocol does not define any formal subgroup analyses, and the substudy is not adequately 
powered to perform subgroup analyses.  
12.11.12  Tabulation of Individual Subject Da ta 
In general, all data will be listed, sorted by cohort and subject, and when appropriate by substudy 
visit number within subject.  
12.11.13  Exploratory Analyses  
Summaries and analysis of immunogenicity data will be presented for the mITT population. If 
there are p rotocol deviations which may affect the analysis, a PP analysis may also be 
performed.  
GMFR and seroconversion analyses will be done using two definitions of baseline. Baseline 1 
will be considered Main Study Day 1 prior to the first mRNA -1273  vaccination (pre-first 
mRNA -1273 dose baseline) and baseline 2 will be considered Substudy Day 1 prior to the third 
mRNA -1273  vaccination  (pre-third mRNA -1273  dose  baseline).  
Seroconversion is defined as a 4 -fold increase in antibody titer over baseline.  
DMID Protocol 20-0003  Version 7.0 
mRNA -1273   30 July  2021  
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 116 of 116 Seroconversi on rates, GMFR and GMT for SARS -CoV -2 as measured by IgG  ELISA, 
neutralization assay using SARS -CoV -2 pseudovirus, neutralization assay using live SARS -
CoV -2, and multiplex assay IgG ELISA to the SARS -CoV -2 S proteins and SARS -CoV -2 N 
protein will be calcu lated for all post third mRNA -1273  timepoints by cohort and will be 
summarized graphically. Seroconversion rates, GMFR and GMT will be presented with their 
corresponding 95% CI estimates at each post-vaccination timepoint and overall peak GMT.  
Summaries an d analysis of cellular assay data will be presented for the mITT population. If there 
are protocol deviations which may affect the analysis, a PP analysis may also be performed.  
The magnitude, phenotype and percentage of cytokine producing S protein -specif ic T cells will 
be summarized at each post-vaccination timepoint by vaccination group.  
12.12  Regulatory, Ethical, and Study Oversight Considerations  
Informed consent for the substudy will be obtained in accordance with Section  10.1.1 . 
As per Section 10.1.1.2 , the right s and privacy of human subjects who participate in genomic or 
phenotypic research studies will be protected at all times.  
If subjects choose not to provide permission for extra blood and secondary research use, they 
will not be eligible for participation in  the optional third mRNA -1273 vaccination substudy.  
Subjects may withdraw permission to use substudy samples for seconda ry use at any time. They 
will need to contact the participating site and the samples will be removed from the study 
repository after this substudy is completed and documentation will be completed that outlines the 
reason for withdrawal of permission for se condary use of samples. Subjects who withdraw 
consent before the last substudy visit will not have the extra blood drawn for secondary use.  